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ABSTRACT 
Objective:  The primary goal of this study was to assess the current state of diabetes, 
specifically type 2 diabetes in Mississippi Medicaid enrolled pediatric population.  
Background: Diabetes is the most prevalent pediatric chronic condition. Recent trends 
indicate that type 2 diabetes in children is increasing. Epidemiology estimates of type 2 
diabetes in children and adolescents are limited. Quality of care and their health care 
utilization estimates are not available.  
Methods: 2002 – 2004 Mississippi Medicaid claims data were used for this study. A 
combination of ICD-9 codes (250.0x – 250.9x, where x=0 or 2) and/or oral hypoglycemic 
(OHG) drug use were used to identify children with type 2 diabetes. Sociodemographic 
characteristics, risk factors, comorbidities and complications were assessed for all 
diabetes children. Medication use/adherence and their association with hospitalization 
and economic outcomes were explored. We also assessed annual screening rates in the 
type 2 diabetes population. Annual health care resource utilization and expenditures were 
assessed and modeled using Poisson regression and GLM with gamma distribution and 
log link respectively. 
Results:  Overall, a sizeable proportion of children enrolled in Mississippi have diabetes, 
especially type 2 diabetes. Very few children with type 2 diabetes use oral hypoglycemic 
and antihypertensive medications, even fewer children use antihyperlipidemics. Among 
users, adherence was poor. Adherence with annual screenings was also suboptimal in this 
 vi 
population indicating poor management of type 2 diabetes overall. Children with both 
diabetes types have higher healthcare resource utilization and expenditures compared to 
all Medicaid enrolled children without diabetes and pediatric population with asthma and 
ADHD.  
Conclusions:  Type 2 diabetes is prevalent in children enrolled in Mississippi Medicaid 
and most of these children don‟t receive optimal care. Healthcare providers should 
inform patients and children the implications of mismanagement and Medicaid should 
offer provider incentives to encourage healthcare providers to implement effective 
interventions.  
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CHAPTER I - INTRODUCTION 
Diabetes Mellitus is a chronic condition characterized by high levels of blood 
glucose, caused by the inability of body to produce (insulin secretion) and/or respond 
appropriately to insulin (insulin resistance). Diabetes is the second most common disease 
among children (1), with type 1 diabetes being long established as a pediatric disease and 
recent trends indicating more cases of type 2 diabetes being diagnosed among children 
and adolescents (2,3,4). Earlier onset of type 2 diabetes implies children are at a risk for 
vascular complications like stroke, myocardial infarction, chronic renal failure, blindness 
earlier in life (5). These life-threatening complications and the condition in itself pose 
enormous economic, social and psychological burden for the patients, their families and 
the society at large, lending type 2 diabetes in children to be a major public health 
concern.  
American Diabetes Association (ADA) reported that the prevalence of new-onset 
type 2 diabetes cases in children and adolescents is anywhere between 8% and 45% 
depending on ethnicity and geographic location (2). The recently concluded SEARCH 
study reported that an estimated 150,000 children and adolescents had diabetes in 2001, 
and the incidence was around 18,000 youth in 2002-2003. Nearly 20% of these cases 
were type 2 and ethnic minorities were disproportionately affected (6). Also, increase in 
obesity prevalence in the US pediatric population paralleled the increase in prevalence of 
type 2 diabetes leading many to believe that the diabetes epidemic is a manifestation of 
the obesity epidemic. With obesity prevalence rates still increasing and more children and 
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adolescents all over the world being diagnosed with type 2 diabetes, health professionals 
have an important issue to address.  
Being a relatively new phenomenon, the type 2 diabetes epidemic in children and 
adolescents raises more questions than answers at this point in time. Population-based 
epidemiological data are limited in groups other than Native American Indians 
(32,37,40). The characteristics of those affected and the risk factors for developing the 
disease are reported from clinics with small samples sizes and the long range outcomes of 
children diagnosed have not been systemically studied. Economic burden and overall 
healthcare utilization among this population is unknown. In an attempt to address some of 
these concerns, Centers for Disease Control and Prevention (CDC) and the National 
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) co-sponsored a trial 
called SEARCH for Diabetes in Youth Study (SEARCH), a population-based study of 
physician diagnosed diabetes in the pediatric population. The research study followed 
children and adolescents in 6 clinical centers since 2000 for 5 years. The primary aim of 
the study was to estimate the incidence and prevalence of different types of diabetes and 
to develop a system for appropriate classification of different types of diabetes. The study 
also aimed to explore the risk factors for the various complications of diabetes, the 
prevalence of these complications, healthcare utilization and quality of life of diabetic 
children (7). So far, the SEARCH trial provided epidemiological estimates of pediatric 
type 2 diabetes - prevalence for the year 2001 alone and incidence for years 2002-2005 
and answered questions pertaining to the predictors of certain complications like diabetic 
ketoacidosis and cardiovascular disease among other important findings (6,8,9,10). 
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However a lot remains to be answered in terms of risk/benefit of the various management 
strategies, service utilization, quality of care provided and economic burden. The study 
was followed up by another study called SEARCH II scheduled for completion in late 
2009 (11).  
The lack of information regarding the consequences of type 2 diabetes in the 
pediatric population also applies to the state of Mississippi. Mississippi reportedly has the 
highest rates of obesity (24.3%) and diabetes (8.8%) compared to all other US states (12). 
According to the Mississippi Department of Health, diabetes is highly prevalent with 
more than 234,500 Mississippians reported to have diabetes. Diabetes also contributes to 
the deaths of 2,200 Mississippians each year and poses a heavy burden to the state‟s 
economy. However, data on childhood and adolescent diabetes cases in the state is not 
available. Though parallels can be drawn from available epidemiology estimates, 
Mississippi children have a noticeably different risk profile. Obesity, racial/ethnic 
minorities and family history of type 2 diabetes are among the noted risk factors for type 
2 diabetes in the pediatric population (13,14). Mississippi children and adolescents are 
more vulnerable to type 2 diabetes than the average youth less than 20 years of age in the 
US, because obesity incidence rate is the highest in Mississippi among all US states, 
Mississippi has a high proportion of African Americans and type 2 diabetes prevalence is 
very high among adults in the state (11).  
It is likely that Medicaid is the single largest payer for pediatric diabetes as 50% 
of the children in the state are enrolled in Medicaid. Also, pediatric population forms the 
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single largest age cohort covered by Medicaid (15). As a result, pediatric diabetes, both 
type 1 and type 2 might pose substantial economic burden to the state Medicaid 
programs. It is important to understand the epidemiology of the condition in the pediatric 
population, the quality of care offered to these patients and the demand and cost of 
medical care services utilized by this population and the consequent economic burden to 
Mississippi Medicaid. The primary purpose of the study was to provide information 
regarding the state of type 2 diabetes. However, we evaluated estimates for diabetes 
overall as well as stratified by type because the there are no existing estimates for type 1 
diabetes or diabetes in general for the state of Mississippi or a state Medicaid program 
and epidemiology studies in other population are also sparse. Secondly, we intended to 
provide comparisons with type 2 diabetes estimates in the same population. 
Apart from assessing resource utilization of children and adolescents with 
diabetes, we also estimated the same for pediatric population in Medicaid without 
diabetes and those with prevalent conditions like asthma and ADHD. The choice of these 
two conditions was based on their high prevalence in pediatric population and we chose 
one physical health and one mental health condition, to understand the comparative 
economic burden due to diabetes. 
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Study Objectives 
The purpose of this study was to assess the current state of diabetes, specifically 
type 2 diabetes among children and adolescents covered under the Mississippi Medicaid 
program. Our aim was to evaluate the treatment patterns for these children, and to assess 
the economic burden of pediatric diabetes on Mississippi Medicaid. The three main 
estimates that were assessed using this dataset include an epidemiological and clinical 
profile of children with diabetes (both type 1 and type 2) in Mississippi Medicaid, the 
quality of care provided and the annual cost of the condition to the state Medicaid 
program.  
Our specific objectives are: 
(a) To estimate the prevalence and incidence of type 1 and type 2 diabetes among 
Mississippi‟s children and adolescents covered by Medicaid.  
(b) To evaluate the current treatment patterns and quality of care among these 
children. 
(c) To evaluate the healthcare utilization and expenditures of children and 
adolescents with type 1 and type 2 diabetes in Mississippi Medicaid and compare 
their health services use with pediatric population without diabetes and those with  
other prevalent pediatric conditions.  
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CHAPTER II – LITERATURE REVIEW 
This chapter contains an overview of epidemiology literature, followed by the 
quality of care recommendations and studies exploring the adherence to these guidelines. 
We also address the existing research in healthcare use by children with diabetes. As the 
primary purpose of this study is to provide information about type 2 diabetes, we place 
greater emphasis on providing an extensive background on type 2 diabetes. Information 
regarding type 1 diabetes is also provided where appropriate but in lesser detail. 
EPIDEMIOLOGY 
Diabetes is a worldwide epidemic affecting an estimated 20.8 million Americans 
representing 7% of the total US population. Another 41 million Americans have 
prediabetes mellitus which might progress to diabetes if it isn‟t diagnosed and treated 
early in its inception (16). Overall prevalence of diabetes has increased by 33% in the 
past decade in US. Diabetes is also known to be one of the most common chronic 
conditions among children, with type 1 diabetes being long established as a pediatric 
disease and recent trends indicating more cases of type 2 diabetes being diagnosed among 
children and adolescents (17). In US, 186,300 young people under 20 are affected by 
diabetes, both type 1 and type 2 (0.2% of Americans less than 20 years) (18). Population-
based epidemiological estimates in North America indicate an estimated prevalence of 
type 1 diabetes to be 2 to 5 per 1000 children (17) and the incidence ranges from 10 to 20 
cases per 100,000 young people less than 18 years (17). Epidemiology of type 2 diabetes 
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in children and adolescents remains understudied because the condition is relatively 
recent in this population and more importantly the consequences are just being realized. 
Studies reporting type 2 diabetes prevalence and incidence are tabulated in table 1 
(adapted from 13,19). 
Historically, type 2 diabetes has been considered a disease that only affects adults 
and old individuals. In 1979, the first cases of type 2 diabetes in children and adolescents 
were reported among the Pima Indians. The affected children were noted to be extremely 
overweight and had a family history of early-onset diabetes related to obesity (19). This 
lead to the belief that childhood Type 2 diabetes may be specific to genetic pools of 
particular racial subtypes like the Native Americans.  
Until recently population-based prevalence data was available exclusively for 
Native American communities in the US. A study exploring type 2 diabetes among Pima 
Indians in Arizona reported a prevalence of 22.3/1000 in 10-14 year old age group and 
the prevalence was 50.9/1000 in the 15-19 year old age group (25). The 1991-1992 
Navajo Health and Nutrition Survey conducted in New Mexico showed that 
approximately 14 percent of children in the 12-19 year age group had type 2 diabetes. 
Other registry-based studies reporting type 2 diabetes cases in the Native American 
population also showed an increasing prevalence. A study conducted using Indian health 
service national outpatient database showed prevalence of type 2 diabetes in the 15 to 19 
year age-group increased from 3.2/1000 in 1990 to 5.4/1000 in 1998. However, over the 
past two decades, an emerging epidemic of type 2 diabetes in children and adolescents in 
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other ethnic groups in North America and other areas of the world put this belief to rest 
(20,21,36,41). 
Table 1: Epidemiological Studies Reporting Type 2 Diabetes 
Geographic 
Location/Study 
Year Race/ethnicity Age 
(yr) 
Estimate Ref 
 
SEARCH (US) 
 
2001 
 
Whites 
 
10-19 
Prevalence per 
1000 
0.18 
 
20 
SEARCH (US) 2001 African 
Americans 
10-19 1.06 21 
SEARCH (US) 2001 Asian and 
Pacific 
Islanders 
10-19 0.52 22 
SEARCH (US) 2001 Hispanics 10-19  23 
SEARCH (US) 2001 Navajo Indians 15-19 2.63 (Female) 
2.07 (Male) 
24 
SEARCH (US) 2001 
 
 
All 0-20 1.82 8 
Arizona (US) 1992-1996 Pima Indians 10-14 
15-19 
22.3 
50.9 
25 
New Mexico 
(US) 
1991-1992 Navajo Indians 12-19 14.1(type 1&2) 26 
Manitoba 
(Canada) 
1996-1997 Cree and 
Ojibway 
Indians 
10-19 
4-19 
36.0 girls 
11.1 
27 
NHANES III 
(US) 
1988-1994 All 12-19 4.1(type 1&2) 19 
Indian Health 
Services (US) 
1996 American 
Indians 
0-14 
15-19 
1.3 
4.5 (type 1&2) 
28 
 
 
Puerto Rico 
 
 
1995-2003 
 
 
Hispanic 
 
 
0-20 
Prevalence per 
100,000 
13.5 
 
 
29 
Birmingham 2000  <18 3.8 30 
UK  2000 All groups <16 0.21 31 
 
SEARCH (US) 
 
2002-2005 
 
Whites 
 
10-19 
Incidence per 
100,000 
3.7 
 
20 
SEARCH (US) 2002-2005 African 10-19 19.0 21 
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Americans 
SEARCH (US) 2002-2005 Asian and 
Pacific 
Islanders 
10-19 12.1 22 
SEARCH (US) 2002-2005 Hispanics 10-19  23 
SEARCH (US) 2002-2005 Navajo Indians 15-19 38.16 (Female) 
32.42 (Male) 
24 
SEARCH (US) 2002-2003 All 0-20 24.3 6 
Cincinnati (US) 1994 Whites and 
African 
Americans 
0-19 
10-19 
3.5 
7.2 
32 
Tokyo (Japan) 1976-1980 
1991-1995 
Asian 12-15 
 
12-15 
7.3 
 
13.9 
33 
 
Asia-Pacific 
region 
 Asian   34 
Japan   Asian   35 
Benghazi 
(Lybia) 
1981-1990  10-14 
15-19 
1.8 
5.9 
36 
 
 
 
Cincinnati (US) 
 
 
 
1982-1994 
 
 
 
Whites and 
African 
American 
 
 
 
0-19 
Percent of type 2 
DM among new 
cases of DM 
16 
 
 
 
32 
 
Charleston (US) 1997 African 
Americans 
10-19 46 37 
San Antonio 
(US) 
1990-1997 Whites, 
Hispanics 
NA 18 38 
San Diego (US) 1993-1994 All 0-16 8 39 
Ventura (US) 1990-1994 Hispanics 0-17 45  
Little Rock 
(US) 
1988-1995 Whites, 
Hispanics, 
African 
Americans 
0-19 50 cases 40 
Berlin 
(Germany) 
2000-2002 Whites 7-18 5.9% among 102 
subjects studied 
41 
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Clinic-based and register-based studies conducted in the US involving pediatric 
population belonging to other racial minorities as well as Caucasians showed an increase 
in prevalence of type 2 diabetes (32,37-39). Despite studies reporting type 2 diabetes in 
all ethnic groups around the world, certain racial groups are still at a greater risk than 
others. African Americans and Hispanics have higher rates than Caucasians. A study 
exploring type 2 diabetes cases in patients 10-19 years old in Cincinnati, Ohio showed 
that the prevalence increased from 0.7/100,000 in 1982 to 7.2/100,000 in 1994 and 69% 
of all patients with type 2 diabetes were African-American whereas African Americans 
constituted 14.5% of the total population (32). In Arkansas, 74% of children reporting to 
a hospital with type 2 diabetes were African American while only 18% of children with 
type 1 diabetes were African American (40). Similarly more Hispanics children had type 
2 diabetes than white children in California (42). SEARCH for Diabetes in Youth Study 
Group results indicate that incidence rates for adolescents was 19.4% for African 
Americans and 17% for Hispanics whereas the incidence rate was only 5.6% for non-
Hispanic White adolescents (6). Smaller studies reporting prevalence rates in clinical 
practice demonstrated higher rates of type 2 diabetes than the population-based surveys 
like the NHANES (43).  
Data from some of the epidemiological studies conducted in other countries is 
summarized in the table and these studies from around the world indicate that there is an 
increasing incidence of type 2 diabetes in children and adolescents.  In Japan 80% of new 
cases of diabetes were found to be type 2, however the prevalence of the condition type 2 
diabetes in 1995 was found to be 2/100,000 for primary school children and 13.0/100,000 
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among junior high school children, which is a lower than US prevalence (33,35). Several 
European countries – Germany, UK, France, and Italy reported cases of type 2 diabetes 
(30,31,44,45). While some countries reported comparable rates of type 2 diabetes as in 
North American, most of the European countries had lower prevalence comparatively 
(table 1). Also, European Caucasians in US were found to be at a lower risk of type 2 
diabetes than children from other ethnic minorities in the US (46,47). Prevalence rates 
similar to US were reported in India, Bangladesh, Thailand, Singapore and some of the 
Middle Eastern countries like United Arab Emirates (48,49,50).  
Despite a lack of population-based prevalence data for all ethnic groups which 
would provide an estimate of the exact risk of the condition in US, existing studies 
reports the prevalence of type 2 diabetes to be ranging from 1.0 – 50.9/1000 in American 
children and adolescents (2). Based on more recent data from SEARCH trial, an 
estimated 150,000 children and adolescents in the US had diabetes in 2001, and the 
incidence was around 18,000 youth in 2002-2003. Nearly 20% of these cases were type 2 
and ethnic minorities were disproportionately affected (6). These estimates are lower than 
the previously reported statistics (37,39). The incidence of type 2 diabetes is increasing at 
a greater pace and type 2 diabetes cases might exceed type 1 diabetes cases in the future. 
In 1994, type 2 diabetes accounted for nearly 16% of pediatric diabetes cases in urban 
areas (51) and by 1999 clinical practices across US reported 8-45% of new cases as type 
2 depending on geographic location (17). In the next 10 years, the prevalence of type 2 
diabetes among American children is expected to increase and exceed the cases of type 1 
diabetes (52, 53). However, results from the SEARCH I study show that currently type 1 
 12 
still represents majority of the cases with diabetes in children under 10 (11). There are no 
epidemiological studies conducted after the SEARCH study to corroborate this evidence. 
Also SEARCH trial included only people from 6 centers and the estimates might not 
represent the prevalence in other areas in the US with a different distribution of diabetes-
related risk factors. 
Metabolic syndrome raises the risk of type 2 diabetes, in fact it is a late 
consequence of metabolic syndrome (54). Ferranti et al. summarized all the 
epidemiological studies reporting pediatric metabolic syndrome cases and 2% to 18.6% 
depending on the study location and the criterion selected. Though not an exact indicator 
of the prevalence of type 2 diabetes, prevalence of metabolic syndrome reflects the risk 
of type 2 diabetes in the pediatric population (54). Pinhas-Hamiel & Zeitler (2005) 
summarized several epidemiological studies conducted all over the world and they 
observed three distinct patterns in the rise of the type 2 diabetes epidemic (50). Firstly, 
the rise was in three waves with the first wave of reports from the native Americans and 
Canadian first people, second wave in mid 1990s formed by reports mainly from ethnic 
minorities in the US like African Americans and Hispanics, also some Caucasians and 
third wave seen a decade later reported some Europeans children with the condition. 
Second commonality is that pediatric type 2 diabetes rise was associated with adult type 2 
diabetes increase. The third pattern is that the emerging problem of type 2 diabetes in 
children and adolescents also coincides with the trend of childhood obesity in the United 
States (50). Unfortunately the adult type 2 diabetes rates and obesity rates in all age-
groups are still increasing. All these indicators of the risk of type 2 diabetes in the 
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pediatric population show that type 2 diabetes cases in this population will continue to 
rise around the world. 
DISEASE CHARACTERISTICS 
Diabetes Mellitus is a chronic condition characterized by high levels of blood 
glucose caused due to the inability of body to produce or respond appropriately to insulin. 
Etiological classification of diabetes is presented below. 
Type 1 Diabetes - Type 1 diabetes, which is also referred to as insulin dependent 
or juvenile diabetes, is an autoimmune disorder in which the immune cells destroy the 
beta cells of the pancreas that produce insulin, usually resulting in absolute insulin 
deficiency.  The onset of type 1 diabetes is acute and often occurs during childhood, 
therefore commonly found in children or young adults. Signs and symptoms that enable 
classification of a person as type 1 include normal weight, acute onset of polyuria, 
polydipsia, recent weight loss, ketonuria. Type 1 diabetes children are also prone to 
autoimmune disorders like thyroiditis and gluten-induced enteropathy (4). Family history 
of type 1 diabetes is not a common clinical characteristic. However, with increasing 
incidence of obesity, a greater proportion of children with type 1 diabetes are also found 
to be overweight (4,55). Evidence by way of the SEARCH trial also substantiates this 
finding (11). Type 1 diabetes predominantly affects European Caucasians and is less 
common in African Americans, Asians and Native North Americans (4,20). 
Complications of type 1 diabetes include life-threatening conditions like diabetic 
ketoacidosis (DKA) and severe hypoglycemia which lead to hospitalizations/ER visits or 
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mortality in children (9).  People with type 1 diabetes are treated with insulin injections to 
prevent ketoacidosis (56). 
Type 2 Diabetes - Previously considered a disease of the aged, type 2 diabetes is 
now being reported in young adults and children. In 2000, ADA and AAP issued an 
official statement that type 2 diabetes is an increasing concern among children and 
adolescents (57). The statement represents the current knowledge concerning the 
classification and pathophysiology of type 2 diabetes in children and adolescents.  
Type 2 diabetes, also called non-insulin dependent or adult-onset diabetes, is a 
polygenic condition caused by insulin resistance, meaning that the body cannot use 
insulin efficiently. Insulin resistance is characterized by inability of insulin to stimulate 
muscles and adipose tissue to use glucose. Pediatric population presenting with a fasting 
blood glucose >= 126 mg/dL are considered to be diabetic (2,5). The body increases 
insulin production in the initial stages as a response to insulin resistance but eventually 
insulin production decreases causing diabetes. So, by when a person is diagnosed with 
type 2 diabetes, insulin resistance and decrease in insulin production are present. The 
natural progression of type 2 diabetes is depicted in figure 1. 
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Figure 1: Natural History of Type 2 Diabetes (Adapted from 2, 57) 
As opposed to type 1 diabetes, patients with type 2 diabetes are generally 
overweight, have glycosuria without ketonuria, mild or absent polyuria and polydipsia 
and little or no weight loss (55,58).74-100% of children with type 2 diabetes have a first 
or second degree relative with type 2 diabetes. Also, glucose toxicity decreases beta cell 
function and causes ketonuria in type 2 diabetes patients. Some of these common 
symptoms associated with both type 1 and type 2 make it complicated for accurate 
classification of DM. However, it is important to diagnose it appropriately because the 
treatment regimens for managing type 1 and type 2 diabetes differ markedly (59). 
Clinical characteristics of patients presented with both type 1 and type 2 diabetes are 
summarized in table 2. 
  
Disability Complications 
Hypertension 
Hyperlipidemia 
NAFDL 
Death 
Blindness 
Renal failure 
CHD 
Amputation 
Retinopathy 
Nephropathy 
Neuropathy 
Onset of 
diabetes 
Obesity Insulin resistance 
P
R
E 
Comorbidities 
Ongoing hyperglycemia 
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Table 2: Clinical and Exogenous Characteristics of Children with Diabetes 
(4,50,57,60) 
Feature Type 1 Diabetes Type 2 Diabetes 
Pathogenesis 
Autoimmune β-cell 
destruction, insulinopenia 
Insulin resistance plus 
relative insulinopenia 
Polydipsia, polyuria and 
polyphagia 
Yes Mild or absent 
Exacerbation by an acute 
disease 
Yes Yes 
Ketonuria/Diabetes 
ketoacidosis (DKA) 
Yes (DKA 35%-45%) 
Possible (Ketonuria 33% 
Mild DKA – 5%-25%) 
Acanthosis nigricans Rare Common 
PCOS No Common in females 
Vaginal infection Rare Common 
Hypertension No Common 
Dyslipidemia Rare Common 
Autoantibodies Positive Negative 
Recent weight loss Yes No 
Weight at diagnosis Normal, usually all ranges Obese/overweight 
Accidental diagnosis Uncommon Common 
Age of onset 
All ages, mostly young 
children 
Puberty is a strong indicator 
but younger children are 
also being diagnosed 
Gender Female=Male (~1:1) Female>Male (~2:1) 
Family history of the 
specific type of diabetes  
Rare (5-10%) Common (75-90%) 
Mothers with gestational 
diabetes 
Rare Common 
Ethnic group with highest 
prevalence 
Whites 
African Americans, 
Hispanics, Native 
Americans and Asians 
Dependence on insulin Lifelong Episodic 
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Classification of diabetes as type 1 or type 2 is difficult at times with few patients 
presenting with the characteristics of both types of diabetes. This is referred to as type 
1.5, hybrid, mixed or double diabetes (61,62,63). There is an increasing incidence of type 
1.5 diabetes being reported (62,63). Patients with type 1.5 diabetes require lower insulin 
than type 1 and higher insulin than type 2 cases. 
CLINICAL CHARACTERISTICS/ RISK FACTORS OF TYPE 2 DIABETES 
Several social, behavioral, environmental and genetic risk factors have been 
associated with type 2 diabetes in the pediatric population, see figure 2. Children and 
adolescents with type 2 diabetes are generally obese, physically inactive, and have a 
strong family history of type 2 diabetes. Other risk factors also include puberty and 
female gender. Those of non-European ancestry (Americans of African, Hispanic/Latino, 
Asian and American Indian descent) are at particular higher risk (20,46,47). Genetic 
susceptibility is well established in literature (64,65) but there is no known evidence of 
sudden change in genetic patterns that might explain the sudden increase in prevalence of 
type 2 diabetes in children. But other environmental factors like obesity rates and family 
history of type 2 diabetes have been on a rise. 
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Figure 2. Risk Factors for Insulin Resistance/Type 2 Diabetes (Adapted from 13,14) 
Some of the other features of insulin resistance that trigger testing for type 2 
diabetes include acanthosis nigricans, characterized by velvety, hyperpigmented patches 
in intertriginous areas and polycystic ovarian syndrome (PCOS). ADA reported that 90% 
of the young people with type 2 diabetes have acanthosis nigricans (2). PCOS affects 
only females and when adolescents with PCOS were screened, 30% had impaired glucose 
tolerance and 4% had type 2 diabetes. Also, a significant proportion of adolescents with 
type 2 diabetes tend to have metabolic syndrome, which is characterized by a group of 
metabolic abnormalities like obesity, diabetes, dyslipidemia and hypertension (54,66). 
Type 2 diabetes is a late consequence of metabolic syndrome. 
Urakami et al. (2005) studying school-aged children with type 2 diabetes in 
Tokyo found similar clinical characteristics as reported by ADA, more females had type 
2 diabetes and 83.4% of children with diabetes were obese and 56.5% of children had a 
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first or second degree relative with type 2 diabetes (68). Reinehr et al. (2005) found 
conflicting evidence to the commonly reported clinical characteristics. They observed 
that more males than females had type 2 diabetes. Also, none of their patients, which 
comprised of European overweight Caucasian developed acanthosis nigricans (67). 
However, their results could be because of the small sample size and the fact that they 
screened the overweight adolescents as opposed to children in US presenting themselves 
to the physicians due to symptoms associated with diabetes.  
SEARCH trial that followed 6000 children with diabetes reported that study 
participants with type 2 diabetes were likely to be older at diagnosis, obese and have 
acanthosis nigricans (11). Children over age of 10 were more likely to have type 2 
diabetes, especially in minority racial groups. 14.9% of all newly diagnosed type 2 
diabetes cases were over 10 years of age in Whites, 46.1% in Hispanics, 57.8% in 
African Americans and 69.7% in Asian/Pacific Islanders and 86.2% in American Indians 
(6). 60% of African American youth with type 2 diabetes were found to be in the lower 
income bracket (annual income <$25,000) and very more likely to have hypertension and 
dyslipidemia (21). 
Diabetes and Obesity 
Type 2 diabetes epidemic is considered by many to be a direct consequence of the 
obesity epidemic in children. The prevalence rates of obesity have increased from 4.2 and 
4.6% in 1963-1970 to 15.3 and 15.5% in 1999-2000 among US children and adolescents 
in the 6-11 and 12-19 year age groups (69,70).  Among children 6 to 19 years of age in 
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the US, nearly 9 million are considered overweight (18). The 2003-04 National Health 
and Nutrition Survey showed that approximately 17 percent of children ages 2-19 years 
are overweight (71). Sinha et al. (2002) found that 4% of obese children who were 
screened for type 2 diabetes had the condition (71). Urakami et al. (2005) studying 
school-aged children with type 2 diabetes in Tokyo found that 83.4% of children with 
diabetes were obese (68). Obesity like type 2 diabetes disproportionately affects people 
of some ethnic groups. African-American and Hispanic children aged 4-12 years in the 
US showed an increase in overweight prevalence of 22% compared to a 12% increase in 
white Caucasians (70). Another study in the US studying obese pediatric population 
reported that of the 4% prevalence of type 2 diabetes found, all cases were African 
American or Hispanic (71). In UK, Asian children were at a 13.5 times higher risk of 
type 2 diabetes than White children (72). Results from SEARCH I trial showed that of 
research participants with type 2 diabetes, 100% of blacks, 95% of whites and 91% of 
Hispanics were overweight (11).  
CO-MORBIDITIES 
Hypertension, dyslipidemia and nonalcoholic fatty liver disease (NAFLD) are the 
most common comorbidities found in children and adolescents with type 2 diabetes. 
Patients with type 1 diabetes are not known to be at a similar risk for having these 
comorbidities. Hypertension was found in 32% among 50 adolescents with type 2 
diabetes in Arkansas (40).  Hypertension increase the risk of nephropathy, retinopathy 
and cardiovascular disease in type 2 diabetes. Therefore, hypertension diagnosis and 
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management is a critical component of diabetes care and ADA recommends checking 
blood pressure during every visit (2,59). Hypertension treatment first starts with lifestyle 
modification like diet, exercise and weight reduction and failure to achieve required 
blood pressure prompts pharmaceutical intervention. Guidelines recommend the use of 
ACEI or ARBs in sight of the cardiovascular and renal benefits offered by these drugs in 
type 2 diabetes patients. In a review of dyslipidemia in children and adolescents, Pinhas-
Hamiel & Zeitler (2007) found that 18% to 61% of patients had dyslipidemia at diagnosis 
(73). In SEARCH, a multicenter study exploring adolescents with diabetes, lipid 
abnormalities were found to be more common in type 2 diabetes patients compared to 
type 1 (74). The study also reported that only 1% of adolescents received 
pharmacological treatment for managing dyslipidemia. Recent data from SEARCH trial 
indicate that 57% of the pediatric population with type 2 diabetes has LDL-c levels 
greater than 100 mg/dL and only 5% received lipid lowering medications (75). ADA 
recommends lipid testing every two years and if lipid abnormalities exist, 
pharmacological treatment with statins is recommended in children over 10 years of age 
if diet modifications and glycemic control cannot help achieve recommended lipid levels 
(2,59). However, there are no studies exploring the outcome associated with 
pharmacological management of dyslipidemia and hypertension among children. Maahs 
et al. (2008) reviewed the current evidence and recommendation for dyslipidemia 
treatment among youth with diabetes. They suggest that there is a need for studies 
exploring costs and effectiveness and for consistent recommendations regarding the 
management of dyslipidemia in youth with diabetes (76). 
 22 
NAFLD is characterized by lipid overload in the liver. In patients with ANFDL, 
liver enzymes like aspartate aminotransferase and alanine aminotransferase are elevated 
twofold to fivefold (66). In a sample of 39 patients with type 2 diabetes at the Children‟s 
hospital in San Diego, 23% and 8% of children and adolescents with type 2 diabetes had 
twice and three times the normal amount of liver enzymes (77). NAFDL may progress to 
chronic liver disease with fibrosis and cirrhosis. NAFDL treatment involves managing 
obesity and glycemic levels. Depression is also reported to be one of the commonly 
found comorbid conditions among type 2 diabetes children (78). 
Type 2 DM and Metabolic Syndrome 
Type 2 diabetes is often found to be a consequence of a much broader disorder 
called the metabolic syndrome. Metabolic syndrome is characterized by a cluster of 
cardiovascular risk factors (hypertension, obesity, dyslipidemia and microalbuminuria) 
along with glucose intolerance (type 2 diabetes, impaired glucose tolerance or insulin 
resistance) (56). World Health Organization (WHO) defines metabolic syndrome as a 
combination of any 1 glucose tolerance conditions along with any two if the 
cardiovascular risk factors which places these patients at a higher risk for cardiovascular 
mortality and morbidity (79). In sight of this multi-component disorder underlying type 2 
diabetes, aggressive treatment regimen targeting hyperglycemia as well as the other 
cardiovascular risk factors is recommended (56). 
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COMPLICATIONS 
Due to its chronic nature, children and adolescent with type 2 diabetes may have 
significant complications over a patient‟s lifetime. In adult population, secondary 
comorbidities associated with both type 1 and type 2 diabetes pose serious challenges 
concerning morbidity and mortality and increase the economic burden associated with the 
condition. Diagnoses at such a young age increase the risk for children and adolescents to 
develop these debilitating complications. While it is too early to determine the full impact 
of the disease, complications will reduce the quality of life for these children and 
significantly increase the health care cost to society.  
The following section summarizes the several complications associated with type 
2 diabetes as microvascular/macrovascular complications and acute/chronic 
complications. 
Macrovascular and Microvascular complications 
The largest trial of type 2 diabetes in adults was the United Kingdom Prospective 
Diabetes Study (UKPDS). Results from UKPDS suggest that type 2 diabetes is a 
progressive disease with beta-cell functions declining overtime and the complications 
from diabetes increasing with time.
 
Macrovascular complications, such as cardiovascular 
disorders, are time-dependent, thus developing over many years (80). 
 
Due to early 
diagnosis, it is almost certain that children and adolescents with type 2 diabetes will 
develop macrovascular complications earlier in life. Recent studies observed 
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complications associated with diabetes in children and adolescents (73,81). Pinhas-
Hamiel & Zeitler (2007) conducted an extensive review on complications associated with 
type 2 diabetes and found that microvascular and macrovascular complications are 
observed in the pediatric patients even at the time of diagnosis (73). Diabetes damages 
blood vessels and leads to vascular complications in patients with both type 1 and type 2 
diabetes. Microvascular diabetic complications include retinopathy, nephropathy and 
neuropathy and macrovascular complications found in diabetic patients include coronary 
artery disease, stroke, and peripheral vascular disease among others. Early onset of type 2 
diabetes was shown to be associated with an equal risk of developing complications as 
seen in the adult population. Also the rate of progression toward complications is higher 
than children and adolescents with type 1 diabetes (73). 
Acute and Chronic Complications 
This section enlists diabetic complications classified based on their acute or 
chronic nature. Acute complications associated with diabetes pose short-term risk in these 
patients and are usually life-threatening. Chronic complications in these patients are 
rather common despite existing management strategies that can potentially avoid these 
complications. 
Acute complications – Diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar 
state and malignant hyperthermia-like syndrome with rhabdomylosis are some of the 
acute complications of type 2 diabetes (73).  DKA and hyperosmolar coma are rare but 
the risk of mortality associated with these conditions is huge. Children presenting with 
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these complications are referred to specialized tertiary pediatric diabetes centers (82). 
SEARCH trial reported that 9.7% of patients with type 2 diabetes presented themselves 
with DKA at the time of diagnosis (9). There are no existing studies reporting the 
morbidity and mortality associated with these conditions in children and adolescents. 
Chronic complications – The long-term complications and natural course of type 
2 diabetes in children and adolescents is still unknown. Chronic complications of type 2 
diabetes result mainly from non-adherence to treatment. Some studies reported poor 
adherence to diabetes care and treatment in adolescents with type 2 diabetes (83,84). 
Apart from these complications, type 2 diabetes is also associated with comorbidities like 
hypertension, dyslipidemia and nonalcoholic fatty liver disease. Poor adherence to 
medical care might result in complications like nephropathy, retinopathy, neuropathy, 
cardiovascular and atherosclerotic complications, and psychiatric disorders among others. 
Rate of progression of hypertension and microalbuminuria is rapid in adolescents with 
type 2 diabetes. Hotu et al. (2004) found that 28% and 42% of adolescents developed 
hypertension and microalbuminuria respectively within 4 years after diagnosis of type 2 
diabetes (81). Compared to adolescents with type 1 diabetes, type 2 diabetes patients 
develop complications quicker. Hypertension, microalbuminuria/nephropathy risk is 
higher in type 2 diabetes adolescents whereas there is conflicting evidence about which 
type of diabetes poses a greater risk of retinopathy (73). Levitt Katz et al.., (2005) 
reported that nearly 20% of children and adolescents presented with type 2 diabetes had 
some sort of psychiatric disorder (85). 
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Health-related quality of life in children and adolescents with type 2 diabetes was 
found to be lower than patients with type 1 diabetes and those without any diabetes (86). 
The ADA and ACP recommended that practitioners monitor the complications of type 2 
diabetes in children and adolescents. Monitoring recommendations include dilated eye 
examination, screening for microalbuminuria and foot examination. Such examinations 
should be performed at least yearly. A patient‟s blood pressure and lipid levels should 
also be checked periodically, although no specific timeframe was given (57). 
MANAGEMENT OF TYPE 2 DIABETES IN CHILDREN AND ADOLESCENTS 
Type 2 diabetes in children and adolescents is a relatively new phenomenon, its 
proper diagnosis, treatment, and prevention has not been well established. There is little 
evidence to support optimal strategies for management of type 2 diabetes in children and 
adolescents. There are no specific outcomes trials reported and it is doubtful whether it is 
ethical even to design and conduct such a trial (2).
 
However, a wealth of knowledge 
exists for type 1 diabetes in children and about type 2 diabetes in adults, thus making 
extrapolation to type 2 diabetic children and adolescents possible.   
In the year 2000, prompted by the epidemic of type 2 diabetes in children and 
adolescents, the American Diabetes Association (ADA) and the American Academy of 
Pediatrics (AAP) issued a joint consensus statement on type 2 diabetes in youth (2,57). 
The statement provides recommendations to prevent, test, and treat this costly and serious 
disease in youth.  In 2003, AAP updated the guidelines for prevention and treatment of 
type 2 diabetes in children (52).  
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The clinical presentation of type 2 diabetes in children and adolescents forms a 
wide spectrum from incidental diagnosis to severe clinical symptoms (2). As noted above 
(see disease characteristics), children with both type 1 and type 2 diabetes exhibit same 
symptoms and sometimes the diagnosis of type 2 diabetes in children is not easy to 
distinguish from type 1 or other types of diabetes. However, it is important to diagnose 
the right type of diabetes because the course of management is different for different 
types. Figure 3 outlines the recommended algorithm for management of type 2 diabetes 
in children and adolescents. 
In practice, pediatric patients with type 2 diabetes are treated similar to adults 
with the condition because the treatment goals in type 2 diabetes are targeted at reducing 
blood glucose and HbA1c levels regardless of the patients‟ age. For asymptomatic or 
mildly symptomatic children, dietary management and lifestyle changes is considered 
first. Successful treatment of type 2 diabetes is characterized by controlling weight gain 
and fasting blood glucose levels <126mg/dL and HbA1c < 7% (2). If treatment goals are 
not met (HbA1c < 7% and fasting plasma glucose (FPG) < 7.0 mmol/L), pharmacologic 
intervention is indicated (2). The preferred first-line oral agent is metformin, which is 
approved by the United Stated Food and Drug Administration (FDA) for use in children 
(13,52,58).
 
A multicenter controlled clinical trial demonstrated that metformin 200 
mg/day (in addition to standard dietary therapy
 
and exercise), improves glycemic control 
in children
 
with type 2 diabetes within two weeks after initiation
 
of therapy (87). The 
improvement with metformin was similar to that of adults. The U.S. Food and Drug 
Administration (FDA) also approved the use of insulin to treat children with type 2 
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diabetes (2). 
 
In some circumstances, insulin may be the only feasible way of controlling 
diabetes (as noted in the figure). Other medications that may be considered in the 
management of type 2 diabetes in children and adolescents include sulphonylureas, 
thiazolidinediones, meglitidine, or glucosidase inhibitors. A recent clinical trial shows 
that glimepiride reduced HbA1c similarly to metformin in the treatment of pediatric type 
2 diabetes; but glimepiride resulted in greater weight gain (88).  
Monotherapy with oral agents is ineffective in most patients on the long run (89). 
Results of UKPDS suggest that nearly half of the patients on sulphonylurea alone at study 
inception required an additional drug in 6 years (89). All the aforementioned oral agents 
for managing type 2 diabetes have different mechanisms of action and target different 
defects in the pathophysiology of the condition and can be used to complement each 
other when monotherapy fails (89).  
As discussed previously, in response to insulin resistance body starts producing 
more insulin and eventually beta-cell deterioration progresses to the point where insulin 
production is decreased permanently. UKPDS demonstrated that this process takes nearly 
6-10 years following an early diagnosis of type 2 diabetes. So, insulin therapy is initiated 
early in the course of treatment to prevent the deterioration of metabolic control (90). 
Other cases in which permanent insulin therapy is indicated include failure of oral agents 
to maintain HbA1c < 7%, when oral therapy isn‟t tolerated and if the patient has 
congestive heart failure (90). Sometime insulin therapy is administered temporarily like 
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in cases of pregnancy, steroid therapy, ESRD, acute MI, sepsis, hypotension among 
others (90). It is important to note that not all patients with an insulin claim have diabetes. 
Apart from appropriate glycemic control, it is extremely important to aggressively 
manage the comorbidities and complications associated with diabetes. AAP and ADA 
provide recommendations for management of dyslipidemia, hypertension, 
microalbuminuria and retinopathy along with glycemic control (see comorbidities and 
complications) (2,52,82). Apart from pharmaceutical interventions, ADA recommends 
annual eye and foot examinations in children with diabetes (2,59). 
There is limited evidence to demonstrate adherence to management of diabetes 
care recommendations laid out by ADA and AAP. A 2-year observational study 
following 129 pediatric patients in specialized diabetes centers in Germany found that 
dyslipidemia and hypertension were not managed as recommended (91). Valent et al. 
(2009) examined 56 charts of adolescents with type 2 diabetes in Ohio and found that 
only 55% patients achieved HbA1c goals and adherence to recommendations was poor 
for all measures - testing glycemic levels, lipid levels, microalbuminuria, and eye and 
foot exams (92).   
The presence of type 2 diabetes in children and adolescents affects both the 
children and their families. Though it‟s vital that this epidemic of type 2 diabetes in 
children and adolescents be adequately addressed by healthcare professionals and 
government agencies, parents should be active in the treatment and monitoring process in 
order to minimize the potential devastating effects of this disease. 
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Figure 3: Management of Type 2 Diabetes (52,58) 
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ECONOMIC BURDEN 
Overall, the cost of diabetes (both type 1 and type 2) for US was nearly $174 
billion in 2007. Direct medical costs of diabetes were estimated to be $116 billion and the 
indirect costs associated with lost productivity due to disability, work loss and premature 
mortality formed the other $58 billion. Undiagnosed diabetes and pre-diabetes cases cost 
an additional $43 billion (93). The study estimated that medical expenditures for people 
with diabetes were 2.3 times greater than the expenditures for people without diabetes 
after adjusting for age and sex. Numerous studies have evaluated the cost of diabetes in 
the adult population from different perspectives (94-98). Studies exploring healthcare 
service utilization of adults with diabetes are also abundant (99-101). However, there are 
limited studies evaluating costs and service utilization among pediatric population with 
either type 1 or type 2 diabetes and there is no evidence of the demand and economic 
impact of pediatric type 2 diabetes on the health care system. Recent studies reporting 
increase in cases of type 2 diabetes in children and adolescents all over the world are 
indicative of the fact that the demand and cost of medical care also increased in this 
population. This study explores the direct medical costs and medical service utilization 
associated with diabetes from Mississippi Medicaid perspective and stratifies the costs by 
type of diabetes. Comparisons were made with other prevalent pediatric conditions like 
asthma and ADHD. Estimates for a random sample of all pediatric patients enrolled in 
Mississippi Medicaid without diabetes are also provided. 
One of the few studies exploring service utilization by Lee et al. (2008) explored 
trends in diabetes related hospitalizations using hospital discharge data in population less 
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than 30 years of age between 1994 and 2003. They found a 48% increase in diabetes 
related hospitalizations in the 20-29 year cohort but there were no statistically significant 
differences in the <20 population (102). Diabetes-related hospitalization charges were 
reported to have increased from $1.05 billion in 1993 to $2.42 billion in 2004 (103% 
increase). However, the study did not differentiate between the types of diabetes and 
included young adults. Another study reported that diabetes related discharges doubled 
from 1.43% in 1979 to 2.30% two decades after for US Americans between ages 6 and 17 
years using National Hospital discharge survey data (103). This study only included 
diabetes discharges associated with obesity and no costs were reported.  
Certain social factors are associated with higher health-care utilization in the 
pediatric population with diabetes. Shatin et al. (1998) compared healthcare utilization by 
children enrolled in Medicaid managed care versus employer-insured managed care 
across 5 different chronic illnesses. They found that more children in Medicaid have 
chronic conditions and were more likely to use ER, outpatient services, laboratory 
services and radiography services compared to children with the other insurance type 
(104). Another study by Keenan, Foster and Bratton (2009) showed that children with 
type 1 diabetes hospitalized for DKA or diabetic coma had longer length of stay if they 
were of non-white race, had Medicaid insurance, and lived in areas of poverty (1). 
As opposed to type 2 diabetes management in adults and the elderly, management 
in the pediatric population poses a greater burden to the family and caregivers in terms of 
health and economic outcomes (105). A study reported that 17% of families with a child 
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with diabetes had out-of-pocket expenses > 10% of their household income (106) 
However, we are not assessing indirect costs associated with the condition in this study. 
Total medical costs of diabetes stem from the cost of managing the condition and the 
associated complications. Though the chronic complications of diabetes are a 
consequence of mismanagement of the glycemic levels and associated comorbidities and 
occur much later in life, some acute complications are reported from the time of 
diagnosis. Most children with type 2 diabetes present themselves with acute 
complications like DKA which require hospitalization or ER admission, making it an 
expensive condition to manage right from the time of diagnosis (107). SEARCH team 
reported that of the 507 patients with type 2 diabetes, 26% and 8% were diagnosed at the 
hospital and ER respectively (9). Also, a study reported that, of children aged 8-13 years 
who were diagnosed with diabetes, 25% were rehospitalized within the next 2.5 years 
(108). Literature on other types of medical services like ER use, diagnostic test use, 
physician service use is limited in pediatric population with diabetes, type 2 diabetes 
specifically. However, studies show that the overall use of resources measured as 
physician office visits, inpatient admissions among the children from low income 
families increases when enrolled in Medicaid (104,109,110).  
Overall, better estimates of cost and demand of medical care by pediatric 
population with type 2 diabetes and diabetes in general is required. Also, children with 
Medicaid insurance are shown to receive less preventative services and more ER visits 
and hospitalizations (111-113) and a lack of effective management of diabetes is known 
to result in life-threatening complications. Therefore it is important to examine medical 
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services use and cost of diabetes from Medicaid‟s perspective and evaluate what patient 
characteristics drive these factors.  
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CHAPTER III – RESEARCH METHODOLOGY 
Data Source 
The Mississippi Medicaid claims data for the period January 2002 through 
December 2004 were used for this study. This data was made available to the Center for 
Pharmaceutical Marketing and Management, The University of Mississippi for research 
purposes. Medicaid eligibility file, pharmacy claims file, medical claims file and inpatient 
claims file will be used in the study. The components of each of the files are enlisted 
below: 
1. Eligibility file: Person-level file with demographic information and 
eligibility periods for the beneficiaries. 
2. Pharmacy claims file: Event level file with information on prescription 
dispensed, amount paid, quantity dispensed, prescription date, prescribing physician. 
3. Medical claims file: Event level file with information on the outpatient 
facility visits (physician office, ER), diagnoses, amount paid, and provider type. 
4. Inpatient claims file: Event level file with information on the admission 
and discharge dates, diagnoses, amount paid. 
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A. EPIDEMIOLOGY OF DIABETES 
The study aim was to estimate the prevalence and incidence of type 2 diabetes 
among Mississippi‟s children and adolescents covered by Medicaid. Overall estimates 
and estimates stratified by age, gender, and race/ethnicity were calculated. Estimates for 
type 1 diabetes along with the estimates for the cohort with unknown diabetes were also 
computed. Prevalence was estimated for the years 2002, 2003 and 2004 and incidence 
during the years 2003 and 2004. 
Study Design  
 A retrospective analysis of Mississippi Medicaid administrative claims data for 
the years 2002 – 2004. Children and adolescents with diabetes were identified using ICD-
9 codes - 250.XX, 357.2, 362.01,02, 366.41, 648.0X or DRG codes 294, 295 from 
hospital and physician visit claims in combination with drug use in prescription claims as 
described in patient selection (see below). Patients were flagged as having type 2 
diabetes, type 1 diabetes or unknown diabetes type based on the inclusion criteria 
described below. 
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Figure 4: Graphical Representation of the Study Period for Assessing Prevalence 
and Incidence 
Patient Selection 
Type 2 diabetes pediatric patients were identified using the following criteria - (a) 
Primary diagnosis for type 2 diabetes (ICD-9-CM = 250.0x-250.9x, where x = 0 or 2) 
(114) recorded in the medical or inpatient claims file during a specific year (2002-2004) 
or (b) At least two paid claims for an oral anti-diabetic medication in the same year for all 
Medicaid beneficiaries 19 years or younger by the end of each year with continuous 
enrollment in Medicaid for at least 11 months of each year during the observation period. 
Pediatric patients with type 1 diabetes were identified using the following criteria - 
Primary diagnosis for type 1 diabetes (ICD9-CM= 250.0x-250.9x, where x = 1) recorded 
in the medical or inpatient claims file during the period for all Medicaid beneficiaries 19 
years or younger by the end of each year with continuous enrollment in Medicaid for at 
least 11 months of each year during the observation period. When patients had claims 
related to both type 1 and type 2 diabetes, proportion of claims related to each diabetes 
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type was assessed and if more than 80% of the claims were for a specific diabetes type, 
then patients were assigned to that particular diabetes type cohort. Patients who could not 
be identified as type 1 or type 2 were grouped into a third category, called unknown 
diabetes. Age as of December 31
st
 of each year (2002-2004) was determined for each 
patient and stratified into 0-12 years and 13-19 years age groups. Race/ethnicity as 
reported in the beneficiary eligibility file was initially categorized into 5 groups - Non-
Hispanic whites, African Americans, Hispanics, Asian and Pacific Islanders and Native 
Americans. However, based on the frequency distribution of race/ethnicity in this 
population, we regrouped race into African American, Non-Hispanic whites and others. 
Gender and geographical region stratified as delta/non-delta were also used in the 
analysis. Institutionalized population is not usually included in prevalence and incidence 
estimations, so patients were not identified from long-term facilities. 
Assessment of Prevalence 
 Numerator for analysis includes all eligible cases with type 2 diabetes prevalent 
in 2002, 2003 and 2004 that met the inclusion criteria to be in the study population. The 
denominator for calculation of prevalence included all children under the age of 19 years 
in Mississippi Medicaid for each year of prevalence estimation. The prevalence of type 2 
diabetes for each year (2002-2004) is expressed as cases per 1,000 children and 
adolescents. The 95% confidence intervals (CIs) was calculated using an inverted score 
test from the binomial distribution. For age, gender and race/ethnicity specific prevalence 
estimates, patients with type 2 diabetes were grouped to the respective age, gender and 
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racial cohorts for the numerator and the respective cohorts for the denominator were 
derived. Prevalence for all 3 years for other types of diabetes was calculated similarly.  
Assessment of Incidence 
Numerator for analysis includes all new cases of type 2 diabetes incident in 2003 
and 2004 that met the inclusion criteria to be in the study population. New cases were 
defined as those children and adolescents who were identified to be diabetic in the current 
year with no claims for diabetes in the previous years, but continuous enrollment in 
Medicaid. The denominator for calculation of incidence includes all children under the 
age of 19 years in Mississippi Medicaid for the two years of incidence estimation. The 
Incidence of type 2 diabetes for 2003 and 2004 is expressed as cases per 100,000 children 
and adolescents. The 95% confidence intervals (CIs) were calculated using an inverted 
score test from the binomial distribution. For age, gender and race/ethnicity specific 
incidence estimates, patients with type 2 diabetes were grouped into the respective age, 
gender and racial cohorts for the numerator and the respective cohorts for the 
denominator were derived. Incidence for the two study years and other types of diabetes 
were calculated similarly.  
Clinical Characteristics 
Clinical risk factors, comorbidities and complications of children with all diabetes 
types were also assessed. Children with diabetes during the three study years were pooled 
to form the study sample. Children were categorized into the three diabetes type cohorts 
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using the inclusion criterion described earlier. Demographic information was obtained 
from the beneficiary file and clinical characteristics were identified by matching ICD-9 
codes for the conditions with the inpatient and medical claims files. Statistical testing 
across sub-groups was conducted using χ2 tests. All statistical analysis was performed 
using SAS version 9.2 (SAS Institute Inc, Cary, NC). IRB approval was obtained for this 
study. 
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B. MANAGEMENT OF TYPE 2 DIABETES (QUALITY OF CARE) 
The study proposed to evaluate the current patterns in management of 
comorbidities associated with the condition and the condition itself among children with 
type 2 diabetes in an attempt to assess the quality of care provided to these children. This 
part of the study does not provide quality of care assessment of children with type 1 
diabetes because the management protocol is different for children with type 1 diabetes, 
making comparisons unnecessary. 
Study Design 
A longitudinal retrospective cohort study was conducted using Mississippi 
Medicaid administrative claims data for the years 2002 – 2004. Considering few children 
have type 2 diabetes, different timelines were used to assess the various components 
studied so as to maximize the sample size for analysis. Type 2 diabetes children were 
identified from January 1, 2002 through January 1, 2004 for assessing medication use and 
adherence. An „index date‟ defined as the date on which the patient was flagged as 
having type 2 diabetes was assigned to each patient.  Patient‟s drug use was observed for 
six months following the index date and patients were flagged as users if they had a 
prescription fill for any OHG. For assessing the predictors of OHG adherence, we only 
need six months post their medication use date to assess if a patient is adhering to OHGs.  
Similar time line was used for assessing utilization of other medications (figure 5).  
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Figure 5: Graphical Representation of the Study Period for Predictors of 
Medication Use 
For examining the relationship between medication use category and outcomes, 
children and adolescents with type 2 diabetes were identified using the patient selection 
criteria (see below) during the period January 1, 2002 through June 30, 2003. Patient‟s 
medication use was observed for six months following the index date (figure 6). 
Outcomes were measured for one year following the medication use measurement period.  
For observing compliance with annual screenings children and adolescents with 
type 2 diabetes were identified during the first two study years, 2002 and 2003 because a 
one-year follow up post index date is required. 
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Index Date 
Medication Use Identification 
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Jun 2004 
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Figure 6: Graphical Representation of the Study Period for Measuring Association 
between Medication Use and Outcomes 
Patient Selection 
Type 2 diabetes pediatric patients were identified using the following criteria - (a) 
Primary diagnosis for type 2 diabetes (ICD-9-CM = 250.0x-250.9x, where x = 0 or 2) 
(114) recorded in the medical or inpatient claims file during the patient identification 
period or (b) At least two paid claims for an oral anti-diabetic medication in this period 
for all Medicaid beneficiaries 19 years or younger by the end of the study period with 
continuous enrollment in Medicaid for at least 11 months of each year during the three 
study years.  
2005 2004 2003 2002 
Patient Identification 
Period 
 
Jun 2003 
May 2003 Jan 2003 
Medication Use Assessment 
Perio  
Index Date 
Outcome 
Measurement Period 
May 2004 
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Assessment of Pharmaceutical Use 
Children with type 2 diabetes are managed with or without pharmaceutical 
therapy. As a result, medication use in this population was described but we did not 
attempt to establish a relationship between medication use/non-use and outcomes. 
However, children who are using medications are required to be adherent to the 
medications to realize the full benefit of the therapy, as a result we calculated adherence 
to medications among these children and assessed the relationship between medication 
use (categorized into three groups as non-adherent users, adherent users and non-users) 
and outcomes. Patient‟s utilization of the three classes of guideline-recommended 
pharmaceuticals, namely, hypoglycemic agents (oral hypoglycemics (APPENDIX A) and 
insulin); anti- hypertension medications (ACEI, β-blockers, Calcium channel blockers, 
diuretics, α-blockers, angiotensin-renin blockers, and centrally-acting agents) and anti-
hyperlipidemic drugs (statins, fibrates, nicotinic acid, and bile acid sequestrants) was 
examined. In patients with any use of the three classes of medications, adherence rate was 
computed for each of three classes of medication as ((number of days with medication 
during the medication use measurement period/365)*100) and relationship between 
medication use category and outcomes was studied (115). Medication use was identified 
by matching the drug claims in pharmacy claims file with National Drug Codes (NDC) of 
the three drug classes obtained from the Multum drug database. Adherence to insulin was 
not computed due to the complexities associated with measuring adherence to injectables 
in general and due to the lack of data in Medicaid claims to even approximately measure 
adherence to insulin. 
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Assessment of Annual Screenings 
Quality of care was also measured by assessing if the patients received the 
recommended annual eye examinations, lipid profile and nephropathy screening. HbA1c 
test is recommended every three months in these patients (2). The diagnostic 
examinations were identified by matching the diagnostic procedure codes in the patient‟s 
medical claims file with the CPT codes for the four recommended procedures listed in 
APPENDIX C. Patients receiving recommended care were hypothesized to have fewer 
hospitalizations and better health outcomes. 
Outcomes 
The primary outcome assessed in the study was the number of diabetes-related 
hospitalizations. Diabetes-related hospitalizations in the outcome measurement period 
were defined as any hospitalization with the primary diagnosis of 250.xx, 357.2, 362.0x, 
366.41, 648.0 OR hospitalizations with primary diagnosis for lipid disorder, 
hypertension, ketonuria, ketoacidosis, hypoglycemia, renal disorder, and, retinopathy 
with a secondary diagnosis of diabetes. All-cause hospitalizations and all-cause mortality 
were also examined. All-cause hospitalizations are defined as any hospitalization 
regardless of the primary diagnosis during the outcome measurement period. All-cause 
mortality is mortality for any cause during the same period. 
Economic outcomes included in the study are diabetes-related and all-cause total 
medical costs accrued by the patients with type 2 diabetes. Costs were measured from 
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Medicaid perspective and do not include patient copayments and deductibles. Total 
health care costs include costs for outpatient services, ER, hospitalization services and 
prescription drug costs. Diabetes-related medical costs were costs associated with 
treatment of type 2 DM, i.e., costs associated with claims where the primary diagnosis is 
type 2 DM or any of the associated comorbidities like lipid disorder, hypertension, 
ketonuria, ketoacidosis, hypoglycemia, renal disorder, and, retinopathy with a secondary 
diagnosis of diabetes. A detailed description of the various costs associated with diabetes 
is presented in the costs and utilization section. All-cause medical costs are any costs 
associated with the patients during the outcome measurement period.  
Data Analysis 
Frequency distributions, means and standard deviations are used to describe the 
characteristics of the study population like the sociodemographics, adherence rates and 
quality of care received. Patients who did and did not receive medications were compared 
for several characteristics. Similar comparisons were made for patients receiving the four 
annual examinations and those not receiving these examinations. Unadjusted differences 
in outcomes across the different groups were tested using ANOVA or t-tests for 
continuous variables and the χ2 test for dichotomous variables. Predictors of medication 
use were assessed using a logistic regression model. A P value of <0.05 was indicative of 
statistical significance. 
Diabetes-related hospitalization and all-cause hospitalization are count variables 
and are usually associated with the issue of outliers resulting from an extremely skewed 
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distribution. The economic outcomes being modeled in the study also have a skewed 
distribution. Considering the very small sample sizes and extremely skewed distributions, 
we did not analyze the relationships between the medication use and outcomes. Only 
descriptive statistics are provided. All analyses were conducted using SAS statistical 
software, version 9.2 (SAS Institute Inc, Cary, NC). IRB approval was obtained for this 
study. CMS approval was obtained to use the data for this project (DUA: 21087). 
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C. ANNUAL EXPENDITURES AND SERVICE UTILIZATION  
Annual expenditure and utilization of services for managing children with type 2 
diabetes were computed and compared with the children without diabetes, children with 
type 1 diabetes, children with asthma and children with ADHD 
Study Design 
The study design was a retrospective cohort design. This study compared a cohort 
of pediatric population with type 2 diabetes with those having type 1 diabetes, unknown 
diabetes, children without diabetes, those with asthma and ADHD in terms of their 
healthcare utilization and costs. The date on which a patient is identified as eligible for 
any of the aforementioned mutually exclusive cohorts between January 1
st
, 2002 and 
December 31
st
, 2003 is termed as the index date and the costs and utilization will be 
computed for each patient for one year following the index date (figure 7).  
 
 
 
 
 
Figure 7: Graphical Representation of the Study Period for Assessing Resource 
Utilization and Expenditures 
2005 2004 2003 2002 
Jun 2003 Jun 2002 
Expenditure and Utilization Outcome 
Measurement 
Index Date 
Patient Identification 
Period 
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Patient Selection 
Type 2 diabetes pediatric patients were identified using the following criteria - (a) 
Primary diagnosis for type 2 diabetes (ICD-9-CM = 250.0x-250.9x, where x = 0 or 2) 
(114) recorded in the medical or inpatient claims file during the period January 1, 2002 
through December 31, 2003 or (b) At least two paid claims for an oral anti-diabetic 
medication in the pharmacy claims file during this period for all Medicaid beneficiaries 
19 years or younger by the end of the study period, with continuous enrollment in 
Medicaid for at least 11 months of each study year. NDC codes for oral hypoglycemics, 
listed in APPENDIX A are obtained from Multum drug database.  
Type 1 diabetes pediatric patients were identified using the following criteria - 
Primary diagnosis for type 1 diabetes (ICD9-CM= 250.0x-250.9x, where x = 1) recorded 
in the medical or inpatient claims file during the period January 1, 2002 through 
December 31, 2003 for all Medicaid beneficiaries 19 years or younger by the end of the 
study period with continuous enrollment in Medicaid for at least 11 months of each year 
during the three study years. When patients had claims related to both type 1 and type 2 
diabetes, proportion of diabetes type related claims was assessed for either diabetes type 
and if more than 80% of the claims were for a specific diabetes type, then patients were 
considered to have that particular diabetes type. Patients who could not be identified as 
type 1 or type 2 were grouped into a third category, called unknown diabetes. 
Pediatric population with asthma were identified using ICD-9 code for asthma 
(493.XX), ADHD cases were identified if they had claims with ADHD ICD-9 code (314-
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314.9) in the medical and inpatient file. Similar to diabetes cases, index date was set to 
the patient identification date. All pediatric beneficiaries enrolled in Mississippi Medicaid 
during the first two study years with at least 12 months post eligibility of which they were 
continuously enrolled for at least 11 months formed the other comparative cohort. The 
date on which the patient had the first claim in either medical, inpatient or prescription 
record was considered the index date for this cohort.  
Since comparisons are being made with children with diabetes, children with 
diabetes were excluded from all three non-diabetes groups. Considering the three 
comparator groups had relatively larger cell sizes, we also created a random sample of 
1000 patients from these groups for sensitivity analysis.  
Assessment of costs and utilization of medical care 
Resource utilization and expenditure variables associated with physician visits, 
non-physician visits, other office-based visits, ER visits, hospitalizations, outpatient 
hospital visits and prescription fills are the main outcomes for this component of the 
study. Considering the study population is children, other services like nursing and home 
health were not included. A detailed description of each component is provided in the 
following section. Utilization variables were measured as counts of unique claims related 
to the specific service category during the outcome measurement period. Expenditures 
were measured by summing all the costs associated with claims belonging to each service 
type. Medicaid payer perspective was considered for calculating costs.  
 51 
Resource Utilization 
Physician/Non-Physician/Other Office-Based Visits 
All-cause visits: Physician/non-physician/other office visits in the outcome 
measurement period were initially defined as physician-related/non-physician related and 
all other office visits in the medical claims file regardless of the primary diagnosis  
Diabetes-specific visits:  Physician/non-physician/other office visits in the 
outcome measurement period were defined as any physician-related/non-physician 
related and all other office visit with the primary diagnosis of 250.xx, 357.2, 362.0x, 
366.41, 648.0 OR assess if the physician-related/non-physician related and all other office 
visit is associated with a primary diagnosis for lipid disorder, hypertension, ketonuria, 
ketoacidosis, hypoglycemia, renal disorder, retinopathy, eye examination, foot 
examination, and patient counseling for diabetes (ICD-9 code for dietary surveillance and 
counseling is V65.3) with secondary diagnosis for diabetes. 
Emergency Room (ER) Visits 
All-cause ER admissions: ER visit in the outcome measurement period was 
defined as any ER admission regardless of the primary diagnosis.  
Diabetes-specific ER admissions:  ER visit in the outcome measurement period 
was defined as any ER admission with the primary diagnosis of 250.xx, 357.2, 362.0x, 
366.41, 648.0 or ER visits with a primary diagnosis for  lipid disorder, hypertension, 
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ketonuria, ketoacidosis, hypoglycemia, renal disorder, and, retinopathy with a secondary 
diagnosis for diabetes. 
Outpatient Hospital Visits 
All-cause outpatient hospital admissions: Outpatient hospital visit in the outcome 
measurement period was defined as any outpatient hospital visit regardless of the primary 
diagnosis.  
Diabetes-specific outpatient hospital admissions:  Outpatient hospital visit in the 
outcome measurement period was defined as any outpatient hospital visit with the 
primary diagnosis of 250.xx, 357.2, 362.0x, 366.41, 648.0 or Outpatient hospital visit 
with a primary diagnosis for  lipid disorder, hypertension, ketonuria, ketoacidosis, 
hypoglycemia, renal disorder, and, retinopathy with a secondary diagnosis for diabetes. 
Other outpatient services  
All-cause visits: Visits in the outcome measurement period in the medical claims 
file which are not categorized as physician/non-physician/other office visits, outpatient 
hospital visits or ER visits were initially defined as other outpatient visits regardless of 
the primary diagnosis. 
Diabetes-specific visits:  Outpatient visits in the outcome measurement period 
which are not categorized as physician/non-physician/other office visits, outpatient 
hospital visits or ER visits with the primary diagnosis of 250.xx, 357.2, 362.0x, 366.41, 
648.0 or visits with primary diagnosis of lipid disorder, hypertension, ketonuria, 
 53 
ketoacidosis, hypoglycemia, renal disorder, retinopathy, eye examination, foot 
examination, and patient counseling for diabetes (ICD-9 code for dietary surveillance and 
counseling is V65.3) were defined as diabetes-related outpatient visits, with a secondary 
diagnosis of diabetes. 
Hospitalizations 
All-cause hospitalizations: Hospitalization in the outcome measurement period 
was initially defined as any hospitalization regardless of the primary diagnosis. Length of 
stay was also assessed. 
Diabetes-specific hospitalizations:  Hospitalizations in the outcome measurement 
period was defined as any hospitalization with the primary diagnosis of 250.xx, 357.2, 
362.0x, 366.41, 648.0 OR hospitalizations with primary diagnosis of lipid disorder, 
hypertension, ketonuria, ketoacidosis, hypoglycemia, renal disorder, and, retinopathy, 
with a secondary diagnosis of diabetes.  
Prescribed medications 
All medication fills: Number of all prescription fills in the outcome measurement 
period in the pharmacy claims file. Number of pharmacy visits was also computed. 
Diabetes-specific medication fills:  Number of prescriptions for diabetes related 
medications, including oral hypoglycemics, antihypertensive medications and 
hyperlipidemic medications. 
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Costs 
 The costs were calculated by summing the Medicaid cost category amount in the 
respective claims file for children and adolescents in all cohorts. Eight discrete cost 
categories shall be considered for the study, similar to the utilization classification 
discussed previously – physician services, non-physician service provider, other office-
based services, outpatient hospital, ER, hospitalizations, other outpatient services and 
medications. Though diabetes-related costs were computed for quality of care section of 
the study, we did not estimate diabetes-related costs in this section because as discussed 
we intend to compare costs of children with diabetes and children without diabetes, 
children with asthma and ADHD. All costs are reported in US dollars.  
Once a claim is identified as belonging to one of the eight aforementioned service 
categories, they were flagged accordingly and costs associated with diabetes claims were 
summed to compute the diabetes-specific costs for each service category for each patient. 
To calculate the all-cause expenditures, costs incurred by the patients for any service 
obtained during the year in each service category were summed. Hospitalization costs 
were obtained from the inpatient claims file, physician, ER and other outpatient costs 
were obtained from medical claims file and medication expenditures were obtained from 
the pharmacy claims file. Also, expenditures were summed across categories and total 
medical costs and total diabetes-related medical costs were included as outcomes in the 
analysis. 
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Independent Variables 
1. Age: The current epidemiological patterns show that children have very 
low prevalence of type 2 DM compared to adolescents, so we used children less than or 
equal to 12 and teens (13-19 years of age) to dichotomize age. 
2. Gender: Male or Female. 
3. Race/ethnicity: Five major racial and ethnic groups were considered -, 
Hispanics, Asian and Pacific Islanders, Native Americans and Others. Based on the 
frequency distribution of race/ethnicity in our population. We regrouped race/ethnicity to 
three categories - Non-Hispanic whites, African Americans, and other races. 
4. Charlson‟s comorbidity index was computed for each patient. 
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Statistical Analysis 
Frequency distributions, means and standard deviations were used to describe the 
characteristics of the study population. Unadjusted differences in costs and utilization 
across all the cohorts – children with type 1, type 2, unknown diabetes and those without 
diabetes, children with asthma, and children with ADHD were assessed using ANOVA 
for continuous variables. Categorical data was examined using χ2 test. Costs and 
utilization were also adjusted for demographics and comorbidities and the associations 
between the patient category and outcomes were modeled. All count variables are usually 
associated with the issue of outliers resulting from an extremely skewed distribution. The 
economic outcomes being modeled in the study also have a skewed distribution. Based 
on the distribution of the data observed, Poisson regression (for count data), generalized 
linear model with gamma distribution and log link (for cost data) were used to model the 
outcomes. All-cause mortality was modeled using logistic regression. Models were 
adjusted for the independent variables described above. All analyses were conducted 
using SAS statistical software, version 9.2 (SAS Institute Inc, Cary, NC). IRB approval 
was obtained for this study. CMS approval was obtained to use the data for this project 
(DUA: 21087). 
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CHAPTER IV - RESULTS 
 
A. EPIDEMIOLOGY 
There were 606,736 pediatric beneficiaries enrolled in Mississippi Medicaid across 
the three study years, 2002-2004. Of these, 2964 children and adolescents under the age 
of 18 years had diabetes. Epidemiology estimates for diabetes, overall and by diabetes 
type, for these children as a whole and stratified by age, gender and race are presented in 
the following section. Of the 2964 children with diabetes, claims were available for 2393 
children for a period of at least one year. Risk factors, demographic characteristics, 
comorbidities and complications are also reported for these children. 
Prevalence of diabetes 
Among children and adolescents under the age of 18, enrolled in Mississippi 
Medicaid, 2964 pediatric beneficiaries were identified as having diabetes mellitus. Of 
these, 1171 young beneficiaries had diabetes in 2002, with 441 type 1 and 550 type 2 
prevalent cases. 192 patients could not be classified as type 1 or type 2 diabetes because 
they had claims associated with both type 1 and type 2 diagnoses. In 2003, 493 pediatric 
beneficiaries with type 1, 865 with type 2 and 205 with unknown diabetes were enrolled 
in Mississippi Medicaid. By the year 2004, 1933 young beneficiaries were known to have 
diabetes mellitus with 523, 1191 and 226 type 1, type 2 and unclassified diabetes cases 
respectively. As the prevalence estimates categorized by age, race and gender had a 
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consistent trend across all three study years, only 2002 prevalence estimates will be 
elaborated on for the sake of brevity. However, prevalence estimates and 95% CIs of 
diabetes for all three study years, classified by age-groups, race and gender are presented 
in table 3.  
The prevalence of type 1 diabetes (1.52/1000) was higher for females (1.69/1000), as 
opposed to males (1.36/1000). The prevalence of type 2 diabetes for all children and 
adolescents <18 years of age was 1.90/1000. The differences in prevalence by gender 
were more pronounced in type 2 diabetes, wherein the prevalence in females of 
2.25/1000 was significantly higher compared to prevalence in males of 1.55/1000. 
Prevalence of both type 1 and type 2 diabetes was higher for adolescents (age >=13 
years) compared to children <=12 years of age. Type 2 diabetes prevalence was 
significantly higher for adolescents (4.53/1000) compared to children (1.17/1000) and 
type 1 diabetes prevalence was only slightly higher for adolescents (2.66/1000) as 
opposed to children less than 12 years of age (1.21/1000). Prevalence of both type 1 and 
type 2 diabetes was higher for white Americans compared to African Americans in all 
study years but the differences in prevalence in type 2 diabetes by race narrowed in the 
subsequent years (2003 and 2004). 
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Table 3: Prevalence of Diabetes Mellitus 
Year/DM Type Diabetes Mellitus Type 1 Diabetes Type 2 Diabetes Unknown  
 Estimate* (95% CI) 
2002 4.04 (3.81 - 4.28) 1.52 (1.39 - 1.67) 1.90 (1.75 - 2.06) 0.66 (0.58 – 0.76) 
Sex     
Female 4.78 (4.43 - 5.15) 1.69 (1.49 - 1.92) 2.25 (2.02 - 2.51) 0.89 (0.75 - 1.06) 
Male 3.30 (3.02 - 3.61) 1.36 (1.18 - 1.56) 1.55 (1.37 - 1.77) 0.42 (0.33 - 0.54) 
Age Group     
<=12 years 2.63 (2.43 - 2.85) 1.21 (1.07 - 1.36) 1.17 (1.03 - 1.32) 0.29 (0.22 - 0.36) 
>=13 years 9.13 (8.42 - 9.90) 2.66 (2.28 - 3.09) 4.53 (4.04 - 5.09) 2.02 (1.70 - 2.40) 
Race     
White 4.48 (4.03 - 4.97) 2.10 (1.81 - 2.45) 2.02 (1.72 - 2.35) 0.36 (0.25 - 0.52) 
Black 3.69 (3.43 - 3.97) 1.23 (1.09 - 1.40) 1.79 (1.62 - 1.99) 0.71 (0.60 - 0.84) 
Other 6.26 (5.13 – 7.63) 2.22 (1.59 - 3.09) 2.61 (1.92 - 3.55) 1.56 (1.05 - 2.33) 
2003 5.43 (5.17 - 5.71) 1.73 (1.58 - 1.89) 3.03 (2.83 - 3.23) 0.72 (0.63 - 0.82) 
Sex     
Female 6.38 (5.98 - 6.81) 1.99 (1.77 - 2.24) 3.52 (3.22 - 3.84) 0.92 (0.78 - 1.10) 
Male 4.48 (4.15 - 4.84) 1.47 (1.29 - 1.69) 2.53 (2.28 - 2.80) 0.50 (0.40 - 0.63) 
Age Group     
<=12 years 3.40 (3.17 - 3.65) 1.25 (1.11 - 1.41) 1.88 (1.71 - 2.07) 0.30 (0.24 - 0.38) 
>=13 years 12.38 (11.56 – 13.27) 3.36 (2.94 - 3.83) 6.94 (6.33 - 7.61) 2.15 (1.82 - 2.54) 
Race     
White 5.98 (5.47 - 6.55) 2.35 (2.03 - 2.71) 3.10 (2.73 - 3.51) 0.55 (0.41 - 0.74) 
Black 4.93 (4.63 - 5.26) 1.40 (1.24 - 1.58) 2.86 (2.63 - 3.11) 0.71 (0.60 - 0.84) 
Other 8.97 (7.59 - 10.60) 2.70 (1.99 - 3.67) 4.75 (3.77 - 5.98) 1.65 (1.12 - 2.43) 
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2004 6.35 (6.07 - 6.63) 1.72 (1.58 - 1.87) 3.91 (3.69 - 4.14) 0.74 (0.65 - 0.85) 
Sex     
Female 7.45 (7.02 - 7.90) 2.02 (1.80 - 2.26) 4.51 (4.18 - 4.86) 0.95 (0.81 - 1.12) 
Male 5.50 (5.14 - 5.88) 1.48 (1.30 - 1.69) 3.46 (3.18 - 3.78) 0.56 (0.45 - 0.70) 
Age Group     
<=12 years 4.19 (3.94 - 4.46) 1.29 (1.16 - 1.45) 2.65 (2.45 - 2.87) 0.26 (0.21 - 0.34) 
>=13 years 13.49 (12.67 - 14.37) 3.12 (2.73 - 3.56) 8.09 (7.46 - 8.78) 2.32 (2.00 - 2.71) 
Race     
White 6.97 (6.44 - 7.55) 2.28 (1.98 - 2.62) 4.14 (3.73 - 4.59) 0.55 (0.41 - 0.73) 
Black 5.94 (5.61 - 6.29) 1.44 (1.29 - 1.62) 3.76 (3.50 - 4.04) 0.78 (0.66 - 0.91) 
Other 7.47 (6.44 - 8.66) 1.94 (1.45 - 2.60) 4.36 (3.59 - 5.29) 1.17 (0.80 - 1.70) 
*prevalence is expressed per 1000 children and adolescents 
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Incidence of diabetes 
Incidence estimates and the 95% CI of diabetes mellitus among Mississippi 
Medicaid children and adolescents aged <= 18 years are presented in table 4. Incidence 
estimates for both type 1 and type 2 diabetes stratified by age groups, gender and race are 
reported for 2003 and 2004. There were 915 incident cases of diabetes mellitus during 
2003 and 2004 with a majority of cases being type 2 diabetes. A total of 445 new cases of 
diabetes mellitus were diagnosed in year 2003, resulting in an incidence of 15.56 new 
cases per 10,000 children and adolescents. Among them, 77, 330 and 38 cases were 
type1, type 2 and unknown diabetes respectively. In 2004, there were 470 new cases of 
diabetes, translating to an incidence of 15.43/10,000, consistent with the incidence for 
2003. Of these, 376 were type 2 diabetes cases and 62 eligible beneficiaries had type 1 
diabetes and diabetes type was unknown for 33 cases. 
In 2003, the incidence of type 1 diabetes among females (3.17/10,000) was 
slightly greater than in male subjects (2.23/10,000).  There was a similar trend in 2004, 
with type 1 diabetes incidence being 2.42/10,000 for female subjects and 1.74/10,000 for 
males. The gender effect was much more pronounced in type 2 diabetes with incidence 
among females (13.61/10,000) being significantly higher than in males (9.49/10,000). 
Adolescents had higher incidence of type 1 and type 2 diabetes compared to children in 
both 2003 and 2004. However, of the new adolescent diabetes cases, the majority were 
type 2. For instance, in 2003, incidence of type 1 diabetes for adolescents was 
4.79/10,000 and the incidence of type 2 diabetes among adolescents was nearly five times 
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higher at 25.51/10,000. Race had a varying effect on incidence of type 1 and type 2 
diabetes during both study years. In 2003, incidence of type 1 diabetes for white race 
(3.32/10,000) was higher than the incidence of type 1 diabetes among African Americans 
(2.23/10,000), but African Americans (11.80/10,000) had a significantly higher incidence 
of type 2 diabetes compared to white subjects (9.44/10,000). A similar trend was 
observed in 2004. 
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Table 4: Incidence of Diabetes Mellitus  
Year/DM Type Diabetes Mellitus Type 1 Diabetes Type 2 Diabetes Unknown 
 Estimate* (95% CI) 
2003 15.56 (14.18 - 17.08) 2.69 (2.16 - 3.37) 11.54 (10.36 - 12.85) 1.33 (0.97 - 1.82) 
Sex     
Female 18.62 (16.51 - 21.01) 3.17 (2.37 - 4.25) 13.61 (11.83 - 15.67) 1.83 (1.25 - 2.69) 
Male 12.56 (10.86 - 14.54) 2.23 (1.58 - 3.15) 9.49 (8.03 - 11.23) 0.84 (0.48 - 1.46) 
Age Group     
<=12 years 10.49 (9.22 - 11.92) 2.08 (1.56 - 2.77) 7.46 (6.40 - 8.68) 0.95 (0.62 - 1.45) 
>=13 years 32.93 (28.80 - 37.65) 4.79 (3.38 - 6.80) 25.51 (21.91 - 29.71) 2.63 (1.64 - 4.21) 
Race     
White 14.16 (11.76 - 17.05) 3.32 (2.26 - 4.86) 9.44 (7.52 - 11.85) 1.40 (0.78 - 2.51) 
Black 15.18 (13.53 - 17.02) 2.23 (1.66 - 3.01) 11.80 (10.36 - 13.44) 1.14 (0.76 - 1.73) 
Other 27.70 (20.50 - 37.42) 5.28 (2.67 - 10.41) 19.13 (13.32 - 27.46) 3.30 (1.41 - 7.72) 
2004 15.43 (14.10 - 16.89) 2.04 (1.59 - 2.61) 12.34 (11.16 - 13.66) 1.08 (0.77 - 1.52) 
Sex     
Female 18.12 (16.08 - 20.41) 2.42 (1.75 - 3.34) 14.43 (12.62 - 16.49) 1.34 (0.87 - 2.07) 
Male 13.38 (11.65 - 15.36) 1.74 (1.19 - 2.55) 10.77 (9.23 - 12.56) 0.87 (0.51 - 1.49) 
Age Group     
<=12 years 11.32 (10.04 - 12.77) 2.05 (1.55 - 2.72) 8.76 (7.64 - 10.04) 0.56 (0.33 - 0.95) 
>=13 years 29.05 (25.34 - 33.30) 1.98 (1.18 - 3.33) 24.23 (20.87 - 28.14) 2.83 (1.84 - 4.38) 
Race     
White 15.91 (13.45 - 18.81) 2.69 (1.79 - 4.04) 12.63 (10.47 - 15.25) 0.58 (0.25 - 1.37) 
Black 14.85 (13.24 - 16.66) 1.68 (1.20 - 2.37) 11.99 (10.56 - 13.63) 1.22 (0.82 - 1.82) 
Other 18.56 (13.78 - 24.99) 2.59 (1.19 - 5.65) 14.24 (10.14 - 20.00) 1.73 (0.67 - 4.44) 
*incidence is expressed per 10,000 children and adolescents 
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Demographic and Clinical Characteristics 
Demographic and clinical characteristics of the 2393 children and adolescents 
with diabetes who were enrolled in Mississippi Medicaid for at least one year during the 
three study years are presented in table 5. Overall, children older than 13 years of age, of 
African American race, female gender were identified as having diabetes. Only 27% of 
children and adolescents were found to be having type 1 diabetes. The majority of type 1 
diabetes cases were children aged 12 years or younger. On the contrary, of the 61% 
patients identified as having type 2 diabetes, majority were greater than or equal to 13 
years of age. Both type 1 and type 2 diabetes was most commonly found in African 
Americans and females. Three-fourth of the children with diabetes were from non-delta 
region. Interesting geographic pattern emerged when we compared the proportion of type 
1 and type 2 cases suggesting a higher prevalence of type 2 diabetes in the delta region 
compared to the non-delta section. While the proportion of type 1 diabetes cases was 7 
times higher in the non-delta region compared to the delta region, proportion of children 
with type 2 diabetes in the non-delta area was only two times higher than in the delta 
region.  
The risk factors among type 1 diabetes and type 2 diabetes were found to be as 
expected. Compared to children with type 1 diabetes, more children and adolescents with 
type 2 diabetes had obesity, acanthosis nigricans and polycystic ovarian syndrome. Also, 
as expected abnormal weight loss was seen in more children with type 1 diabetes 
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compared to those with a diagnosis of type 2 diabetes. Patients with unknown diabetes 
had a risk profile similar to type 2 diabetes. 
The most common diabetes-related comorbidities found among children and 
adolescents with diabetes include hypertension (6.44%), dyslipidemia (3.30%), 
depression (2.21%) and vaginitis (4.47%, among females). Hypertension, dyslipidemia, 
metabolic syndrome and vaginitis was found more commonly in type 2 diabetes children 
than in type 1 cases. Type 1 diabetes children were more likely to have depression. CCI 
and total number of chronic comorbidities were not different among the different diabetes 
types. 
Considering the patient population is young, chronic complications of diabetes are 
rare among these patients, however, acute complications of diabetes are observed. 
Hypoglycemia and diabetes ketoacidosis are the most common acute complications, with 
a prevalence of 4.26% and 1.76% respectively. Type 1 diabetes children were found to be 
more likely to have both complications. Renal disease was the most common chronic 
complication found in children with diabetes.   
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Table 5: Demographics and Clinical Characteristics of Children with Diabetes 
Variable/DM Type 
Diabetes 
Mellitus 
Type 1 
Diabetes 
Type 2 
Diabetes 
Unknown 
Diabetes 
 
% of Unique Subjects  27.08% 60.72% 12.20%  
 N= 2393; µ or % p-value 
Age Group     <0.0001 
<=12 Years 43.5 55.2 42.3 24.0  
>=13 Years 56.5 44.8 57.7 76.0  
Race     <0.0001 
White 30.8 39.5 29.3 19.2  
Black 60.7 52.6 62.6 69.2  
Other 8.4 7.9 8.1 11.6  
Sex     0.0208 
Female 57.8 55.6 57.5 64.4  
Male 41.8 44.3 42.1 34.6  
Region     <0.0001 
Delta 25.2 12.6 31.2 23.9  
Non-Delta 74.8 87.4 68.8 76.1  
Clinical Risk Factors      
Obesity/ Morbid Obesity/ 
Abnormal Weight Gain 
10.36 3.70 12.25 15.75 <0.0001 
Acanthosis Nigricans 1.38 0.00 2.00 1.37 0.0014 
Polycystic Ovarian Syndrome* 0.65 0.00 0.96 0.53 0.1642 
Abnormal Weight Loss 1.30 2.62 0.76 1.03 0.0020 
Comorbidities      
Diabetes-Related Comorbidities      
Hypertension 6.44 3.70 6.47 12.33 <0.0001 
Dyslipidemia 3.30 2.47 3.17 5.82 0.0260 
Metabolic Syndrome 0.71 0.15 0.76 1.71 0.0296 
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Depression 2.21 2.31 1.79 4.11 0.0477 
Vaginitis* 4.77 2.22 5.74 5.32 0.0301 
Polydipsia/ Polyphagia 0.54 0.46 0.62 0.34 0.7981 
Polyuria 0.67 0.46 0.89 0.00 0.1741 
Glycosuria 0.46 0.62 0.21 1.37 0.0216 
Total Comorbidities      
CCI 0.34 0.32 0.35 0.39 0.3668 
Total Chronic Comorbidities 0.29 0.26 0.30 0.30 0.3412 
Acute Complications      
Diabetes Ketoacidosis 1.76 3.24 0.21 6.16 <0.0001 
Ketonuria 0.25 0.46 0.07 0.68 0.0710 
Hypoglycemia 4.26 5.56 3.37 5.82 0.0271 
Proteinuria      
Chronic Complications      
Congestive Heart Failure 0.21 0.15 0.28 0.00 0.6032 
Myocardial Infarction 0.04 0.00 0.07 0.00 0.7235 
Renal Disease/ Chronic Kidney 
Disease 
1.63 2.16 0.89 4.11 0.0002 
Retinopathy 0.42 0.77 0.00 1.71 0.4388 
Neuropathy 0.54 0.46 0.21 2.40 <0.0001 
Lower Extremity Amputations 0.21 0.31 0.07 0.68 0.0885 
*denominator is females 
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B. ASSESSMENT OF QUALITY OF CARE 
Pharmaceutical use and guideline recommended annual screenings among 
children and adolescents identified as having type 2 diabetes and eligible for at least 11 
months in a year during the study period are presented in the following section. Use of, 
and adherence to oral hypoglycemic medications (OHGs) is addressed, followed by a 
brief discussion of the use of antihypertensive medications. Patient characteristics are not 
reported for antihyperlipidemics because only 15 patients were found to be using these 
medications. Following this, outcomes of OHG use are reported. Compliance with 
recommended screenings like HbA1C test, annual eye examination, lipid profile and 
nephropathy testing among Medicaid pediatric beneficiaries with diabetes is presented. 
Oral Hypoglycemic Medications 
After applying the inclusion criterion of having at least six months follow-up 
period after being identified as having type 2 diabetes, 915 children and adolescents were 
included in the study.  Of these, 215 children (23.5%) were found to be using oral 
hypoglycemic medications.   64.0%, 26.8% and 9.2% of the patients were African 
American, White and other races respectively and 56.2% were female. For OHGs to be 
effective, patients using them should be adherent to these medications. Among the 215 
pediatric beneficiaries using OHGs, only 58 children and adolescents (27%) are adherent 
to these medications, characterized as proportion of days covered (PDC) greater than or 
equal to 0.80. Characteristics of the pediatric patients with type 2 diabetes using oral 
hypoglycemic are presented in table 6. 
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Predictors of utilization of OHGs 
In unadjusted analysis, pediatric beneficiaries aged 13 years and older, of female 
gender, and African American race were more likely to be using OHGs, as seen in table 
6. In the multivariable analysis, adjusting for all other predictors, OHG use was found to 
be significantly higher among females, adolescents 13 years and older and those with 
lower CCI (table 7). Females were 50% more likely to be using oral hypoglycemic 
compared to males (OR = 1.50, 95% CI: 1.07 – 2.09), after adjusting for other 
demographics and CCI. Multivariable results are presented in table 7. The effect of race 
was not significant after adjusting for other variables. However, age is a significant 
predictor of oral hypoglycemic use with children less than 12 years of age 55% less likely 
to be using OHGs compared to those 13 years of age and older. This is not surprising, 
considering children only use medications upon progression of disease that is not 
managed by diet and exercise. 
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Table 6. Characteristics of the Patient Population Using OHGs 
Patient Characteristics  
OHG Use  (n=915) 
p 
Yes No 
% of unique subjects  23.5% 76.5% 
 
Sex  
Male  33.0% 47.1% 
0.0003 
Female  67.0% 52.9% 
Age, mean (SD), yr  12.04 (3.31) 8.70 (5.06) < 0.0001 
Age  
<=12 years 48.4% 69.1% 
< 0.0001 
>=13 years 51.6% 30.9% 
Race  
White  27.9% 26.4% 
0.7292 Black  64.2% 64.0% 
Other  7.9% 9.6% 
CCI, mean (SD)  0.25 (0.54) 0.42 (0.80) 0.0048 
Total Comorbidities 0.23 (0.47) 0.36 (0.61) 0.0036 
 
Table 7. Adjusted Multivariable Analysis of Predictors of OHG Use 
Patient Characteristics* Adjusted OR (95% CI)  p 
Sex  
Male  - 
 
Female  1.50 (1.07 – 2.09) 0.0172 
Age  
<=12 years 0.45 (0.33 – 0.62) < 0.0001 
>=13 years - 
 
Race  
White  - 
 
Black  0.95 (0.66 – 1.36) 0.9378 
Other  0.93 (0.50 – 1.73) 0.8702 
CCI, mean (SD)  0.70 (0.54 – 0.91) 0.0088 
* Each variable in the model was adjusted for the other factors in the table 
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Adherence to OHG medications 
Among OHG users, only 58 pediatric beneficiaries with type 2 diabetes were 
found to be adherent to OHGs after applying the inclusion criterion. Considering the very 
small sample size, only patient characteristics and unadjusted associations among 
predictors and adherence to OHGs are presented in table 8. None of the demographic 
characteristics were found to be significant predictors of adherence to OHGs. 
Table 8. Characteristics of the Patient Population Adherent to OHGs 
Patient Characteristics  
OHG Adherence  (n=215) 
p 
Yes No 
% of unique subjects  27.0% 73.0% 
 
Sex  
Male  39.7% 30.6% 
0.2088 
Female  60.3% 69.4% 
Age, mean (SD), yr  11.81 (3.61) 12.13 (3.21) 0.5348 
Age  
<=12 years 48.3% 48.4% 
0.9863 
>=13 years 51.7% 51.6% 
Race  
White  34.5% 25.5% 
0.2426 Black  55.2% 67.5% 
Other  10.3% 7.0% 
CCI, mean (SD)  0.28 (0.45) 0.24 (0.57) 0.6846 
Total Comorbidities 0.28 (0.45) 0.22 (0.47) 0.4083 
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Utilization of Antihypertensive Medications 
Children and adolescents with type 2 diabetes are recommended to use 
antihypertensive and anti-hyperlipidemic medications to avoid chronic complications. Of 
the 915 type 2 diabetes pediatric beneficiaries, 83 patients (9%) use antihypertensive 
medications and there are very few antihyperlipidemic medication users (<1%). 
Characteristics of type 2 diabetes children using antihypertensive medications are 
presented in table 9.  
Table 9. Characteristics of the Patient Population Using Antihypertensive Medications 
Patient Characteristics  
Antihypertensive Medication Use  
(n=915) P 
Yes No 
% of unique benes  9.1% 90.9% 
 
Sex  
Male  36.1% 44.6% 
0.1392 
Female  63.9% 55.4% 
Age, mean (SD), yr  12.50 (3.89) 9.18 (4.91) <0.0001 
Age  
<=12 years 36.1% 67.1% <0.0001 
 >=13 years 63.9% 32.9% 
Race  
White  30.1% 26.4% 
0.0778 Black  67.5% 63.7% 
Other  2.4% 9.9% 
CCI, mean (SD)  0.60 (1.23) 0.35 (0.68) 0.0040 
Total Comorbidities 0.49 (0.85) 0.32 (0.55) 0.0083 
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Nearly 64% of antihypertensive medication users were aged 13 years or older and 
the average age of these patients was 12.5 years, which is higher than the average age of 
non-users which is 9.2 years. Race and gender weren‟t significant predictors of 
antihypertensive use. Also, children using antihypertensive medications had a greater 
CCI than non-users. The characteristics of antihypertensive medication users that were 
found to be significant predictors of utilization in the multivariable analysis are age and 
comorbidity score, consistent with the descriptive in table 9.  Of the 83 pediatric 
beneficiaries using antihypertensive medications, only 22 (26.5%) were adherent. 
Outcomes of OHG Use 
To accommodate for the measurement of drug utilization followed by outcomes, 
patient identification period was restricted to the first one and half years of the study 
period i.e., January 1, 2002 through June 30, 2003. A total of 438 patients were identified 
as having type 2 diabetes of which 66.4% were non-users of OHG medications and of the 
remaining users, 8.0% were adherent to OHGs and 25.6% used OHGs but were not 
adherent. Approximately 28% of these patients were white, 63% African American and 
8.5% of the patients belong to other racial groups. 56% of the patients eligible for the 
study were female and a majority (61%) were less than or equal to 12 years of age. A 
summary of patients‟ demographic characteristics and utilization measures for the three 
groups are presented in table 10. Two types of outcomes were measured, hospitalizations 
(both diabetes related and overall hospitalizations) and economic outcomes. 
Multivariable logistic regression was used to analyze the relationship between 
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hospitalization, measured as a dichotomous variable, and the demographic and clinical 
predictors. 
Association between OHG Use and Hospitalizations 
Overall, 50 patients (11.4%) had hospitalizations in the follow-up period. Twenty-
eight (9.6% of all non-users), 19 (17.0% of all non-adherent users) and 3 (8.6% of all 
adherent users) of the 50 hospitalizations were associated with non-users, non-adherent 
users and adherent users respectively.  Only 8 diabetes-related hospitalizations were 
observed. Considering the very small sample size, associations between OHG use and 
outcomes were not assessed.  
Association between OHG Use and Healthcare Costs 
All-cause and diabetes-related hospitalization, prescription medication, all other 
service and total costs were assessed for patients in all three categories of OHG use. 
Children and adolescents adherent to OHGs had higher overall costs and significantly 
higher diabetes-related costs compared to both non-adherent users and non-users of oral 
hypoglycemics. This is possibly a reflection of their overall health status or diabetes 
progression. OHG use indicates that these patients have a more severe case of type 2 
diabetes that could not be managed by diet and exercise, as compared to the non-users. 
As expected diabetes-related prescription costs were the highest for adherent users and 
total prescription costs were also higher in this group indicating a poorer health in these 
children. Average total prescription cost for adherent users was $3379, which is 
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approximately double the cost of non-adherent users ($1570). Non-users of OHGs 
however incurred almost the same total prescription cost as non-adherent users of OHG. 
On the contrary, hospitalization costs were the least for adherent OHG users at $482 
compared to non-adherent users ($1272) and non-users ($858). Diabetes-related 
hospitalization cost was also higher for non-adherent users compared to adherent users. 
Ambulatory service costs for all-causes were almost similar across the three groups, but 
diabetes-related ambulatory costs were the highest for adherent users and significantly 
lower for non-users of OHGs. There were no statistically significant differences in case 
of all-cause costs, while the cost differences were statistically significant across all 
diabetes-related cost groups. Though multivariable analysis was proposed, considering 
the small sample size, associations between the OHG user groups and cost categories, 
controlling for patient demographic and clinical characteristics were not analyzed. 
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Table 10. Descriptive Results of Medication Use and Outcomes 
Patient Characteristics  
OHG Use  (n=438) 
p 
Adherent Users Non-adherent Users Non Users 
% of unique benes  8.0% 25.6% 66.4% 
 
Sex  
Male  37.1% 26.8% 50.9% <0.0001 
 Female  62.9% 73.2% 49.1% 
Age, mean (SD), yr  12.66 (3.22) 12.00 (3.27) 8.97 (5.17) < 0.001 
Age  
<=12 years 37.1% 53.6% 67.4% 0.0003 
 >=13 years 62.9% 46.4% 32.7% 
Race  
White  31.4% 23.2% 29.6% 
0.6446 
 
Black  57.1% 68.8% 62.2% 
Other  11.4% 8.0% 8.2% 
CCI, mean (SD)  0.34 (0.54) 0.21 (0.56) 0.41 (0.82) 0.0687 
Total Comorbidities 0.34 (0.54) 0.19 (0.44) 0.36 (0.62) 0.0286 
Outcome: Hospitalizations 
All-Cause 8.6% 17.0% 9.6% 0.0995 
Diabetes-Related* 2.9% 5.4% 0.3% 0.0031 
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Outcome: Costs 
All-Cause Hospitalization 482.46 (1547.29) 1272.29 (3064.61) 857.96 (3107.88) 0.3025 
Diabetes-Related 
Hospitalization  
198.97 (820.03) 366.00 (1188.97) 
5.58 (95.26) 
<0.0001 
Total Prescription  3379.17 (4686.76) 1570.15 (1879.13) 1451.05 (3953.41) 0.0119 
Diabetes-related Prescription 583.71 (552.79) 456.14 (765.47) 60.43 (302.49) <0.0001 
Total Ambulatory 2701.43 (3607.91) 2785.32 (3177.74) 2612.24 (6562.63) 0.9624 
Diabetes-Related Ambulatory 754.40 (1224.98) 654.35 (1162.43) 73.82 (223.07) <0.0001 
Total All-Cause 6563.06 (8023.75) 5627.77 (6128.71) 4921.25 (11697.02) 0.6017 
Total Diabetes-Related 1537.09 (2311.05) 1476.49 (2310.87) 139.84 (499.00) <0.0001 
*very small cell size. Chi-square test may not be appropriate. 
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Annual Screenings 
Since, a one-year follow up period is required to observe compliance with annual 
screening, only 582 pediatric beneficiaries with type 2 diabetes were included. 40.4%, 
21.5%, 11.0% and 4.0% of these patients received at least one eye examination, HbA1c 
test, lipid profile and nephropathy test in a year. Patients are recommended HbA1c test 
every three months, meaning 4 or at least 3 in a year, but only 17 of the 582 patients 
(2.9%) complied with this recommendation. Overall, only 12 patients, i.e., 2.1% of the 
patients received at least three of the four tests during the follow-up year. Average age of 
these patients was 12.6 years, 92% were female and 75% were African-Americans. 
Table 11 presents the characteristics of the patients with and without the four 
annual screenings (eye, HbA1C, lipid and nephropathy) during the study year. Of the 
children receiving annual eye examination, there were significant differences in sex and 
age compared to those that did not receive eye exams. Children receiving an eye exam 
were on an average 2 years older than those not receiving it. There were no differences 
across the racial groups. Majority of the pediatric patients receiving an eye exam were 
female, black and the average age was 11 years. When predictors of receiving an eye 
examination were assessed using a multivariable regression model, none of the predictors 
were found to be significant after controlling for the other variables in the model. 
Children are recommended HbA1c tests every 3 months. However, of the 21.5% 
pediatric beneficiaries who received an HbA1c during the year, only 17 children received 
the test at least 3 times in the year. Children complying with the recommendation were an 
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average age of 12 years, mainly female and black. Average age of these children was 
significantly higher than the children not receiving HbA1c tests and none of the other 
demographic factors were different across the groups. Multivariable regression was not 
conducted due to a small sample size. 
Similar to the results above, children and adolescents who were screened for their 
lipid levels were significantly different from those who did not receive an exam across 
their age and gender. Patients on whom lipid tests were conducted were mostly female 
(73.4%) and their mean age was 12 years. In adjusted analysis, females were 100% more 
likely to receive a lipid screening compared to males after controlling for age, race and 
comorbidity score. Also, children less than or equal to 12 years of age were 44% less 
likely to be screened for lipid compared to those children 13 years and older. Likewise, 
nephropathy tests were conducted more often in females (78.3%) than males and these 
patients were, on average, one year older than those that were not screened. Multivariable 
regression was not conducted in this group due to the problem of micronumerosity. 
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Table 11. Characteristics of the Patient Population Receiving Guideline Recommended Annual Screenings 
Patient 
Characteristics  
Eye Exam  (n=582) 
P 
HbA1c Tests  (n=582) 
p Yes No Yes No 
% of unique benes  40.4% 59.6% 2.9% 97.1% 
Sex  
Male  38.7% 47.3% 
0.0416 
35.3% 44.1% 
0.4724 
Female  61.3% 52.7% 64.7% 55.9% 
Age, mean (SD), yr  10.98 (3.87) 8.82 (5.41) <0.0001 12.12 (2.37) 9.62 (5.00) 0.0409 
Age  
<=12 years 58.3% 66.0% 
0.0593 
52.9% 63.2% 
0.3890 
>=13 years 41.7% 34.0% 47.1% 36.8% 
Race  
White  24.7% 27.7% 
0.7176 
29.4% 26.4% 
0.4233 Black  66.0% 63.7% 70.6% 64.4% 
Other  9.4% 8.6% 0.0% 9.2% 
CCI, mean (SD)  0.36 (0.73) 0.35 (0.81) 0.8785 0.41 (0.62) 0.35 (0.79) 0.7644 
Total Comorbidities 0.32 (0.58) 0.31 (0.62) 0.8109 0.41 (0.62) 0.31 (0.60) 0.5060 
 
Lipid Profile  (n=582) 
 
Nephropathy Test  (n=582) 
 
% of unique benes  11.0% 89.0%% 4.0% 96.0% 
Sex  
Male  26.6% 45.9% 
0.0032 
21.7% 44.7% 
0.0295 
Female  73.4% 54.1% 78.3% 55.3% 
Age, mean (SD), yr  11.81 (4.01) 9.43 (5.00) 0.0003 11.78 (3.93) 9.61 (4.98) 0.0393 
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Age  
<=12 years 46.9% 64.9% 
0.0049 
47.8% 63.5% 
0.1271 
>=13 years 53.1% 35.1% 52.2% 36.5% 
Race  
White  28.1% 26.3% 
0.9140 
30.4% 26.3% 
0.3052 Black  64.1% 64.7% 69.6% 64.4% 
Other  7.8% 9.1% 0.0% 9.3% 
CCI, mean (SD)  0.42 (1.15) 0.34 (0.72) 0.4733 0.43 (0.79) 0.35 (0.78) 0.6210 
Total Comorbidities 0.34 (0.78) 0.31 (0.58) 0.6973 0.35 (0.57) 0.31 (0.60) 0.7967 
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C. ANNUAL EXPENDITURES AND SERVICE UTILIZATION OF 
CHILDREN WITH DIABETES 
The study population comprised of a 564,512 pediatric beneficiaries less than 18 
years of age enrolled in Mississippi Medicaid between January 2002 and December 2004. 
Of these, 253,092 children had continuous enrollment for at least one year during the 
study period. Overall, 1,360 children and adolescents had diabetes mellitus with 422 
patients identified as having type 1 diabetes, 735 with type 2 diabetes and 203 patients 
whose diabetes type could not be determined using the available data. Utilization and 
expenditures of diabetic children were compared to pediatric beneficiaries with asthma 
(without diabetes), ADHD (without diabetes) and a cohort of all pediatric beneficiaries in 
Mississippi Medicaid without diabetes.  
Baseline Characteristics 
Table 12 shows the baseline characteristics of children in the different groups. 
The demographic pattern of the pediatric population in each group is as expected, based 
on the risk profile of children with each of these conditions. For instance, children with a 
diagnosis of type 2 diabetes tend to be older than children with type 1 diabetes or asthma. 
Correspondingly in our study sample, the mean age of children with type 2 diabetes was 
higher at 10.1 years compared to the average age of children with type 1 diabetes which 
was 9.8 years. Asthma cohort was the youngest with an average age of 4.7 years, while 
the mean age of children with ADHD was 8.6 years. Children with unknown diabetes 
type were an average age of 12.8 years, which was higher than both known diabetes 
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types. Across all categories, majority of children were African American with 
frequencies ranging from 68.5 to 47.3%. Approximately there were equal number of 
males and females in the all pediatric patients group, however majority of children with 
diabetes are female compared to asthma and ADHD were in a greater proportion of 
children were male. Children with asthma had the highest comorbidity score followed by 
the three diabetes groups. 
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Table 12. Characteristics of Eligible Patients by Disease Type 
Patient Characteristics  
All Pediatric 
Patients 
Type 1 
Diabetes 
Type 2 
Diabetes 
Unknown 
Diabetes 
Asthma ADHD 
Number of unique 
patients  
249773 422 
735 203 27790 15773 
Sex  
Male  49.8% 39.5% 43.0% 32.2% 57.9% 72.8% 
Female  50.2% 60.3% 56.5% 66.8% 41.3% 27.2% 
Age, mean (SD), yr  6.25 (5.37) 9.82 (4.82) 10.09 (5.45) 12.80 (3.95) 4.69 (4.81) 8.59 (3.51) 
Age  
<=12 years 83.6% 65.2% 58.6% 39.9% 90.7% 85.0% 
>=13 years 16.4% 34.8% 41.4% 60.1% 9.3% 15.0% 
Race  
White  26.5% 35.1% 27.3% 19.7% 26.4% 40.0% 
Black  68.1% 55.7% 64.1% 68.5% 65.7% 47.3% 
Other  5.4% 9.2% 8.6% 11.8% 8.0% 13.7% 
CCI, mean (SD)  0.18 (0.47) 0.34 (0.76) 0.36 (0.84) 0.55 (1.17) 1.05 (0.34) 0.19 (0.46) 
Total Comorbidities 0.17 (0.40) 0.28 (0.54) 0.31 (0.60) 0.42 (0.78) 1.03 (0.19) 0.17 (0.40) 
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Utilization Measures 
Table 13 shows the average number of encounters with each health care service 
across the different study groups. Compared to all pediatric patients eligible for the study 
without diabetes, children with all three diabetes types, asthma and ADHD have higher 
health resource utilization. For instance, children with diabetes tend to have twice as 
many physician visits and hospitalizations compared to those without diabetes. Of the 
three disease states, children with diabetes have the highest use of healthcare resources 
compared to all other cohorts. Also, there were differences among the three diabetes 
cohorts. For instance, children with type 1 diabetes had higher number of physician visits 
and hospitalizations compared to type 2 diabetes cohort.  
Table 14 presents the univariate and multivariable associations between the 
disease groups and resource utilization measures. In unadjusted analysis, resource 
utilization of children with diabetes was compared to children with asthma, ADHD and 
all pediatric patients in separate models using Poisson regression. Adjusted analysis 
controls for demographic characteristics and comorbidity score. Of all office-based visits, 
children with diabetes have a higher number of  physician visits compared to asthma, 
ADHD and all pediatric patient groups in that order. Expected total number of non-
physician service provider visits and all other office-based visits for children with type 1 
diabetes was lower compared to the three comparator groups whereas the other two 
diabetes groups have a higher average non-physician and all other office-based visits. 
Children with type 1 diabetes have a lower number of ER visits compared to asthmatic 
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children but higher number of ER visits compared to the all pediatric patients category. 
On the contrary, children with type 2 diabetes have higher expected total number of ER 
visits compared to asthma, ADHD and all pediatric patients groups. Number of 
hospitalizations, number of days in the hospital, number of pharmacy visits, prescription 
fills and all other services received were higher for diabetes children compared to the 
other groups, after controlling for demographics and comorbidities. 
When compared to type 2 diabetes, children with type 1 diabetes had higher 
number of physician visits, hospitalizations and number of days in the hospital, lower 
non-physician service provider visits, other office-based visits and ER visits. There were 
no significant differences in the expected visits among type 1 and type 2 diabetes groups 
across other resource utilization categories. Pediatric beneficiaries with unclassified 
diabetes have significantly lower ER visits and higher hospital and pharmacy use 
compared to patients with type 2 diabetes. 
 87 
Table 13. Health Services Utilization among Pediatric Patients by Disease Type  
(Mean, 
SE) 
Physician 
Visits 
Non-
Physician 
Visits 
Other 
Office 
Visits 
Outpatient 
Hospital 
Visits 
Emergency 
Room 
Visits 
Inpatient 
Hospital 
Visits 
Length of 
Stay 
Pharmacy 
Visits 
Prescription 
Fills 
All Other 
Services 
All 
Pediatric 
Patients 
2.38 
(0.01) 
1.89 
(0.00) 
1.43 
(0.01) 
1.62 
(0.01) 
0.43 
(0.00) 
0.93 
(0.01) 
0.45 
(0.01) 
4.54 
(0.01) 
7.42 
(0.02) 
3.70 
(0.02) 
Type 1 
Diabetes 
4.73 
(0.24) 
1.78 
(0.10) 
1.64 
(0.15) 
3.12 
(0.18) 
0.44 
(0.05) 
2.81 
(0.39) 
2.03 
(0.38) 
10.88 
(0.43) 
18.06 
(0.75) 
7.73 
(0.58) 
Type 2 
Diabetes 
3.79 
(0.19) 
2.34 
(0.10) 
2.57 
(0.14) 
3.19 
(0.33) 
0.84 
(0.06) 
1.99 
(0.35) 
1.87 
(0.54) 
10.57 
(0.37) 
18.43 
(0.73) 
7.65 
(0.68) 
Unknown 
Diabetes 
4.48 
(0.45) 
2.34 
(0.18) 
2.95 
(0.34) 
4.86 
(0.42) 
0.66 
(0.11) 
5.00 
(0.72) 
3.42 
(0.66) 
14.16 
(0.65) 
24.01 
(1.52) 
10.83 
(1.04) 
Asthma 
3.44 
(0.03) 
2.11 
(0.01) 
2.37 
(0.03) 
2.54 
(0.02) 
0.81 
(0.01) 
1.25 
(0.03) 
0.74 
(0.02) 
8.60 
(0.04) 
15.56 
(0.08) 
3.70 
(0.07) 
ADHD 
3.21 
(0.03) 
1.89 
(0.02) 
1.97 
(0.04) 
1.60 
(0.02) 
0.37 
(0.01) 
1.67 
(0.05) 
0.93 
(0.04) 
9.52 
(0.06) 
14.79 
(0.11) 
18.48 
(0.23) 
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Table 14. Unadjusted and Adjusted Associations between Disease Categories and Health Service Utilization Measures 
 § 
Physician 
Visits 
Non-
Physician 
Visits 
Other 
Office 
Visits 
Outpatient 
Hospital 
Visits 
Emergency 
Room 
Visits 
Inpatient 
Hospital 
Visits 
Length of 
Stay 
Pharmacy 
Visits 
Prescription 
Fills 
All 
Other 
Services 
Type 1 
Diabetes 
Vs Asthma 
U 
1.37 
(1.31-
1.44) 
0.84 
(0.79-
0.91) 
0.69 
(0.64-
0.75) 
1.23 
(1.16-
1.29) 
0.55 
(0.47-
0.63) 
2.25 
(2.13-
2.39) 
2.78 
(2.59-
2.97) 
1.27 
(1.23-
1.30) 
1.16 
(1.13-
1.19) 
2.09 
(2.02-
2.17) 
A 
1.44 
(1.37-
1.50) 
0.86 
(0.80-
0.92) 
0.74 
(0.68-
0.79) 
1.36 
(1.29-
1.44) 
0.63 
(0.55-
0.73) 
2.50 
(2.36-
2.66) 
2.97 
(2.77-
3.19) 
1.30 
(1.27-
1.34) 
1.22 
(1.19-
1.25) 
2.11 
(2.04-
2.19) 
Type 2 
Diabetes 
Vs Asthma 
U 
1.10 
(1.06-
1.14) 
1.11 
(1.06-
1.16) 
1.09 
(1.04-
1.14) 
1.25 
(1.20-
1.31) 
1.04* 
(0.96-
1.13) 
1.60 
(1.51-
1.68) 
2.56 
(2.42-
2.70) 
1.23 
(1.20-
1.26) 
1.18 
(1.16-
1.21) 
2.07 
(2.02-
2.13) 
A 
1.21 
(1.16-
1.26) 
1.16 
(1.11-
1.22) 
1.18 
(1.13-
1.24) 
1.39 
(1.34-
1.45) 
1.23 
(1.13-
1.33) 
1.75 
(1.66-
1.85) 
2.69 
(2.54-
2.85) 
1.29 
(1.26-
1.32) 
1.26 
(1.24-
1.28) 
2.03 
(1.97-
2.09) 
Unknown 
Diabetes 
Vs Asthma 
U 
1.30 
(1.22-
1.39) 
1.11 
(1.02-
1.22) 
1.25 
(1.15-
1.35) 
1.91 
(1.80-
2.04) 
0.82 
(0.69-
0.97) 
4.01 
(3.77-
4.27) 
4.67 
(4.33-
5.04) 
1.65 
(1.59-
1.71) 
1.55 
(1.51-
1.59) 
2.93 
(2.81-
3.06) 
A 
1.44 
(1.35-
1.54) 
1.18 
(1.08-
1.30) 
1.30 
(1.20-
1.42) 
1.91 
(1.79-
2.04) 
0.97* 
(0.82-
1.16) 
3.77 
(3.53-
4.02) 
3.93 
(3.63-
4.25) 
1.68 
(1.61-
1.74) 
1.58 
(1.54-
1.63) 
2.48 
(2.38-
2.59) 
Type 1 
Diabetes 
U 
1.47 
(1.41-
0.94* 
(0.88-
0.84 
(0.77-
1.95 
(1.84-
1.20 
(1.03-
1.70 
(1.60-
2.18 
(2.03-
1.14 
(1.11-
1.22 
(1.19-
0.42 
(0.40-
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Vs ADHD 1.54) 1.01) 0.90) 2.06) 1.39) 1.80) 2.33) 1.18) 1.25) 0.43) 
A 
1.40 
(1.34-
1.46) 
0.89 
(0.83-
0.96) 
0.76 
(0.70-
0.82) 
1.75 
(1.66-
1.86) 
1.11* 
(0.96-
1.29) 
1.50 
(1.41-
1.59) 
1.85 
(1.72-
1.98) 
1.11 
(1.08-
1.14) 
1.16 
(1.14-
1.19) 
0.41 
(0.40-
0.43) 
Type 2 
Diabetes 
Vs ADHD 
U 
1.18 
(1.14-
1.23) 
1.24 
(1.18-
1.30) 
1.31 
(1.25-
1.37) 
2.00 
(1.91-
2.08) 
2.27 
(1.09-
2.47) 
1.20 
(1.14-
1.27) 
2.01 
(1.90-
2.12) 
1.11 
(1.09-
1.14) 
1.25 
(1.22-
1.27) 
0.41 
(0.40-
0.43) 
A 
1.17 
(1.13-
1.22) 
1.21 
(1.15-
1.27) 
1.23 
(1.17-
1.29) 
1.72 
(1.64-
1.80) 
2.15 
(1.97-
2.35) 
0.99* 
(0.93-
1.04) 
1.53 
(1.44-
1.62) 
1.11 
(1.08-
1.13) 
1.20 
(1.18-
1.22) 
0.39 
(0.38-
0.40) 
Unknown 
Diabetes 
Vs ADHD 
U 
1.40 
(1.31-
1.49) 
1.24 
(1.14-
1.36) 
1.50 
(1.38-
1.63) 
2.04 
(2.86-
3.24) 
1.79 
(1.51-
2.13) 
3.02 
(2.84-
3.22) 
3.66 
(3.39-
3.95) 
1.49 
(1.43-
1.54) 
1.63 
(1.58-
1.68) 
0.59 
(0.56-
0.61) 
A 
1.31 
(1.22-
1.40) 
1.20 
(1.09-
1.31) 
1.32 
(1.21-
1.43) 
2.17 
(2.03-
2.33) 
1.58 
(1.32-
1.89) 
2.04 
(1.90-
2.18) 
2.17 
(2.00-
2.36) 
1.41 
(1.35-
1.46) 
1.44 
(1.40-
1.48) 
0.53 
(0.51-
0.56) 
Type 1 
Diabetes 
Vs All 
Pediatric 
Patients 
U 
1.99 
(1.90-
2.07) 
0.94* 
(0.88-
1.01) 
1.15 
(1.06-
1.23) 
1.92 
(1.82-
2.03) 
1.02* 
(0.89-
1.18) 
3.01 
(2.84-
3.18) 
4.47 
(4.18-
4.78) 
2.39 
(2.33-
2.47) 
2.43 
(2.38-
2.49) 
2.09 
(2.02-
2.16) 
A 
1.73 
(1.66-
1.81) 
0.91 
(0.85-
0.98) 
1.04* 
(0.97-
1.12) 
1.66 
(1.58-
1.76) 
1.07 
(0.93-
1.24) 
2.59 
(2.45-
2.74) 
3.31 
(3.09-
3.54) 
2.07 
(2.01-
2.13) 
2.15 
(2.10-
2.19) 
1.88 
(1.81-
1.94) 
Type 2 
Diabetes 
Vs All 
U 
1.59 
(1.53-
1.65) 
1.24 
(1.18-
1.30) 
1.79 
(1.72-
1.88) 
1.97 
(1.89-
2.05) 
1.94 
(1.80-
2.10) 
2.13 
(2.02-
2.24) 
4.12 
(3.91-
4.34) 
2.33 
(2.28-
2.38) 
2.48 
(2.44-
2.53) 
2.07 
(2.02-
2.12) 
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Pediatric 
Patients 
A 
1.46 
(1.40-
1.51) 
1.25 
(1.19-
1.31) 
1.66 
(1.58-
1.73) 
1.69 
(1.63-
1.76) 
2.11 
(1.95-
2.29) 
1.81 
(1.72) 
2.85 
(2.71-
3.01) 
2.05 
(2.01-
2.10) 
2.20 
(2.17-
2.24) 
1.80 
(1.75-
1.85) 
Unknown 
Diabetes 
Vs All 
Pediatric 
Patients 
U 
1.88 
(1.76-
2.01) 
1.24 
(1.13-
1.36) 
2.06 
(1.90-
2.23) 
3.00 
(2.82-
3.20) 
1.53 
(1.29-
1.82) 
5.36 
(5.04-
5.70) 
7.52 
(6.98-
8.10) 
3.12 
(3.00-
3.23) 
3.25 
(3.16-
3.34) 
2.93 
(2.81-
3.05) 
A 
1.62 
(1.52-
1.73) 
1.26 
(1.15-
1.38) 
1.74 
(1.61-
1.89) 
2.23 
(2.09-
2.37) 
1.79 
(1.51-
2.12) 
3.90 
(3.66-
4.14) 
3.82 
(3.55-
4.12) 
2.51 
(2.42-
2.60) 
2.63 
(2.56-
2.70) 
2.27 
(2.18-
2.37) 
Type 1 
Diabetes 
Vs Type 2 
Diabetes 
U 
1.25 
(1.18-
1.32) 
0.76 
(0.70-
0.83) 
0.64 
(0.59-
0.70) 
0.98* 
(0.91-
1.05) 
0.53 
(0.45-
0.62) 
1.41 
(1.31-
1.53) 
1.08 
(1.00-
1.18) 
1.03* 
(0.99-
1.07) 
0.98* 
(0.95-
1.01) 
1.01* 
(0.97-
1.06) 
A 
1.24 
(1.17-
1.31) 
0.75 
(0.69-
0.82) 
0.62 
(0.57-
0.68) 
1.03 
(0.96-
1.10) 
0.53 
(0.44-
0.62) 
1.52 
(1.40-
1.64) 
1.17 
(1.07-
1.27) 
1.02* 
(0.98-
1.06) 
1.24 
(1.18-
1.29) 
1.01 
(0.96-
1.05) 
Unknown 
Diabetes 
Vs Type 2 
Diabetes 
U 
1.18 
(1.10-
1.27) 
1.00* 
(0.91-
1.11) 
1.15 
(1.05-
1.26) 
1.53 
(1.42-
1.64) 
0.79 
(0.65-
0.95) 
2.52 
(2.32-
2.73) 
1.83 
(1.67-
2.00) 
1.34 
(1.28-
1.40) 
1.31 
(1.26-
1.35) 
1.41 
(1.35-
1.49) 
A 
1.07* 
(0.99-
1.15) 
0.96 
(0.87-
1.07) 
1.07* 
(0.98-
1.18) 
1.31 
(1.21-
1.41) 
0.72 
(0.59-
0.87) 
1.94 
(1.79-
2.10) 
1.39 
(1.27-
1.53) 
1.24 
(1.18-
1.29) 
1.20 
(1.16-
1.24) 
1.24 
(1.18-
1.31) 
§U – unadjusted analysis; A – adjusted analysis 
Exponentiated beta-coefficients from the Poisson regression model and the 95% CI are reported 
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Expenditure Measures 
Average health care expenditures across the six categories are presented in table 
15. Average total cost was the highest for children with diabetes, followed by ADHD and 
Asthma. Total expenditures of type 1 and type 2 diabetes children were three times the 
expenditure of children without diabetes and children with unclassified diabetes had five 
times the mean total cost of all pediatric patients cluster. Majority of the cost differences 
in total costs across the different disease groups was due to inpatient hospital costs, with 
diabetic children incurring thrice the inpatient costs compared to Asthma and ADHD 
groups. 
Unadjusted associations between the disease type and the various expenditure 
categories and the associations adjusted for demographics and comorbidities were 
modeled using generalized linear models with a gamma distribution and log link. Results 
of these associations are presented in table 16. Consistent with expectations, expenditures 
were the highest for children with diabetes across majority of the service categories, 
however there are few differences across the three diabetes groups. There were no 
significant differences in the expenditure measures when type 2 diabetes children were 
compared to the children with unknown diabetes type. The expected total cost did not 
differ between type 1 and type 2 diabetes children. But, pediatric patients with type 1 
diabetes have lower expected non-physician service provider costs, all other office-based 
visit costs and ER visit related costs.  
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Compared to asthma and all pediatric patient categories, children with all types of 
diabetes have higher expected total costs. However, there were no statistically significant 
differences in the expected total costs when type 1 diabetes and type 2 diabetes children 
were compared to children with ADHD.  This is because children with type 1 diabetes 
have higher physician and hospital-related costs and lower non-physician and other 
miscellaneous service costs compared to children with ADHD. Children with type 2 
diabetes on the other hand, had much lower miscellaneous service costs compared to 
ADHD children and higher expected costs across all other service categories.  
In adjusted analysis, expected cost of ER visits did not differ between unknown 
diabetes and asthma, type 1 diabetes and ADHD, type 1 diabetes and all pediatric patient 
groups. It is interesting to note that, expected costs of ER visits are lower for children 
with type 1 diabetes compared to asthma. Expected costs of most other services were 
higher for diabetes patients when compared to other patient clusters. 
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Sensitivity Analysis 
The analysis was repeated comparing children with different types of diabetes and 
a random sample of 1000 patients with asthma (without diabetes), 1000 patients with 
ADHD (without diabetes) and a random sample of 1000 pediatric beneficiaries without 
diabetes. Table 15 presents the baseline characteristics of these patients, table 18 and 19 
present the average utilization and expenditure measures across the different groups. The 
average utilization and expenditure measures are consistent with the primary analysis. 
Table 20 and 21 present the unadjusted and adjusted association between the disease 
groups and expenditure and utilization measures. Majority of the results are consistent 
with the results discussed in the previous section.
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Table 15. Average Health Care Expenditures Categorized by Health Service Type among Pediatric Patients by Disease 
Type 
(Mean, SE) 
Total 
Cost 
Physician 
Services 
Non-
Physician 
Services 
Other 
Office-
based 
Services 
Outpatient 
Hospital 
Services 
Emergency 
Room 
Services 
Inpatient 
Hospital 
Services 
Pharmacy 
Services 
All Other 
Services 
All 
Pediatric 
Patients 
1863.97 
(10.63) 
135.40 
(0.51) 
154.67 
(0.39) 
119.29 
(0.60) 
302.21 
(2.42) 
32.74   
(0.21) 
516.50 
(7.72) 
342.10 
(2.75) 
261.07 
(3.29) 
Type 1 
Diabetes 
5335.26 
(474.31) 
273.40 
(14.39) 
168.93 
(10.01) 
133.35 
(14.52) 
519.78 
(53.51) 
41.56   
(6.36) 
2076.49 
(372.31) 
1123.37 
(91.53) 
998.38 
(91.85) 
Type 2 
Diabetes 
5727.67 
(862.52) 
265.15 
(49.63) 
209.82 
(8.19) 
195.46 
(12.59) 
794.24 
(174.86) 
84.76   
(6.95) 
2108.07 
(667.62) 
1296.80 
(144.47) 
773.37 
(96.66) 
Unknown 
Diabetes 
8606.94 
(1033.12) 
277.39 
(24.83) 
213.43 
(14.49) 
217.21 
(26.98) 
902.06 
(129.30) 
63.60 
(13.39) 
3783.85 
(795.26) 
1909.40 
(258.54) 
1240.00 
(144.23) 
Asthma 
3102.47 
(37.79) 
184.18 
(1.59) 
163.21 
(1.17) 
196.17 
(2.59) 
496.59 
(9.50) 
72.82   
(0.95) 
768.32 
(26.10) 
885.63 
(10.75) 
335.54 
(11.08) 
ADHD 
4278.93 
(51.70) 
183.86 
(2.05) 
181.00 
(1.65) 
153.95 
(3.44) 
340.44 
(11.00) 
33.14   
(0.79) 
828.57 
(36.58) 
1022.66 
(10.64) 
1535.31 
(25.35) 
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Table 16. Unadjusted and Adjusted Associations between Disease Categories and Health Service Expenditure Measures 
 
§ 
Total 
Cost 
Physician 
Services 
Non-
Physician 
Services 
Other 
Office-
Based 
Services 
Outpatient 
Hospital 
Services 
Emergency 
Room 
Services 
Inpatient 
Hospital 
Services 
Pharmacy 
Services 
All 
Other 
Services 
Type 1 Diabetes 
Vs Asthma 
U 1.72 
(1.41-
2.10) 
1.48 
(1.27-
1.74) 
1.04* 
(0.92-
1.16) 
0.68 
(0.55-
0.84) 
1.05* 
(0.76-
1.43) 
0.57 
(0.46-0.71) 
2.70 
(1.59-
4.61) 
1.27 
(1.04-
1.55) 
2.98 
(1.76-
5.02) 
A 2.27 
(1.92-
2.68) 
1.73 
(1.50-
2.00) 
1.01* 
(0.89-
1.13) 
0.83* 
(0.67-
1.03) 
1.60 
(1.20-
2.14) 
0.67 
(0.53-0.83) 
4.12 
(2.62-
6.49) 
1.44 
(1.19-
1.74) 
4.85 
(2.85-
8.24) 
Type 2 Diabetes 
Vs Asthma 
U 1.85 
(1.59-
2.15 
1.44 
(1.28-
1.62) 
1.29 
(1.18-
1.40) 
1.00* 
(0.85-
1.17) 
1.60 
(1.26-
2.03) 
1.16* 
(0.99-1.37) 
2.74 
(1.83-
4.12) 
1.46 
(1.26-
1.70) 
2.30 
(1.55-
3.43) 
A 1.97 
(1.73-
2.24) 
1.43 
(1.28-
1.60) 
1.26 
(1.15-
1.39) 
1.21 
(1.02-
1.43) 
1.60 
(1.29-
2.00) 
1.35 
(1.14-1.60) 
2.60 
(1.85-
3.65) 
1.50 
(1.29-
1.74) 
2.79 
(1.84-
4.23) 
Unknown Diabetes 
Vs Asthma 
U 2.77 
(2.08-
3.69) 
1.51 
(1.20-
1.89) 
1.31 
(1.11-
1.54) 
1.11* 
(0.82-
1.50) 
1.82 
(1.16-
2.86) 
0.87* 
(0.64-1.19) 
4.92 
(2.29-
10.6) 
2.16 
(1.62-
2.87) 
3.70 
(1.74-
7.84) 
A 2.90 
(2.29-
3.67) 
1.75 
(1.43-
2.14) 
1.25 
(1.05-
1.47) 
1.25* 
(0.93-
1.68) 
2.15 
(1.43-
3.24) 
0.89* 
(0.65-1.21) 
5.38 
(2.84-
10.2) 
2.13 
(1.63-
2.78) 
4.46 
(2.13-
9.31) 
Type 1 Diabetes 
U 1.25 
(1.05-
1.49 
(1.26-
0.93* 
(0.84-
0.87* 
(0.66-
1.53 
(1.02-
1.25 
2.51 
(1.45-
1.10* 
(0.95-
0.65 
(0.53-
 96 
Vs ADHD 1.47) 1.76) 1.04) 1.13) 2.27) (0.94-1.67) 4.34) 1.26) 0.80) 
A 1.12* 
(0.96-
1.31) 
1.44 
(1.26-
1.65) 
0.88 
(0.79-
0.99) 
0.85* 
(0.65-
1.13) 
1.45 
(0.98-
2.16) 
1.19* 
(0.89-1.61) 
2.06 
(1.14-
3.71) 
1.02* 
(0.90-
1.16) 
0.74 
(0.59-
0.93) 
Type 2 Diabetes 
Vs ADHD 
U 1.34 
(1.18-
1.52) 
1.44 
(1.27-
1.64) 
1.16 
(1.06-
1.26) 
1.27 
(1.04-
1.56) 
2.33 
(1.72-
3.17) 
2.56 
(2.05-3.19) 
2.54 
(1.67-
3.87) 
1.27 
(1.14-
1.41) 
0.50 
(0.43-
0.59) 
A 0.99* 
(0.87-
1.12) 
1.18 
(1.06-
1.31) 
1.13 
(1.03-
1.23) 
1.25 
(1.01-
1.55) 
1.52 
(1.12-
2.07) 
2.53 
(2.00-3.19) 
1.41* 
(0.88-
2.27) 
1.04* 
(0.94-
1.15) 
0.49 
(0.41-
0.58) 
Unknown Diabetes 
Vs ADHD 
U 2.01 
(1.58-
2.56) 
1.51 
(1.19-
1.92) 
1.18 
(1.01-
1.38) 
1.41* 
(0.96-
2.07) 
2.65 
(1.49-
4.70) 
1.92 
(1.27-2.90) 
4.57 
(2.08-
10.0) 
1.87 
(1.53-
2.28) 
0.81* 
(0.60-
1.09) 
A 1.40 
(1.12-
1.75) 
1.43 
(1.18-
1.75) 
1.12 
(0.95-
1.32) 
1.31* 
(0.88-
1.94) 
1.85 
(1.04-
3.28) 
1.55 
(1.01-2.38) 
2.55 
(1.09-
5.96) 
1.46 
(1.21-
1.75) 
0.75* 
(0.54-
1.04) 
Type 1 Diabetes 
Vs All Pediatric 
Patients 
U 2.86 
(2.18-
3.75) 
2.02 
(1.68-
2.42) 
1.09* 
(0.97-
1.23) 
1.12* 
(0.88-
1.43) 
1.72 
(1.17-
2.52) 
1.27* 
(0.94-1.71) 
4.02 
(1.99-
8.12) 
3.28 
(2.23-
4.83) 
3.82 
(2.09-
7.00) 
A 2.37 
(1.90-
2.96) 
1.78 
(1.49-
2.13) 
1.03* 
(0.91-
1.16) 
1.08* 
(0.85-
1.37) 
1.56 
(1.12-
2.17) 
1.33* 
(0.97-1.81) 
3.24 
(1.69-
6.19) 
2.91 
(1.99-
4.26) 
3.70 
(1.94-
7.05) 
Type 2 Diabetes 
Vs All Pediatric 
Patients 
U 3.07 
(2.50-
3.77) 
1.96 
(1.71-
2.25) 
1.36 
(1.24-
1.49) 
1.64 
(1.36-
1.97) 
2.63 
(1.97-
3.51) 
2.59 
(2.06-3.25) 
4.08 
(2.40-
6.95) 
3.79 
(2.83-
5.08) 
2.96 
(1.87-
4.69) 
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A 1.94 
(1.64-
2.30) 
1.41 
(1.23-
1.61) 
1.30 
(1.18-
1.42) 
1.57 
(1.31-
1.88) 
1.56 
(1.22-
2.01) 
2.85 
(2.25-3.61) 
1.67 
(1.02-
2.73) 
2.88 
(2.17-
3.84) 
2.22 
(1.36-
3.62) 
Unknown Diabetes 
Vs All Pediatric 
Patients 
U 4.62 
(3.13-
6.82) 
2.05 
(1.58-
2.66) 
1.38 
(1.16-
1.65) 
1.82 
(1.28-
2.58) 
2.98 
(1.72-
5.18) 
1.94 
(1.26-2.99) 
7.33 
(2.66-
20.2) 
5.58 
(3.20-
9.75) 
4.75 
(1.99-
11.4) 
A 2.88 
(2.09-
3.96) 
1.65 
(1.28-
2.13) 
1.28 
(1.07-
1.52) 
1.58 
(1.12-
2.23) 
2.02 
(1.26-
3.25) 
1.86 
(1.19-2.91) 
- 
3.99 
(2.31-
6.88) 
3.63 
(1.44-
9.19) 
Type 1 Diabetes 
Vs Type 2 Diabetes 
U 0.93* 
(0.63-
1.38) 
1.03* 
(0.65-
1.63) 
0.81 
(0.71-
0.92) 
0.68 
(0.54-
0.86) 
0.65* 
(0.38-
1.14) 
0.49 
(0.36-0.68) 
0.99* 
(0.44-
2.22) 
0.87* 
(0.64-
1.17) 
1.29* 
(0.92-
1.80) 
A 1.19* 
(0.93-
1.52) 
1.27 
(1.09-
1.48) 
0.79 
(0.69-
0.90) 
0.68 
(0.54-
0.86) 
1.01* 
(0.75-
1.36) 
0.49 
(0.37-0.66) 
1.80 
(1.03-
3.15) 
0.99* 
(0.81-
1.20) 
1.51 
(1.09-
2.09) 
Unknown Diabetes 
Vs Type 2 Diabetes 
U 1.50* 
(0.91-
2.49) 
1.05* 
(0.58-
1.90) 
1.02* 
(0.86-
1.21) 
1.11* 
(0.82-
1.50) 
1.14* 
(0.55-
2.33) 
0.75* 
(0.50-1.14) 
1.79* 
(0.63-
5.14) 
1.47* 
(0.99-
2.18) 
1.60 
(1.04-
2.47) 
A 1.41 
(1.03-
1.93) 
1.10* 
(0.90-
1.35) 
0.96* 
(0.81-
1.14) 
1.05* 
(0.77-
1.42) 
1.25* 
(0.84-
1.85) 
0.58 
(0.40-0.66) 
1.99* 
(0.97-
4.07) 
1.35 
(1.05-
1.74) 
1.56 
(1.05-
2.33) 
§U – unadjusted analysis; A – adjusted analysis 
Exponentiated beta-coefficients from the GLM with gamma distribution and log link and the 95% CIs are reported 
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Table 17. Characteristics of Eligible Patients by Disease Type – A Random Sample 
Patient Characteristics  
All Pediatric 
Patients 
Asthma ADHD 
Type 1 
Diabetes 
Type 2 
Diabetes 
Unknown 
Diabetes 
Number of unique 
patients  
1000 
1000 1000 
422 
735 203 
Sex  
Male  50.1% 57.9% 75.4% 43.0% 32.2% 72.8% 
Female  49.9% 42.1% 24.6% 56.5% 66.8% 27.2% 
Age, mean (SD), yr  6.17 (5.41) 4.68 (4.79) 8.54 (3.41) 9.82 (4.82) 10.09 (5.45) 12.80 (3.95) 
Age  
<=12 years 82.9% 91.0% 86.1% 58.6% 39.9% 85.0% 
>=13 years 17.1% 9.0% 13.9% 41.4% 60.1% 15.0% 
Race  
White  28.2% 27.5% 39.0% 27.3% 19.7% 40.0% 
Black  67.4% 63.5% 46.9% 64.1% 68.5% 47.3% 
Other  4.4% 9.0% 14.1% 8.6% 11.8% 13.7% 
CCI, mean (SD)  0.20 (0.47) 1.06 (0.62) 0.18 (0.51) 0.34 (0.76) 0.36 (0.84) 0.55 (1.17) 
Total Comorbidities 0.18 (0.40) 1.03 (0.30) 0.17 (0.40) 0.28 (0.54) 0.31 (0.60) 0.42 (0.78) 
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Table 18. Health Services Utilization among Pediatric Patients by Disease Type - A Random Sample 
(Mean, 
SE) 
Physician 
Visits 
Non-
Physician 
Visits 
Other 
Office 
Visits 
Outpatient 
Hospital 
Visits 
Emergency 
Room Visits 
Inpatient 
Hospital 
Visits 
Length 
of Stay 
Pharmacy 
Visits 
Prescription 
Fills 
All 
Other 
Services 
All 
Pediatric 
Patients 
2.56 
(0.14) 
2.01 
(0.08) 
1.42 
(0.09) 
1.73 
(0.09) 
0.44 (0.03) 
0.95 
(0.10) 
0.42 
(0.06) 
4.76 
(0.18) 
7.87 (0.31) 
3.84 
(0.34) 
Asthma 
3.36 
(0.15) 
2.06 
(0.08) 
2.33 
(0.12) 
2.35 
(0.12) 
0.71 (0.04) 
1.39 
(0.22) 
0.89 
(0.25) 
8.24 
(0.22) 
14.94 
(0.40) 
3.56 
(0.32) 
ADHD 
3.33 
(0.15) 
1.79 
(0.07) 
1.68 
(0.13) 
1.62 
(0.11) 
0.29 (0.02) 
1.68 
(0.21) 
0.92 
(0.17) 
9.82 
(0.27) 
15.43 
(0.47) 
17.44 
(0.84) 
Type 1 
Diabetes 
4.73 
(0.24) 
1.78 
(0.10) 
1.64 
(0.15) 
3.12 
(0.18) 
0.44 (0.05) 
2.81 
(0.39) 
2.03 
(0.38) 
10.88 
(0.43) 
18.06 
(0.75) 
7.73 
(0.58) 
Type 2 
Diabetes 
3.79 
(0.19) 
2.34 
(0.10) 
2.57 
(0.14) 
3.19 
(0.33) 
0.84 (0.06) 
1.99 
(0.35) 
1.87 
(0.54) 
10.57 
(0.37) 
18.43 
(0.73) 
7.65 
(0.68) 
Unknown 
Diabetes 
4.48 
(0.45) 
2.34 
(0.18) 
2.95 
(0.34) 
4.86 
(0.42) 
0.66 (0.11) 
5.00 
(0.72) 
3.42 
(0.66) 
14.16 
(0.65) 
24.01 
(1.52) 
10.83 
(1.04) 
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Table 19. Average Health Care Expenditures among Pediatric Patients by Disease Type - A Random Sample 
(Mean, SE) 
Total 
Cost 
Physician 
Services 
Non-
Physician 
Services 
Other 
Office-
based 
Services 
Outpatient 
Hospital 
Services 
Emergency 
Room 
Services 
Inpatient 
Hospital 
Services 
Pharmacy 
Services 
All Other 
Services 
All 
Pediatric 
Patients 
1764.10 
(111.08) 
141.54 
(7.62) 
161.07 
(6.40) 
115.45 
(7.52) 
281.59 
(25.66) 
31.93   
(3.01) 
477.95 
(68.07) 
322.03 
(23.53) 
232.56 
(36.50) 
Asthma 
3231.37 
(324.63) 
181.13 
(8.79) 
159.71 
(6.19) 
192.16 
(10.21) 
424.42 
(37.21) 
62.56   
(4.38) 
950.66 
(280.5) 
906.75 
(53.83) 
353.99 
(66.48) 
ADHD 
4202.00 
(193.46) 
190.13 
(8.93) 
176.89 
(6.52) 
134.11 
(10.39) 
337.02 
(44.42) 
25.67   
(2.55) 
779.98 
(128.05) 
1086.45 
(43.93) 
1471.75 
(100.29) 
Type 1 
Diabetes 
5335.26 
(474.31) 
273.40 
(14.39) 
168.93 
(10.01) 
133.35 
(14.52) 
519.78 
(53.51) 
41.56   
(6.36) 
2076.49 
(372.31) 
1123.37 
(91.53) 
998.38 
(91.85) 
Type 2 
Diabetes 
5727.67 
(862.52) 
265.15 
(49.63) 
209.82 
(8.19) 
195.46 
(12.59) 
794.24 
(174.86) 
84.76   
(6.95) 
2108.07 
(667.62) 
1296.80 
(144.47) 
773.37 
(96.66) 
Unknown 
Diabetes 
8606.94 
(1033.12) 
277.39 
(24.83) 
213.43 
(14.49) 
217.21 
(26.98) 
902.06 
(129.30) 
63.60 
(13.39) 
3783.85 
(795.26) 
1909.40 
(258.54) 
1240.00 
(144.23) 
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Table 20. Unadjusted and Adjusted Associations between Disease Categories and Health Service Utilization Measures – 
A Random Sample 
 
§ 
Physician 
Visits 
Non-
Physician 
Visits 
Other 
Office 
Visits 
Outpatient 
Hospital 
Visits 
Emergency 
Room 
Visits 
Inpatient 
Hospital 
Visits 
Length 
of Stay 
Pharmacy 
Visits 
Prescription 
Fills 
All 
Other 
Services 
Type 1 
Diabetes 
Vs 
Asthma 
U 1.41 
(1.33-
1.49) 
0.86 
(0.80-
0.94) 
0.70 
(0.65-
0.76) 
1.32 
(1.24-
1.42) 
0.62 
(0.53-0.73) 
2.02 
(1.87-
2.18) 
2.29 
(2.09-
2.52) 
1.32 
(1.27-
1.37) 
1.21 
(1.18-1.24) 
2.18 
(2.07-
2.28) 
A 1.42 
(1.34-
1.51) 
0.84 
(0.77-
0.92) 
0.73 
(0.66-
0.79) 
1.54 
(1.43-
1.65) 
0.67 
(0.57-0.80) 
2.40 
(2.20-
2.62) 
3.71 
(3.33-
4.14) 
1.31 
(1.26-
1.36) 
1.22 
(1.19-1.26) 
2.19 
(2.09-
2.31) 
Type 2 
Diabetes 
Vs 
Asthma 
U 1.13 
(1.07-
1.19) 
1.14 
(1.07-
1.21) 
1.10 
(1.04-
1.17) 
1.35 
(1.28-
1.43) 
1.17 
(1.05-1.31) 
1.43 
(1.33-
1.54) 
2.12 
(1.94-
2.30) 
1.28 
(1.24-
1.32) 
1.23 
(1.21-1.26) 
2.15 
(2.06-
2.24) 
A 1.16 
(1.10-
1.23) 
1.13 
(1.05-
1.21) 
1.17 
(1.09-
1.25) 
1.54 
(1.45-
1.64) 
1.30 
(1.15-1.46) 
1.62 
(1.49-
1.76) 
3.26 
(2.95-
3.61) 
1.29 
(1.24-
1.33) 
1.25 
(1.22-1.29) 
2.18 
(2.08-
2.28) 
Unknown 
Diabetes 
Vs 
Asthma 
U 1.33 
(1.24-
1.43) 
1.14 
(1.03-
1.26) 
1.26 
(1.15-
1.38) 
2.07 
(1.92-
2.23) 
0.93 
(0.77-1.11) 
3.59 
(3.31-
3.90) 
3.86 
(3.50-
4.27) 
1.72 
(1.65-
1.79) 
1.61 
(1.56-1.67) 
3.04 
(2.89-
3.21) 
A 1.29 
(1.20-
1.40) 
1.11 
(1.00-
1.24) 
1.29 
(1.17-
1.42) 
2.12 
(1.95-
2.30) 
0.97 
(0.80-1.18) 
3.27 
(2.98-
3.59) 
4.73 
(4.21-
5.33) 
1.63 
(1.55-
1.70) 
1.54 
(1.49-1.60) 
2.75 
(2.59-
2.91) 
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Type 1 
Diabetes 
Vs ADHD 
U 1.42 
(1.34-
1.50) 
1.00 
(0.92-
1.09) 
0.98 
(0.90-
1.07) 
1.93 
(1.79-
2.07) 
1.51 
(1.26-1.81) 
1.67 
(1.55-
1.80) 
2.20 
(2.00-
2.41) 
1.11 
(1.07-
1.15) 
1.17 
(1.14-1.20) 
0.44 
(0.43-
0.46) 
A 1.25 
(1.18-
1.32) 
0.90 
(0.82-
0.98) 
0.90 
(0.82-
0.99) 
1.81 
(1.67-
1.95) 
1.39 
(1.15-1.69) 
1.45 
(1.34-
1.57) 
1.86 
(1.69-
2.06) 
1.05 
(1.01-
1.09) 
1.11 
(1.07-1.14) 
0.43 
(0.41-
0.44) 
Type 2 
Diabetes 
Vs ADHD 
U 1.14 
(1.08-
1.20) 
1.31 
(1.23-
1.40) 
1.53 
(1.44-
1.64) 
1.97 
(1.85-
2.10) 
2.87 
(2.49-3.29) 
1.18 
(1.10-
1.27) 
2.03 
(1.87-
2.20) 
1.08 
(1.04-
1.11) 
1.19 
(1.17-1.22) 
0.44 
(0.43-
0.45) 
A 1.02 
(0.97-
1.08) 
1.21 
(1.13-
1.30) 
1.44 
(1.35-
1.55) 
1.77 
(1.65-
1.89) 
2.66 
(2.30-3.09) 
0.95 
(0.88-
1.03) 
1.60 
(1.46-
1.75) 
1.03 
(1.00-
1.07) 
1.13 
(1.10-1.16) 
0.41 
(0.39-
0.42) 
Unknown 
Diabetes 
Vs ADHD 
U 1.34 
(1.25-
1.45) 
1.31 
(1.19-
1.45) 
1.76 
(1.60-
1.93) 
3.01 
(2.78-
3.26) 
2.26 
(1.84-2.77) 
2.98 
(2.76-
3.22) 
3.70 
(3.36-
4.09) 
1.44 
(1.38-
1.50) 
1.56 
(1.51-1.61) 
0.62 
(0.59-
0.65) 
A 1.10 
(1.02-
1.19) 
1.17 
(1.05-
1.31) 
1.58 
(1.43-
1.75) 
2.31 
(2.12-
2.52) 
1.92 
(1.54-2.40) 
1.95 
(1.78-
2.13) 
2.33 
(2.09-
2.61) 
1.29 
(1.23-
1.35) 
1.36 
(1.31-1.41) 
0.52 
(0.50-
0.55) 
Type 1 
Diabetes 
Vs All 
Pediatric 
Patients 
U 1.85 
(1.74-
1.96) 
0.89 
(0.82-
0.96) 
1.15 
(1.05-
1.26) 
1.80 
(1.68-
1.94) 
1.00 
(0.85-1.19) 
2.96 
(2.72-
3.22) 
4.81 
(4.28-
5.41) 
2.30 
(2.21-
2.40) 
2.29 
(2.22-2.37) 
2.20 
(1.92-
2.11) 
A 1.64 
(1.54-
1.74) 
0.85 
(0.78-
0.92) 
1.07 
(0.98-
1.18) 
1.57 
(1.46-
1.69) 
0.93 
(0.78-1.11) 
2.39 
(2.19-
2.60) 
3.81 
(3.38-
4.29) 
2.00 
(1.92-
2.09) 
2.01 
(1.94-2.07) 
1.74 
(1.66-
1.83) 
Type 2 U 1.48 1.17 1.81 1.84 1.91 2.09 4.44 2.24 2.34 1.99 
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Diabetes 
Vs All 
Pediatric 
Patients 
(1.40-
1.56) 
(1.09-
1.24) 
(1.69-
1.94) 
(1.73-
1.96) 
(1.69-2.15) (1.93-
2.27) 
(3.98-
4.95) 
(2.16-
2.32) 
(2.28-2.41) (1.91-
2.08) 
A 1.34 
(1.26-
1.41) 
1.14 
(1.06-
1.21) 
1.71 
(1.59-
1.84) 
1.53 
(1.44-
1.63) 
1.79 
(1.57-2.03) 
1.56 
(1.43-
1.69) 
3.21 
(2.87-
3.60) 
1.98 
(1.90-
2.05) 
2.05 
(2.00-2.11) 
1.70 
(1.63-
1.78) 
Unknown 
Diabetes 
Vs All 
Pediatric 
Patients 
U 1.75 
(1.62-
1.89) 
1.17 
(1.06-
1.29) 
2.07 
(1.88-
2.28) 
2.81 
(2.60-
3.04) 
1.50 
(1.24-1.82) 
5.27 
(4.82-
5.76) 
8.10 
(7.18-
9.14) 
3.00 
(2.86-
3.14) 
3.06 
(2.95-3.17) 
2.82 
(2.68-
2.97) 
A 1.44 
(1.33-
1.56) 
0.99 
(0.96-
1.02) 
1.84 
(1.66-
2.04) 
1.98 
(1.82-
2.16) 
1.32 
(1.08-1.62) 
3.05 
(2.77-
3.36) 
4.47 
(3.92-
5.08) 
2.45 
(2.33-
2.57) 
2.46 
(2.37-2.56) 
2.11 
(1.99-
2.23) 
Type 1 
Diabetes 
Vs Type 2 
Diabetes 
U 1.25 
(1.18-
1.32) 
0.76 
(0.70-
0.83) 
0.64 
(0.59-
0.70) 
0.98* 
(0.91-
1.05) 
0.53 
(0.45-0.62) 
1.41 
(1.31-
1.53) 
1.08 
(1.00-
1.18) 
1.03* 
(0.99-
1.07) 
0.98* 
(0.95-1.01) 
1.01* 
(0.97-
1.06) 
A 1.24 
(1.17-
1.31) 
0.75 
(0.69-
0.82) 
0.62 
(0.57-
0.68) 
1.03 
(0.96-
1.10) 
0.53 
(0.44-0.62) 
1.52 
(1.40-
1.64) 
1.17 
(1.07-
1.27) 
1.02* 
(0.98-
1.06) 
1.24 
(1.18-1.29) 
1.01 
(0.96-
1.05) 
Unknown 
Diabetes 
Vs Type 2 
Diabetes 
U 1.18 
(1.10-
1.27) 
1.00* 
(0.91-
1.11) 
1.15 
(1.05-
1.26) 
1.53 
(1.42-
1.64) 
0.79 
(0.65-0.95) 
2.52 
(2.32-
2.73) 
1.83 
(1.67-
2.00) 
1.34 
(1.28-
1.40) 
1.31 
(1.26-1.35) 
1.41 
(1.35-
1.49) 
A 1.07* 
(0.99-
1.15) 
0.96 
(0.87-
1.07) 
1.07* 
(0.98-
1.18) 
1.31 
(1.21-
1.41) 
0.72 
(0.59-0.87) 
1.94 
(1.79-
2.10) 
1.39 
(1.27-
1.53) 
1.24 
(1.18-
1.29) 
1.20 
(1.16-1.24) 
1.24 
(1.18-
1.31) 
§U – unadjusted analysis; A – adjusted analysis 
Exponentiated beta-coefficients from the Poisson regression model and the 95% CIs are reported 
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Table 21. Unadjusted and Adjusted Associations between Disease Categories and Health Service Expenditure Measures 
– A Random Sample 
 
§ 
Total 
Cost 
Physician 
Services 
Non-
Physician 
Services 
Other 
Office-
based 
Services 
Outpatient 
Hospital 
Services 
Emergency 
Room 
Services 
Inpatient 
Hospital 
Services 
Pharmacy 
Services 
All 
Other 
Services 
Type 1 Diabetes 
Vs Asthma 
U 1.65 
(1.14-
2.38) 
1.51 
(1.06-
2.14) 
1.06 
(0.93-
1.21) 
0.69 
(0.56-
0.85) 
1.22 
(0.78-
1.92) 
0.66 
(0.50-0.88) 
2.18 
(0.88-
5.40) 
1.24 
(0.96-
1.61) 
2.82 
(1.71-
4.66) 
A 2.38 
(1.88-
3.01) 
1.69 
(1.42-
2.00) 
0.98 
(0.85-
1.13) 
0.80 
(0.63-
1.02) 
1.78 
(1.28-
2.48) 
0.80 
(0.59-1.08) 
5.01 
(2.76-
9.11) 
1.35 
(1.09-
1.67) 
3.88 
(2.51-
6.00) 
Type 2 Diabetes 
Vs Asthma 
U 1.77 
(1.30-
2.41) 
1.46 
(1.09-
1.96) 
1.31 
(1.18-
1.47) 
1.02 
(0.86-
1.21) 
1.87 
(1.28-
2.73) 
1.35 
(1.07-1.72) 
2.22 
(1.04-
4.73) 
1.43 
(1.15-
1.78) 
2.22 
(1.04-
4.73) 
A 2.01 
(1.65-
2.44) 
1.34 
(1.16-
1.55) 
1.23 
(1.09-
1.40) 
1.17 
(0.95-
1.44) 
1.79 
(1.36-
2.36) 
1.61 
(1.24-2.10) 
2.79 
(1.72-
4.51) 
1.36 
(1.13-
1.63) 
2.46 
(1.69-
3.58) 
Unknown Diabetes 
Vs Asthma 
U 2.66 
(1.64-
4.33) 
1.53 
(0.96-
2.44) 
1.34 
(1.12-
1.59) 
1.13 
(0.86-
1.49) 
2.13 
(1.17-
3.86) 
1.02 
(0.70-1.48) 
3.98 
(1.20-
13.2) 
2.11 
(1.49-
2.97) 
3.98 
(1.20-
13.2) 
A 2.88 
(2.12-
3.92) 
1.52 
(1.21-
1.91) 
1.20 
(0.99-
1.45) 
1.22 
(0.90-
1.65) 
2.31 
(1.49-
3.59) 
0.94 
(0.64-1.38) 
6.05 
(2.79-
13.1) 
1.84 
(1.40-
2.42) 
3.93 
(2.25-
6.86) 
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Type 1 Diabetes 
Vs ADHD 
U 1.27 
(0.94-
1.72) 
1.44 
(1.01-
2.04) 
0.96 
(0.84-
1.09) 
0.99 
(0.78-
1.27) 
1.54 
(0.93-
2.56) 
1.62 
(1.17-2.25) 
2.66 
(1.32-
5.36) 
1.03 
(0.81-
1.31) 
0.68 
(0.51-
0.91) 
A 1.06 
(0.85-
1.32) 
1.27 
(1.08-
1.49) 
0.85 
(0.75-
0.98) 
0.94 
(0.72-
1.24) 
1.54 
(1.01-
2.34) 
1.38 
(0.98-1.95) 
2.06 
(1.07-
3.99) 
0.92 
(0.77-
1.10) 
0.62 
(0.46-
0.84) 
Type 2 Diabetes 
Vs ADHD 
U 1.36 
(1.06-
1.75) 
1.39 
(1.04-
1.87) 
1.19 
(1.07-
1.32) 
1.46 
(1.19-
1.79) 
2.36 
(1.54-
3.60) 
3.30 
(2.51-4.34) 
2.70 
(1.50-
4.86) 
1.19 
(0.98-
1.46) 
0.53 
(0.41-
0.67) 
A 0.89 
(0.73-
1.09) 
1.01 
(0.88-
1.16) 
1.08 
(0.96-
1.21) 
1.38 
(1.10-
1.74) 
1.56 
(1.10-
2.20) 
2.80 
(2.07-3.78) 
1.18 
(0.64-
2.17) 
0.92 
(0.79-
1.08) 
0.40 
(0.31-
0.53) 
Unknown Diabetes 
Vs ADHD 
U 2.05 
(1.37-
3.05) 
1.46 
(0.92-
2.32) 
1.21 
(1.02-
1.43) 
1.62 
(1.17-
2.24) 
2.68 
(1.37-
5.23) 
2.48 
(1.60-3.83) 
4.85 
(1.92-
12.3) 
1.76 
(1.28-
2.41) 
0.84 
(0.57-
1.24) 
A 1.28 
(0.94-
1.74) 
1.14 
(0.91-
1.42) 
1.04 
(0.87-
1.25) 
1.46 
(1.02-
2.09) 
1.98 
(1.13-
3.46) 
1.68 
(1.05-2.69) 
2.54 
(1.05-
6.13) 
1.25 
(0.98-
1.60) 
0.63 
(0.41-
0.95) 
Type 1 Diabetes 
Vs All Pediatric 
Patients 
U 3.02 
(2.20-
4.15) 
1.93 
(1.36-
2.75) 
1.05 
(0.92-
1.20) 
1.16 
(0.92-
1.45) 
1.85 
(1.17-
2.91) 
1.30 
(0.95-1.79) 
4.34 
(2.22-
8.52) 
3.49 
(2.64-
4.61) 
4.29 
(2.77-
6.66) 
A 2.56 
(2.07-
3.16) 
1.71 
(1.44-
2.04) 
0.99 
(0.87-
1.14) 
1.14 
(0.90-
1.44) 
1.70 
(1.25-
2.31) 
1.17 
(0.86-1.60) 
3.73 
(2.28-
6.11) 
3.04 
(2.48-
3.73) 
3.89 
(2.40-
6.32) 
Type 2 Diabetes U 3.25 1.87 1.30 1.69 2.82 2.65 4.41 4.03 3.33 
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Vs All Pediatric 
Patients 
(2.49-
4.23) 
(1.39-
2.52) 
(1.17-
1.46) 
(1.40-
2.04) 
(1.93-
4.12) 
(2.03-3.47) (2.51-
7.75) 
(3.19-
5.08) 
(2.30-
4.80) 
A 2.13 
(1.77-
2.55) 
1.36 
(1.17-
1.57) 
1.25 
(1.12-
1.40) 
1.66 
(1.36-
2.02) 
1.74 
(1.34-
2.25) 
2.41 
(1.83-3.17) 
2.00 
(1.29-
3.08) 
3.11 
(2.61-
3.71) 
2.43 
(1.60-
3.70) 
Unknown Diabetes 
Vs All Pediatric 
Patients 
U 4.88 
(3.20-
7.43) 
1.96 
(1.23-
3.13) 
1.33 
(1.11-
1.58) 
1.88 
(1.40-
2.54) 
3.20 
(1.76-
5.85) 
1.99 
(1.30-3.04) 
7.92 
(3.24-
19.3) 
5.93 
(4.10-
8.57) 
5.33 
(2.98-
9.55) 
A 3.06 
(2.29-
4.08) 
1.53 
(1.21-
1.94) 
1.19 
(0.99-
1.43) 
1.71 
(1.25-
2.34) 
2.21 
(1.45-
3.36) 
1.49 
(0.97-2.29) 
4.25 
(2.18-
8.29) 
4.27 
(3.23-
5.64) 
3.92 
(2.05-
7.50) 
Type 1 Diabetes 
Vs Type 2 Diabetes 
U 0.93* 
(0.63-
1.38) 
1.03* 
(0.65-
1.63) 
0.81 
(0.71-
0.92) 
0.68 
(0.54-
0.86) 
0.65* 
(0.38-
1.14) 
0.49 
(0.36-0.68) 
0.99* 
(0.44-
2.22) 
0.87* 
(0.64-
1.17) 
1.29* 
(0.92-
1.80) 
A 1.19* 
(0.93-
1.52) 
1.27 
(1.09-
1.48) 
0.79 
(0.69-
0.90) 
0.68 
(0.54-
0.86) 
1.01* 
(0.75-
1.36) 
0.49 
(0.37-0.66) 
1.80 
(1.03-
3.15) 
0.99* 
(0.81-
1.20) 
1.51 
(1.09-
2.09) 
Unknown Diabetes 
Vs Type 2 Diabetes 
U 1.50* 
(0.91-
2.49) 
1.05* 
(0.58-
1.90) 
1.02* 
(0.86-
1.21) 
1.11* 
(0.82-
1.50) 
1.14* 
(0.55-
2.33) 
0.75* 
(0.50-1.14) 
1.79* 
(0.63-
5.14) 
1.47* 
(0.99-
2.18) 
1.60 
(1.04-
2.47) 
A 1.41 
(1.03-
1.93) 
1.10* 
(0.90-
1.35) 
0.96* 
(0.81-
1.14) 
1.05* 
(0.77-
1.42) 
1.25* 
(0.84-
1.85) 
0.58 
(0.40-0.66) 
1.99* 
(0.97-
4.07) 
1.35 
(1.05-
1.74) 
1.56 
(1.05-
2.33) 
§U – unadjusted analysis; A – adjusted analysis 
Exponentiated beta-coefficients from the GLM model with gamma distribution and log link and the 95% CIs are reported 
CHAPTER V – DISCUSSION AND CONCLUSIONS 
 
Our research provides an in-depth understanding of diabetes in children enrolled 
in the Mississippi Medicaid and SCHIP programs. Considering Medicaid/SCHIP-
enrolled children constitute nearly 50% of the total children in the state of Mississippi 
(116), we will not be too unrealistic in extending our estimates to the state of Mississippi. 
In an attempt to provide an extensive understanding of the condition, we studied the 
epidemiology of diabetes, clinical characteristics of children with diabetes, the quality of 
care received by these pediatric beneficiaries, and their healthcare resource utilization. 
Apart from being the first study to assess the state of pediatric diabetes in Mississippi, to 
our knowledge, this is the only study providing a comprehensive overview of children 
with diabetes by diabetes type.  
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A. EPIDEMIOLOGY 
Prevalence and Incidence 
This part of the study provides an insight into diabetes prevalence and incidence 
in a state Medicaid pediatric population. To summarize, diabetes was found to be a 
prevalent pediatric condition in this population and type 2 diabetes incidence was found 
to be increasing in children and adolescents. We reported prevalence and incidence 
estimates for diabetes, overall and by types apart from providing age, race and gender-
specific estimates. Diabetes prevalence increased in Mississippi children through the 3 
study years, with nearly 4.0, 5.4 and 6.4 in 1000 children having diabetes during 2002, 
2003 and 2004, which is significantly higher than the most recent national estimates that 
reported a prevalence estimate of 1.82 diabetes cases per 1000 children and adolescents 
(8). The incidence was an approximate 15.5/10,000 cases in 2003 and 2004. A quick 
comparison with the existing studies indicate that diabetes incidence in Mississippi 
Medicaid was almost 6.3 times the incidence of diabetes in US, 10 times the incidence 
among African American children and adolescents in Chicago (15.2/100,000) and in 
Pittsburg (16.5/100,000 in White and 17.6/100,000 in Nonwhite children and 
adolescents) and five times the American Indian youth in Wyoming and Montana 
(33.6/100,000) (6,117,118,119).    
Consistent with the growing evidence suggesting an increase in pediatric type 2 
diabetes (2,3,4,49,51), our study found a large number of children with type 2 diabetes. 
Indeed, of all diabetes cases, majority were type 2 with the prevalence of type 2 diabetes 
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being twice as many as type 1 in 2003 and 2004. But, similar to our results, a study 
exploring diabetes in American Indian youth reported twice as many type 2 diabetes 
cases compared to type 1 diabetes between 1999 and 2001 (119).  
Type 1 diabetes prevalence was consistent across the three years at 1.5 to 
1.7/1000 children whereas type 2 diabetes prevalence almost doubled from 1.9/1000 in 
2002 to 3.9/1000 in 2004. Type 1 diabetes estimates are within the range reported in the 
US from the 1970s to present i.e., 0.6 to 1.9 cases per 1000 children and adolescents 
(8,120-123) and worldwide (124). There is an extremely wide range of type 2 diabetes 
prevalence estimates reported in literature (0.5 to >53/1000 cases), making comparisons 
with our estimates unsubstantial (8,25).  
Comparing our results to a study providing the most comprehensive national 
estimates of diabetes epidemiology in the US offers partly congruent, partly conflicting 
results (6,8). While the prevalence of type 1 diabetes is at par with the most recent 
estimates, type 2 diabetes among children in Mississippi Medicaid is much more 
pronounced than the national assessment. The recently concluded SEARCH study 
estimated the overall prevalence of type 1 diabetes at 1.8 in 1000, which is very close the 
prevalence of type 1 diabetes in our study. The prevalence of type 2 diabetes in our study 
population was much lower than the estimates reported by SEARCH (8).  
In our study, overall incidence of diabetes was around 15.5/10,000 children, with 
type 2 and unspecified diabetes cases representing 80% of the new diabetes cases. Also, 
incidence of type 2 diabetes was found to be six times the incidence of type 1 diabetes 
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during 2003 and 2004, which is completely in sync with a Taiwanese study which 
reported the ratio of incident type 1 to type 2 cases as 1 to 6 (125). 
A plausible explanation for this dramatic difference in type 1 and type 2 diabetes 
incidence is that type 2 diabetes in the pediatric population has been on a rise according 
to several studies, while there is no such sudden increase in type 1 diabetes cases (2,3,4). 
The emerging problem of type 2 diabetes in children and adolescents coincides with the 
trend of childhood obesity in the United States (50). In fact, type 2 diabetes epidemic is 
considered to be a consequence of increasing obesity prevalence in children. 
Unfortunately, with the adult type 2 diabetes rates and obesity rates in all age-groups still 
increasing, type 2 diabetes cases in the pediatric population are expected to rise around 
the world. 
A greater number of children were found to be diagnosed with type 2 diabetes 
each year, either because of an actual increase in prevalence or due to increasing 
awareness of the condition. The increase in awareness has both positive and negative 
connotations. On one hand, it will help diagnose previously undiagnosed cases. Another 
point of view is that the increasing awareness of the presentation of type 2 diabetes in 
children and converging risk profile of both type 1 and type 2 diabetes might have raised 
the confusion about appropriate classification of the type of diabetes. This could have 
resulted in healthcare providers falsely classifying children as having type 2 diabetes or 
unspecified diabetes, which because of a common ICD-9 code falls in the type 2 diabetes 
category by way of our study design.  
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As expected, adolescents had higher prevalence and incidence of diabetes than 
children less than 12 years of age. Incidence of type 2 diabetes among adolescents was 
almost 5 times the incidence of type 1 diabetes for adolescents (6,8,31). We observed that 
white pediatric subjects have a higher prevalence of diabetes than African American 
subjects, with type 1 diabetes prevalence among whites being nearly twice the prevalence 
in African Americans, a similar trend was noted in the SEARCH trial (8). Surprisingly, 
African Americans also had a lower prevalence of type 2 diabetes than whites despite 
high incidence of type 2 diabetes. Incidence of type 2 diabetes was higher in African 
Americans compared to whites in 2003 and incidence was almost the same in both racial 
groups in 2004. This is contrary to results reported in most studies which suggest that the 
prevalence of type 2 diabetes is higher for African American children and adolescents 
compared to whites. However, since we included all age groups and not just the 
adolescents while looking at the prevalence of type 2 diabetes, we probably have lower 
estimates than those reported in other studies. But considering African American 
population exceeds whites in Mississippi, in terms of number of children with the 
condition, there are more African American children with diabetes (both types) than 
Whites. Gender specific estimates are in agreement with other studies reporting higher 
prevalence and incidence of diabetes in females compared to males (6,8,21,25,31,119). 
Clinical Characteristics 
Clinical presentation of children with type 1 and type 2 diabetes is as expected. 
We observed that children with type 2 diabetes are likely to be obese, have acanthosis 
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nigricans whereas type 1 diabetes subjects are either underweight or have abnormal 
weight loss at presentation (4,50,57,60). While it is true that more children with type 2 
diabetes had acanthosis nigricans and none of the children with type 1 diabetes did, only 
2% of cases with acanthosis nigricans were reported which is much lower than the 
estimates in the literature which range from 48 to 92% (29). DKA was the most common 
acute complication found in these children and consistent with the literature, type 1 
diabetes subjects were more likely to get DKA than type 2 across all racial groups 
(9,20,21,22). The overall prevalence of hypertension (3.7%, 6.5%) and dyslipidemia 
(2.5%, 3.2%), which are likely manifestations of the metabolic syndrome, was 
surprisingly high among both type 1 and type 2 children compared to other diabetes-
related comorbidities, but slightly higher in type 2 cases. Hypertension and dyslipidemia 
rates were much higher among type 2 diabetes youth compared to type 1 among all racial 
groups (20,21,22).  
All these comorbid conditions and complications increase the health and 
economic burden among children and reflect the suboptimal management of their 
diabetes. Considering the inadequate emphasis on healthy behaviors in lower 
socioeconomic households, the prevalence of clinical complications might be higher in 
this population than usual. If poor management continues, it might further deteriorate 
their micro and macro-vascular conditions resulting in more serious complications like 
cardiovascular disease, blindness and death. Healthcare practitioners should provide 
special care and interventions designed to improve glycemic control and better manage 
diabetes among children. 
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Our study adds substantially to the existing literature. It is the only study that 
provides epidemiology estimates and an overview of the clinical characteristics, 
comorbidities and complications of children with diabetes overall and by diabetes types. 
Though there are national epidemiological estimates available from the SEARCH trial, it 
was not a random sample of children and does not represent the entire US pediatric 
population, making it difficult to extrapolate the estimates to all pediatric population 
groups in the US. Epidemiological estimates of pediatric diabetes in Mississippi 
Medicaid are expected to be different from the national estimates because of an 
uncommon sociodemographic distribution.  Mississippi has a predominant African 
American population and considering our sample constitutes Medicaid beneficiaries, 
these children come from relatively lower income families, both of which were noted in 
previous studies as markers of high type 2 diabetes prevalence (21). Mississippi also has 
the highest rates of obesity compared to all other US states (24.3%), making Mississippi 
children more vulnerable to type 2 diabetes (12). 
Besides the SEARCH trial, which is a prospective national sample, our study has 
a fairly large sample of diabetic children compared to studies exploring the epidemiology 
of diabetes in other states, making our epidemiological estimate adequately precise. For 
instance, a study exploring diabetes in American Indian youth in Wyoming and Montana 
had a sample size of 55 prevalent diabetes cases (119) and a study examining diabetes 
among African American and Latino children in Chicago studied only 735 children 
(117). 
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The results of our study should be viewed in the light of a few limitations. One 
limitation of this study is the use of claims data in identifying diabetes type in the 
pediatric population. It is possible that a considerable proportion of diabetes cases are 
misclassified either due to misdiagnosis or miscoding. It is reported that children often 
present with symptoms and risk profile of both type 1 and type 2 diabetes, which makes it 
difficult to accurately classify the diabetes type. If children were falsely classified as 
having a specific diabetes type, we cannot reclassify them correctly without a chart 
review or clinical data to confirm the diagnosis. Since, children with diabetes were 
predominantly type 1, with type 1 diabetes referred to as the juvenile diabetes, when 
children are presented with mixed clinical characteristics, physicians are more than likely 
to classify them as type 1. However, more children are probably being diagnosed with 
type 2 diabetes because type 2 diabetes received increased attention as an epidemic in the 
scientific literature in recent times, which might have increased the likelihood of 
classifying children as having type 2 diabetes when they are presented with mixed 
clinical characteristics. On the contrary, the increased awareness of type 2 diabetes could 
have resulted in the diagnosis of formerly undiagnosed pediatric patients with the 
condition. 
Another concern with using ICD-9 codes for identifying type 2 diabetes cases is 
that the ICD-9 code for type 2 diabetes also includes unspecified diabetes, thereby 
overestimating the actual type 2 diabetes prevalence. Considering we used ICD-9 codes 
in patient identification, there is a major concern that our type 2 diabetes cases are 
overestimated. However, SEARCH study mentioned that of the 6379 children and 
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adolescents, 96.7% were identified as having type 1 or type 2 with only 140 patients 
without a specific diagnosis (8). Also, it is common practice to use ICD-9 codes to 
identify type 2 diabetes among adults, elderly and children in most studies using 
administrative claims data (126,127,128). Typically in adults and the elderly, there is no 
major problem of misclassification of the type of diabetes and 90 to 95% of the cases are 
typically type 2 but there has been evidence suggesting that children‟s diabetes type 
could be often misclassified, making it difficult to correctly estimate the prevalence and 
incidence of type 2 diabetes (61,62,63).  
Based on the existing literature, there is no standard algorithm for ascertainment 
of diabetes type in children using retrospective data. Despite the presence of clinical 
information, it is not always possible to accurately classify the type of diabetes in 
children. Moore et al. (2003) used age at diagnosis less than or equal to five years, low 
body weight and a positive antibody test results to  identify type 1 diabetes and  obesity, 
acanthosis nigricans, elevated c-peptide levels, family history of type 2 diabetes and 
pharmacological treatments to flag type 2 diabetes cases (119). The accuracy of this 
method of categorizing diabetes is questionable. Their method is likely to underestimate 
the prevalence of type 1 diabetes and overestimate type 2 diabetes. For instance, while it 
is very likely that thin children with diabetes are usually type 1 and not type 2, ensuring 
correct classification of type 1 children, we are underestimating the overall prevalence 
because children who are obese could also have type 1 diabetes (4,11,55). Also a quick 
look at the clinical characteristics of children with diabetes (Table 2) will show that while 
it is rare for children with type 1 diabetes to have acanthosis nigricans, it is probable.  
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On the other hand, using ICD-9 codes in identifying diabetes types is common 
practice among adults. In the pediatric population, studies show that using ICD-9 codes 
in identifying type 1 diabetes has a predictive value of 97%, which ensures that our type 
1 classification is accurate (129). This particular study reported that ICD-9 codes for type 
2 diabetes have a poor predictive value. But that study was conducted using data from 
one hospital with low type 2 diabetes prevalence. Other studies have used ICD-9 codes in 
identifying type 2 diabetes in children (128). We do not have sufficient clinical 
information to attest the validity of our classification method, but considering the 
demographic and clinical characteristics of both type 1 and type 2 diabetes cases in our 
study are consistent with the literature, we are comfortable using ICD-9 codes to classify 
diabetes type. For instance, more girls than boys have type 2 diabetes and type 2 diabetes 
prevalence increases during adolescence. 
Apart from the potential misclassification concern, nearly 13.3% of children could 
not be classified as type 1 or type 2 diabetes patients, thereby underestimating our 
epidemiological estimates. Also, we did not address the case of secondary diabetes in our 
study but children with secondary diabetes could be coded as having unspecified diabetes 
due to lower awareness of ICD-9 codes related to secondary diabetes. Overall, it will be 
beneficial to create separate set of ICD-9 codes for type 2 diabetes and unspecified 
diabetes for future researchers to better isolate the cases for epidemiology estimates. 
We estimated incident diabetes cases as children enrolled in Medicaid for one 
year without any diabetes related claims in the prior year and having diabetes-related 
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claims in subsequent years. While this method is not validated in literature it is highly 
unlikely for diabetes cases to not have any healthcare encounters for prolonged periods of 
time. Specifically, it is highly improbable for type 1 diabetes patients to not have a 
healthcare encounter after diagnosis considering the seriousness of the condition. Type 2 
diabetes on the other hand is less life-threatening in the initial stages but most guidelines 
suggest that children receive certain annual screenings for diabetes which will require 
them to have a doctor‟s visit at the very least.  
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B. MANAGEMENT OF TYPE 2 DIABETES (QUALITY OF CARE) 
The epidemic of type 2 diabetes in children makes it crucial for researchers to 
study the extent of the problem and the current management protocol. An appropriate 
management strategy that includes a combination of lifestyle modification and 
medication regimen tailored to each child‟s need is of utmost importance. 
Pharmacotherapy aside, children‟s blood glucose levels should be constantly monitored 
and they need to be screened annually for possible complications so that microvascular 
and macrovascular disorders can be avoided in the future. Although glycemic control is 
the cornerstone of diabetes therapy, it is important to monitor comorbid conditions like 
dyslipidemia and hypertension and manage them with either diet and exercise or 
appropriate medications, as necessary. Despite a general consensus on the importance of 
medication use and annual screenings, it is not reflected in practice. There is a paucity of 
research exploring the pattern of care among children and adolescents with diabetes. This 
study adds to the existing knowledge on the management of type 2 diabetes among 
pediatric patients.  
Oral Hypoglycemic Medication Use 
OHGs are underused in the pediatric population, with only 23.5% of children with 
type 2 diabetes taking these medications. In comparison, a smaller study assessing the 
treatment patterns among 40 adolescents with metabolic syndrome reported higher 
insulin use (93%) and OHG utilization rates with 85% (34 patients) of the patients using 
metformin, 25% using thiazolidinediones and 15% on sulfonylureas (130). Lower 
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utilization observed in our study could be because our patient population is much 
younger with the average age of our study population at 9.5 years compared to 16.7 in the 
other study. Medications are typically administered in children only upon progression of 
the disease not managed by diet and exercise. We used a retrospective cohort study 
design to identify the predictors of OHG use and sex, age and comorbidity score were 
found to be significant predictors. Consistent with our expectations, older children were 
more likely to use OHGs than younger children and lower comorbidity score led to 
higher adherence rate. Surprisingly there were no racial disparities in OHG use in our 
population as seen in other drug utilization studies (126,131,132).  To our knowledge, no 
other study explored the patient characteristics as predictors of OHG utilization in 
children with type 2 diabetes for us to draw comparisons.  
Fewer children and adolescents with type 2 diabetes are using OHGs may also be 
because of the limited options available to them. Metformin is the only FDA approved 
OHG for glycemic control in a pediatric population apart from insulin (13,52,58). Despite 
being a well-tolerated and effective medication (87), metformin may not help in 
achieving the required glycemic goals in all of the target population. Also, monotherapy 
with oral agents is reported to be ineffective in the long run, causing children to move to 
insulin therapy when metformin does not prove to be effective (89). Another apparent 
reason for seeing few children use OHGs is that physicians typically recommend intense 
lifestyle modification instead of pharmacotherapy with metformin and other off-label 
OHGs.  
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Adherence to OHGs 
Children prescribed oral hypoglycemic medications should be adherent to the 
therapy to achieve full benefit of the medication. But only 27% of the patients were found 
to be adherent to OHGs i.e., a nonadherence rate of 73%. We are unable to make direct 
comparisons with other studies exploring adherence towards OHGs among children with 
type 2 diabetes due to a lack of studies addressing this topic. Nevertheless, a comparison 
with OHG nonadherence rates in an older population group reveals that nonadherence 
rates are much higher in children compared to adults and the elderly. A systematic review 
of studies examining nonadherence to OHGs across different population subgroups 
reported a range of values between 7% - 64% among diabetes patients using OHGs (133). 
Nonadherence rates were reported to be around 30 to 35% among older population in two 
studies examining adherence to OHGs using retrospective data (126,134). Most 
adherence studies exploring predictors of nonadherence report that, young patients are 
less likely to adhere to medications than older patients (135,136). This is especially the 
case when the medications do not have an immediate impact, like in the case of diabetes. 
Adherence to medications seems to be a major concern in this population. 
Importance of medication adherence in avoiding future micro- and macrovascular 
complications is well established in the adult literature. Nonadherence with diabetes 
medications was related to poorer clinical and economic outcomes (115,127,136). 
However, the implications of nonadherence might not be realized among children as 
quickly as one would expect them to occur among adults and elderly but it is still 
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important for children to avoid complications as they begin to grow into their adult years. 
There could be several reasons for a lack of adherence in pediatric population. Children 
once on the medication do not have to continue using them if they can get their HbA1c 
levels within target goals by lifestyle modification. Also, the physician could have 
switched the patient from OHGs to insulin which leads to falsely flagging the patient as 
nonadherent. Another reason is that adherence in children and adolescents, depends on 
both them and their parents, complicating the situation. So it is important for healthcare 
practitioners to communicate the importance of adherence to both stakeholders to see 
improvement in adherence behaviors. 
Hypertension and Dyslipidemia Medications 
In our study, only 9% of the patients with type 2 diabetes were on 
antihypertensive medications and there were fewer children using antihyperlipidemics (~ 
1%). A study investigating drug use among children with type 2 diabetes and metabolic 
syndrome reported that antihypertensive medications are highly underused in the 
population despite a majority of them having elevated blood pressure. Only 44.4% of 
patients with a blood pressure level higher than recommended received antihypertensive 
medications (130). Considering we are looking at type 2 diabetes cases, elevated blood 
pressure levels might not be as common as seen in the other study. For example, we 
found that of all children with type 2 diabetes in Mississippi Medicaid between 2002 
through 2004, only 6% had a diagnosis of hypertension. Dyslipidemia medications were 
rarely used in our subjects but underutilization of lipid lowering drugs was reported in the 
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aforementioned study as well. Only 10% of patients received lipid lowering drugs in that 
study despite 75% of the patients not meeting the ADA recommended cholesterol levels 
(130). Underutilization of lipid lowering drugs seems to be of bigger concern in the 
pediatric population compared to the antihypertensive medication use. Dyslipidemia is a 
serious comorbid condition and has a major impact on the cardiovascular health of the 
child in subsequent years. So, annual lipid screenings as well as lifestyle modification 
and medication use to maintain target lipid levels in high-risk children are warranted. 
Antihyperlipidemics agents including statins are approved in pediatric population and 
there is short-term data that indicates safety and effectiveness of using statins in children 
with a family history of dyslipidemia (137). But a long term risk benefit assessment of 
the treating young patients with statins is yet to be established. 
Inadequate use of medications in this population could be resulting from the fact 
that physicians recommend diet and exercise before moving onto pharmacotherapy or it 
could be a general lack of awareness regarding the benefits or usability of these 
medications in a pediatric population. Due to a lack of clinical information in our dataset, 
we could not assess the severity of the condition, which would have helped us understand 
the lack of medication use in this population. We also did not have information regarding 
the age at diagnosis for all patients included in the study, to use as a proxy for disease 
severity. 
Outcomes of OHG Medication Use 
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We could not establish a relationship between hospitalizations and OHG use due 
to an insufficient sample size. However, the average all-cause and diabetes-related 
hospital expenditures were lower for adherent group compared to those who were non-
adherent. The overall expenditures on the other hand were the highest for the adherent 
group, mainly because of the higher prescription expenditures. This may be because, the 
effect of medication adherence on health outcomes is not immediate. For us to observe 
the effect of suboptimal adherence to spill over into other healthcare expenditures 
requires a longer study period. 
Annual Screenings  
Screening rates were low in our population with eye, HbA1c, lipid and 
nephropathy screenings performed only on 40%, 22%, 11% and 4% of the population 
with type 2 diabetes annually. In one other study conducted in the US by Valent et al.., 
(2009) assessing compliance with ADA guidelines in a type 2 pediatric population, 
44.6% of patients received HbA1c tests every 3 months, 60.7% received a lipid screening 
at least once every two years, 26.7% had nephropathy screenings and annual eye exam 
was performed on 53.5% of the patients. The screening rates may be lower among 
patients in our study either because of a lack of awareness of the importance of these 
screenings. Also, physicians may choose to not perform these screenings on a regular 
basis in a pediatric population because of the long term nature of most of the 
complications being screened for. For instance, retinopathy and nephropathy are not as 
common in a pediatric population with type 2 diabetes compared to adults with the 
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condition. A revised set of guidelines for pediatric population with type 2 diabetes would 
be beneficial considering the risk of long-term complications is different in children.  
A large number of studies discussed the standards of management of type 2 
diabetes in children (2,49), but very few studies provide an empirical evidence of practice 
patterns of these guidelines. This study provides an initial understanding of how type 2 
diabetes is managed in a pediatric population. Overall, OHGs, antihypertensives and 
antihyperlipidemics are underused in this population and recommended screenings are 
not performed annually. Future studies should explore the extent of this problem in other 
populations. Studies exploring the predictors of nonadherence with medications in 
pediatric population as well as relationship between pharmacotherapy and clinical and 
economic outcomes in the pediatric population are warranted.  
Limitations 
The results of our study should be viewed in the light of a few limitations. One 
limitation of this study is the use of claims data in identifying diabetes type in the 
pediatric population. It is possible that a considerable proportion of diabetes cases are 
misclassified either due to misdiagnosis or miscoding. It is reported that children often 
present with symptoms and risk profile of both type 1 and type 2 diabetes, which makes it 
difficult to accurately classify the diabetes type. If children were falsely classified as 
having a specific diabetes type, we cannot reclassify them correctly without a chart 
review or clinical data to confirm the diagnosis. Since, children with diabetes were 
predominantly type 1, with type 1 diabetes referred to as the juvenile diabetes, when 
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children are presented with mixed clinical characteristics, physicians are more than likely 
to classify them as type 1. However, more children are probably being diagnosed with 
type 2 diabetes because type 2 diabetes received increased attention as an epidemic in the 
scientific literature in recent times, which might have increased the likelihood of 
classifying children as having type 2 diabetes when they are presented with mixed 
clinical characteristics. On the contrary, the increased awareness of type 2 diabetes could 
have resulted in the diagnosis of formerly undiagnosed pediatric patients with the 
condition. 
Another concern with using ICD-9 codes for identifying type 2 diabetes cases is 
that the ICD-9 code for type 2 diabetes also includes unspecified diabetes, thereby 
overestimating the actual type 2 diabetes prevalence. Considering we used ICD-9 codes 
in patient identification, there is a major concern that our type 2 diabetes cases are 
overestimated. However, SEARCH study mentioned that of the 6379 children and 
adolescents, 96.7% were identified as having type 1 or type 2 with only 140 patients 
without a specific diagnosis (8). Also, it is common practice to use ICD-9 codes to 
identify type 2 diabetes among adults, elderly and children in most studies using 
administrative claims data (126,127,128). Typically in adults and the elderly, there is no 
major problem of misclassification of the type of diabetes and 90 to 95% of the cases are 
typically type 2 but there has been evidence suggesting that children‟s diabetes type 
could be often misclassified, making it difficult to correctly estimate the prevalence and 
incidence of type 2 diabetes (61,62,63).  
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Based on the existing literature, there is no standard algorithm for ascertainment 
of diabetes type in children using retrospective data. Despite the presence of clinical 
information, it is not always possible to accurately classify the type of diabetes in 
children. Moore et al. (2003) used age at diagnosis less than or equal to five years, low 
body weight and a positive antibody test results to  identify type 1 diabetes and  obesity, 
acanthosis nigricans, elevated c-peptide levels, family history of type 2 diabetes and 
pharmacological treatments to flag type 2 diabetes cases (119). The accuracy of this 
method of categorizing diabetes is questionable. Their method is likely to underestimate 
the prevalence of type 1 diabetes and overestimate type 2 diabetes. For instance, while it 
is very likely that thin children with diabetes are usually type 1 and not type 2, ensuring 
correct classification of type 1 children, we are underestimating the overall prevalence 
because children who are obese could also have type 1 diabetes (4,11,55). Also a quick 
look at the clinical characteristics of children with diabetes (Table 2) will show that while 
it is rare for children with type 1 diabetes to have acanthosis nigricans, it is probable.  
On the other hand, using ICD-9 codes in identifying diabetes types is common 
practice among adults. In the pediatric population, studies show that using ICD-9 codes 
in identifying type 1 diabetes has a predictive value of 97%, which ensures that our type 
1 classification is accurate (129). This particular study reported that ICD-9 codes for type 
2 diabetes have a poor predictive value. But that study was conducted using data from 
one hospital with low type 2 diabetes prevalence. Other studies have used ICD-9 codes in 
identifying type 2 diabetes in children (128). We do not have sufficient clinical 
information to attest the validity of our classification method, but considering the 
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demographic and clinical characteristics of both type 1 and type 2 diabetes cases in our 
study are consistent with the literature, we are comfortable using ICD-9 codes to classify 
diabetes type. For instance, more girls than boys have type 2 diabetes and type 2 diabetes 
prevalence increases during adolescence. 
Apart from the potential misclassification concern, nearly 13.3% of children could 
not be classified as type 1 or type 2 diabetes patients, thereby underestimating our 
epidemiological estimates. Also, we did not address the case of secondary diabetes in our 
study but children with secondary diabetes could be coded as having unspecified diabetes 
due to lower awareness of ICD-9 codes related to secondary diabetes. Overall, it will be 
beneficial to create separate set of ICD-9 codes for type 2 diabetes and unspecified 
diabetes for future researchers to better isolate the cases for epidemiology estimates. 
There are several challenges in using administrative claims data in understanding 
medication utilization of patients. Like all administrative claims based studies, our study 
is prone to the common limitation of miscoded data. Second, we measure utilization and 
adherence based on prescription fills and it is possible that the patient did not take the 
medication after filling it. Third, when assessing outcomes associated with medication 
use, only health outcomes like diabetes-related complications, healthcare utilization and 
economic outcomes can be assessed using administrative claims data and these outcomes 
are not reflected immediately upon appropriate medication use. Availability of clinical 
(intermediate) outcomes like HbA1c levels, would give us a better understanding of the 
effectiveness of medications in the target population but this clinical data is not available. 
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Also, using administrative claims data restricts the factors we can assess as potential 
predictors of underutilization or nonadherence. Despite these limitations, administrative 
claims data offers us a real-world assessment of medication utilization. 
 
C. ANNUAL EXPENDITURES AND SERVICE UTILIZATION 
Pediatric population forms 57% of the total Medicaid population in the state of 
Mississippi (116), which means pediatric expenditures constitute a considerable 
proportion of Medicaid spending. We explored the healthcare utilization and 
expenditures for children with type 1, type 2 and unknown diabetes groups and compared 
them with pediatric population with asthma, ADHD and all children/adolescent 
beneficiaries without diabetes, to provide estimates of the relative economic burden due 
to these conditions on the state Medicaid program.  
Our findings indicate that children with type 1, type 2 and unknown type of 
diabetes have significantly higher healthcare utilization and expenditures compared to 
pediatric patients without diabetes, those with asthma and ADHD. While utilization 
patterns for all service categories are markedly different across all the patient groups 
studied, it is crucial to note that the biggest difference in utilization are among physician 
visits, outpatient hospital, inpatient hospital and pharmacy visits. Higher health services 
utilization among all diabetes categories also translated to higher expenditures for 
pediatric population with diabetes. Children with diabetes had higher total expenditure 
compared to other patient cohorts mainly because of hospitalizations and prescription 
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medications. Also, the distribution of expenditures in our study indicate that a relatively 
small proportion of children account for a large proportion of expenditures. It is 
important to understand the underlying reasons for high healthcare costs in the most 
expensive patient subgroups so as to develop targeted interventions that reduce healthcare 
expenditures and provide good quality of care. 
Medicaid beneficiaries tend to use emergency rooms as their primary source of 
healthcare. Surprisingly, ER visits were lower among all patient groups in our study, 
compared to outpatient hospital, hospital and physician visits. However, the average 
number of ER visits for all patients without diabetes in our study were three times the 
number of ER visits for all pediatric patients in 2000 MEPS data (138).  
Physician utilization in children in the three diabetes groups was twice the 
average visits among all children and adolescents without diabetes. Physician visits were 
also higher among diabetes patients in our study compared to other populations. For 
instance, the average number of physician visits in the type 2 diabetes group is 3.8 in our 
study compared to a study that reported 1.9 physician office visits also among type 2 
diabetes youth (128). This study population comprised of youth with private insurance 
and Medicaid managed care (16%) and found that there were no significant differences in 
the two groups. It is interesting to note that while you would expect children enrolled in 
Medicaid to have inadequate access to physicians and overall barriers to care, children 
with type 2 diabetes have twice as many physician visits as the other study population. 
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Another health service category that accounts for a major proportion of 
expenditures is hospitalizations. Children with type 1, type 2 and unknown diabetes 
stayed in a hospital two to three times more than children with asthma and ADHD. One 
study reported that children enrolled in Medicaid were likely to have 27-439% more 
hospital days than children enrolled in employee-based insurance programs (139). This 
reflects the need for proper management and education in Medicaid-enrolled patients. 
Hospitalizations in this population are mainly due to hypoglycemia and diabetic 
ketoacidosis, and these can be avoided by communicating the importance of proper 
glycemic control. Counseling parents and patients about the benefits of appropriate 
management can prove to be cost-effective. 
Ours is the first study to compare health services utilization and expenditures by 
type of diabetes. Compared to type 2 diabetes, children with type 1 diabetes have 24% 
higher expected physician visits, 52% higher number of hospitalizations and 47% lower 
ER visits. Non-physician service provider visits and all other office visits were also lower 
for type 1 diabetes children. However, there were no significant differences in 
expenditures between type 1 and type 2 diabetes cohorts. Higher number of 
hospitalizations in children with type 1 diabetes might be because DKA which is the most 
common acute complication is more common in type 1 than type 2 cases. Children with 
proper access to primary care are less likely to have ER visits and this is reflected in our 
population. Children with type 2 diabetes have fewer physician visits and more ER visits, 
indicating disparities in access. As we noted in the earlier section of our study, a 
considerable proportion of children with type 2 diabetes belong to the Mississippi delta 
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region, which has poorer access to healthcare and people with lower socioeconomic 
status. 
Most studies assessing expenditures consider total costs incurred by the patients, 
including out of pocket expenditures, secondary insurance sources apart from the cost to 
the primary payer‟s perspective. While there is no issue in using that method, we assessed 
expenditures from Medicaid‟s perspective because we wanted to understand the 
economic burden to Mississippi Medicaid resulting from pediatric diabetes and how it 
compares to other pediatric conditions. However, our utilization measures are more 
global measures and not specific to Mississippi Medicaid and should be directly 
comparable to other studies. Another advantage of our study design is that typically 
expenditure studies report measures for a year and not follow each eligible patient for 365 
days. So, our estimates truly reflect annual health care utilization and expenditures. 
Expenditures and utilization variables were highly skewed, so we used 
generalized linear models (GLM) with a gamma distribution and log link to model 
expenditures and zero inflated poisson models for utilization measures. There are other 
competing models suggested in the literature like logged expenditures, two-part models 
and heckit selection models to name a few. While there is no one right model to estimate 
costs, few simulation studies have demonstrated that GLM is a suitable choice for 
modeling health care expenditures (140). Our model choice was also driven in part by the 
ease of interpreting and understanding results from GLM model compared to ordinary 
least squares regression model with log transformed expenditures.  
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The results of our study should be viewed in the light of a few limitations. One 
limitation of this study is the use of claims data in identifying diabetes type in the 
pediatric population. It is possible that a considerable proportion of diabetes cases are 
misclassified either due to misdiagnosis or miscoding. It is reported that children often 
present with symptoms and risk profile of both type 1 and type 2 diabetes, which makes it 
difficult to accurately classify the diabetes type. If children were falsely classified as 
having a specific diabetes type, we cannot reclassify them correctly without a chart 
review or clinical data to confirm the diagnosis. Since, children with diabetes were 
predominantly type 1, with type 1 diabetes referred to as the juvenile diabetes, when 
children are presented with mixed clinical characteristics, physicians are more than likely 
to classify them as type 1. However, more children are probably being diagnosed with 
type 2 diabetes because type 2 diabetes received increased attention as an epidemic in the 
scientific literature in recent times, which might have increased the likelihood of 
classifying children as having type 2 diabetes when they are presented with mixed 
clinical characteristics. On the contrary, the increased awareness of type 2 diabetes could 
have resulted in the diagnosis of formerly undiagnosed pediatric patients with the 
condition. 
Another concern with using ICD-9 codes for identifying type 2 diabetes cases is 
that the ICD-9 code for type 2 diabetes also includes unspecified diabetes, thereby 
overestimating the actual type 2 diabetes prevalence. Considering we used ICD-9 codes 
in patient identification, there is a major concern that our type 2 diabetes cases are 
overestimated. However, SEARCH study mentioned that of the 6379 children and 
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adolescents, 96.7% were identified as having type 1 or type 2 with only 140 patients 
without a specific diagnosis (8). Also, it is common practice to use ICD-9 codes to 
identify type 2 diabetes among adults, elderly and children in most studies using 
administrative claims data (126,127,128). Typically in adults and the elderly, there is no 
major problem of misclassification of the type of diabetes and 90 to 95% of the cases are 
typically type 2 but there has been evidence suggesting that children‟s diabetes type 
could be often misclassified, making it difficult to correctly estimate the prevalence and 
incidence of type 2 diabetes (61,62,63).  
Based on the existing literature, there is no standard algorithm for ascertainment 
of diabetes type in children using retrospective data. Despite the presence of clinical 
information, it is not always possible to accurately classify the type of diabetes in 
children. Moore et al. (2003) used age at diagnosis less than or equal to five years, low 
body weight and a positive antibody test results to  identify type 1 diabetes and  obesity, 
acanthosis nigricans, elevated c-peptide levels, family history of type 2 diabetes and 
pharmacological treatments to flag type 2 diabetes cases (119). The accuracy of this 
method of categorizing diabetes is questionable. Their method is likely to underestimate 
the prevalence of type 1 diabetes and overestimate type 2 diabetes. For instance, while it 
is very likely that thin children with diabetes are usually type 1 and not type 2, ensuring 
correct classification of type 1 children, we are underestimating the overall prevalence 
because children who are obese could also have type 1 diabetes (4,11,55). Also a quick 
look at the clinical characteristics of children with diabetes (Table 2) will show that while 
it is rare for children with type 1 diabetes to have acanthosis nigricans, it is probable.  
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On the other hand, using ICD-9 codes in identifying diabetes types is common 
practice among adults. In the pediatric population, studies show that using ICD-9 codes 
in identifying type 1 diabetes has a predictive value of 97%, which ensures that our type 
1 classification is accurate (129). This particular study reported that ICD-9 codes for type 
2 diabetes have a poor predictive value. But that study was conducted using data from 
one hospital with low type 2 diabetes prevalence. Other studies have used ICD-9 codes in 
identifying type 2 diabetes in children (128). We do not have sufficient clinical 
information to attest the validity of our classification method, but considering the 
demographic and clinical characteristics of both type 1 and type 2 diabetes cases in our 
study are consistent with the literature, we are comfortable using ICD-9 codes to classify 
diabetes type. For instance, more girls than boys have type 2 diabetes and type 2 diabetes 
prevalence increases during adolescence. 
Apart from the potential misclassification concern, nearly 13.3% of children could 
not be classified as type 1 or type 2 diabetes patients, thereby underestimating our 
epidemiological estimates. Also, we did not address the case of secondary diabetes in our 
study but children with secondary diabetes could be coded as having unspecified diabetes 
due to lower awareness of ICD-9 codes related to secondary diabetes. Overall, it will be 
beneficial to create separate set of ICD-9 codes for type 2 diabetes and unspecified 
diabetes for future researchers to better isolate the cases for epidemiology estimates. 
Another limitation of the study is the small sample size, especially the number of 
subjects in the three diabetes groups. The small sample size makes it difficult to 
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understand if the non-significant differences in expenditures and utilization measures 
between the three diabetes types are due to a lack of statistical power. Another study 
limitation is that we did not adjust for inflation because by way of our study design part 
of the expenditures incurred by a patient could fall in two different years. 
Despite the limitations, our findings provide an initial understanding of the 
healthcare utilization and expenditure patterns of pediatric population split by diabetes 
type. Although these results cannot be extrapolated to the entire pediatric population, they 
provide an estimate of spending in the Medicaid population in the state of Mississippi. 
Medicaid constitutes nearly 30% of US pediatric population (141). So, if these healthcare 
expenditure patterns can be validated using data from other state Medicaid programs, we 
can have a better understanding of the resource utilization of children and adolescents 
with different diabetes types.  Economic burden on Medicaid due to pediatric diabetes 
emphasize the need for proper disease management and an understanding of expenditures 
will help Medicaid design strategies that can prove to be cost-effective. 
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CONCLUSIONS 
Overall, a sizeable proportion of children enrolled in Mississippi have type 1 and type 2 
diabetes. Interestingly, more children have type 2 diabetes compared to type 1. Very few 
children with type 2 diabetes use oral hypoglycemic and antihypertensive medications, 
even fewer children use antihyperlipidemics. Among users, adherence was poor. 
Adherence with annual screenings was also suboptimal in this population indicating poor 
management of type 2 diabetes overall. Children with diabetes, both types, have higher 
healthcare resource utilization and expenditures compared to children with asthma and 
ADHD. As expected, their health services use and costs were distinctly higher than 
pediatric population without diabetes. Healthcare providers should inform patients and 
children the implications of mismanagement and develop interventions to improve 
patient‟s compliance with their therapies. Also, Medicaid should offer provider incentives 
to encourage healthcare professionals to implement effective interventions. 
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     List of Oral Drugs Used to Manage Diabetes 
Medication Class Drugs 
Biguanides Metformin 
Α-Glucosidase inhibitors Acarbose, Miglitol 
Meglitinides Repaglinide, Nateglinide 
Sulfonylureas 
Glimepiride, Glyburide, Chlorpropamide, Glipizide, 
Tolazamide, Tolbutamide 
Thiazolidinediones Rosiglitazone, Pioglitazone 
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ICD-9 codes for Identification of Comorbidities and Complications 
Condition Identification Protocol 
Diabetes 250.xx, 357.2, 362.0x, 366.41, 648.0 
Hypertension 401–405, 272, 410–417, 425, 428, 429.0–429.3, 433–438, 
440, 444 
Dyslipidemia 272, 401–405, 410–417, 425, 428, 429.0–429.3, 433–438, 
440, 444 
NAFDL 571.8 
Metabolic syndrome ICD-9 code 277.7 in any claim for the patient 
DKA 250.1 in hospitalization and ER visit claims 
Severe hypoglycemia ICD-9 codes for coma or seizure along with a diagnosis for 
diabetes. Glucagon injection and dextrose administered 
intravenously will be used as indicators of a hypoglycemia 
episode. 
Congestive heart failure 398.91, 402.01, 401.91, 402.01, 402.11, 402.91, 404.01, 
404.03, 404.11, 404.13, 404.93, 404.91, 404.93, 428.0, 428.1, 
428.9, 
4251, 4254, 4255, 4257 
Stroke 433, 434, 436 
Myocardial Infarction 410-410.9, 412 
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     CPT Codes for Diagnostic Tests 
Diagnostic 
Procedure 
CPT codes 
Annual eye 
examination 
Patients with claims data reflecting that the patient has been 
referred to an eye care professional for dilated eye exam, 
CPT codes - 67028, 67030, 67031, 67036, 67038-67043, 
67101, 67105, 67107, 67108, 67110, 67112, 
67113, 67121, 67141, 67145, 67208, 67210, 
67218, 67220, 67221, 67227, 67228, 92002, 
92004, 92012, 92014, 92018, 92019, 92225, 
92226, 92230, 92235, 92240, 92250, 92260, 
99203-99205, 99213-99215, 99242-99245 
Lipid profile Patients with claims data reflecting a lipid profile, CPT 
codes - 80061, 83715, 83716, 83721.  
Claims data must reflect all of the following CPT codes 
present on the same date to count towards a lipid profile: 
serum cholesterol, 82465; high-density cholesterol (HDL), 
83718; triglycerides, 84478. 
HbA1c Patients with claims data reflecting a glycosylated 
hemoglobin during the measurement year, CPT code - 
83036, 83037 
Nephropathy 
screening tests 
Patients with claims data reflecting nephropathy screening 
during the measurement year, CPT codes - 82042, 82043, 
82044, and 84156 
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List of ICD-9 Codes to Compute Deyo-Adapted CCI 
Condition ICD-9-CM codes Weight 
Myocardial infarction  410-410.9, 412 1 
Congestive heart failure  428-428.9 1 
Peripheral vascular disease  443.9, 441-441.9, 785.4, V43.4 1 
Cerebrovascular disease  430-438 1 
Dementia  290-290.9 1 
Chronic pulmonary disease  490-496, 500-505, 506.4 1 
Rheumatologic disease  710.0, 710.1, 710.4, 714.0-714.2, 714.81, 725 1 
Peptic ulcer disease  531-534.9, 531.4-531.7, 532.4-532.7, 533.4, 533.7, 
534.4-534.7 
1 
Mild liver disease  571.2, 571.5, 571.6, 571.4-571.49 1 
Diabetes  250-250.3, 250.7 1 
Diabetes w/chronic 
complications  
250.4-250.6 
2 
Hemi- or paraplegia  344.1, 342-342.9 2 
Moderate/severe renal disease  582-582.9, 583-583.7, 585, 586 2 
Any malignancy  140-172.9, 174-195.8, 200-208.9 2 
Moderate/severe liver disease  572.2-572.8, 456.0-456.21 3 
Metastatic solid tumor 196-199.1 6 
AIDS  042-044.9 6 
 
  
157 
 
VITA 
Vennela Thumula was born in Hyderabad, India on August 12, 1984. She is the daughter 
of Dharma Rao Thumula and Saraswathi Ponugoti. She received her Bachelor‟s of 
Pharmacy (Hons.) from the Birls Institute of Technology & Sciences, Pilani in 2005. 
Vennela started working towards a Doctor of Philosophy degree in Pharmaceutical 
Sciences with an emphasis in pharmaceutical marketing and management in 2006 at the 
University of Mississippi. At the university she held research and teaching assistantship 
positions in the Department of Pharmacy Administration and a Research Fellowship from 
the Center for Pharmaceutical Marketing and Management. She holds membership in Phi 
Kappa Phi Honor Society, Rho Chi Honor Society and other professional organizations 
like APHA and ISPOR. She is the current president of the ISPOR chapter at the 
University of Mississippi. Vennela has a particular interest and expertise in evaluating 
quality indicators, analyzing large claims data sets, examining disparities in 
healthcare/medication utilization, pharmaceutical product adoption, pricing and 
reimbursement issues. Vennela had recently done an internship with the Agency for 
Healthcare Research & Quality, Rockville, Maryland. Vennela would like to eventually 
work as a health care researcher in India. 
 
